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Introduction 
This introduction describes a number of topics related to medication safety for the elderly 
and it gives an overview of the literature concerning these subjects. It also provides an 
outline of the studies we performed in our research project with the aim to improve 
medication safety in the elderly.   
 
Medication safety 
Patient safety is a relevant topic since the publication of the report ”To err is Human” of 
the Institute Of Medicine1. This report showed that the health care system in the United 
States is not as safe as it should be, and gives recommendations for improvement. Patients 
die or suffer from harm because of medical errors that could have been prevented. Besides 
the personal harm as caused by these medical errors they are associated with high health-
care expenditures. The report indicated that human failure is responsible for a number of 
medical errors, but high numbers of problems are related to faulty systems and processes 
that enhance the risk at medical errors. Although it is impossible to prevent human failure, 
it seems wise to look carefully at the systems and processes and optimise them to minimise 
the risk at medical errors1. 
 Studies have shown that improvement can be made in patient safety in the Netherlands 
too. In a study aimed at unintentional harm in Dutch hospitals the medical records of 7926 
patients admitted to 21 hospitals were investigated. One of the conclusions of this study 
was that about 10.000 patients in the Netherlands were suffering from continuing 
unintentional harm caused by medical errors, in about 40 percent of the patients this harm 
could have been prevented. This study showed also that the elderly are especially at risk at 
medical errors. Furthermore it seemed that in about 30 percent of the preventable medical 
errors medication was included2.  
 When patient safety is narrowed to the safe use of medicines the term medication safety 
is used. This term is defined as freedom of actual injury during the course of medication 
use. It includes activities to avoid, prevent or correct adverse drug events which may result 
from the use of medications 3.  
 A study of the Health Care Expectorate aimed at safe use of medicines and medical 
devices in the Netherlands showed that elderly are too often prescribed harmful drugs or 
combinations of drugs, too little attention is devoted to the specific characteristics of this 
group when prescribing medicines4. Two recent studies of medication related hospital 
admission in the Netherlands showed that elderly are especially at risk for medication 
related hospital admissions5,6. These studies indicate that improvement can be made in 
medication safety in the Netherlands and that special attention should be paid to the group 
of elderly drug users.    
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Medication safety and geriatric prescribing 
The sensitivity of the elderly to medication related problems is partly caused by 
physiological changes related to ageing. Both the incidence and the manifestation of drug 
toxicity are different in the elderly when compared to younger individuals. The ability to 
excrete and metabolise medications, the distribution of drugs over body compartments, and 
the organ sensitivity to medicines all change with ageing. Elderly do experience difficulties 
in taking medicines as prescribed, because of problems with coordination, vision, hearing 
and cognition. Table 1 gives an overview of the problems, the underlying mechanisms and 
some examples of medicines of which the effectiveness is affected by ageing.  
 Although the body functions in elderly generally decline there is a large variability 
within this population. For some elderly there are almost no signs of ageing, while for 
others, especially when suffering from a number of diseases, ageing is apparent. As the 
response to normal dosages of medicines is unpredictable medicines should be started in 
low dosages in an elderly population, depending on the effect of the medicine the dosage 
can then be adjusted until the desired effect is reached (Start low and go slow)7-9.  
 
Table 1  Overview of functions that are influenced by ageing with examples of medicines being affected 7,8,10-12 
 
 Mechanism Examples 
Renal function Glomerulosclerosis and decrease of renal blood-flow, both 
leading to a decline in clearance 
Digoxin 
Lithium 
Hepatic function Decrease of hepatic blood-flow causing a decline in first pass 
metabolism resulting in higher plasma levels.  
Morphine 
Propranolol 
Drug distribution Body water contents declines (causing high plasma 
concentrations of  hydrophilic medicines, especially when 
diuretics are used)  
Body fat increases (causing higher half life times for 
hydrophobic drugs) 
Lithium 
Aspirin 
 
Flurazepam 
Diazepam 
Pharmacodynamic 
changes 
Many organs have altered sensitivity to medications even at 
normal drugs concentrations   
Beta-blocking agents 
Vision Problems reading labels and written information All medicines 
Hearing Problems hearing verbal instruction from general practitioner 
and pharmacy-assistant 
All medicines 
Coordination Problems opening packages and administration of complicated 
administration forms  
Inhalation medicines 
Eye drops 
Cognition Problems in taking the right medicine at the right time (getting 
especially complicated when using more medicines) 
All medicines 
Depression  Depression gives decreased adherence to pharmacotherapy, 
elderly have an increased risk of depression 
All medicines 
 
To study and improve prescribing for the elderly various criteria for (inappropriate) 
geriatric prescribing have been published. A well-known example of such criteria is the 
Beers list, consisting of medicines that should not be prescribed for geriatric patients 13. In 
an updated version of this list drug-disease interactions that are especially important for the 
elderly are included 14. A number of researchers did use this list or modifications of this list 
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to study inappropriate prescribing in the elderly. Percentages of patients using at least one 
drug of the Beers list ranged from 10-38% 15-19. 
 In other studies different criteria were developed to study inappropriate prescribing for 
the elderly such as the Medication Appropriateness Index (MAI 20,21). In this index a 
number of implicit criteria are included, like indication, effectiveness, dosage, drug-drug 
and drug-disease interactions, therapeutic duplication, duration of therapy, costs of the 
therapy and correct en practical directions for the patient. In studies using these criteria 
improvements were needed in about 40% of all medicines22.  
 Another example are the ACOVE quality indicators for “Assessing Care Of Vulnerable 
Elders”. These ACOVE indicators concern a number of conditions from which elderly are 
frequently suffering. Medication use in the elderly has its own ACOVE indicators, most of 
which aim at good monitoring practice. Furthermore, a number of explicit criteria are 
posed (when a hypoglycaemic drug is indicated, then chlorpropamide should not be 
used)23,24.     
 
Polypharmacy  
Literally, polypharmacy means using more than one medicine at the same time. In the 
literature the term polypharmacy generally is used when a substantial number of medicines 
is used by a patient in a specific period of time, although no official definition exists that 
includes a specific number of medicines. Another definition for polypharmacy is using too 
many medicines, for example, medicines with no clear indication or medicines used to treat 
side-effects caused by another drug. This last example is known as the prescribing cascade; 
e.g. amlodipine causes oedema, which is treated with hydrochlorothiazide, causing 
hypokalemia which is treated with potassium supplements, causing stomach problems 
which is treated with protonpump inhibitors etc.  
 It seems particularly important to deal critically with polypharmacy in elderly patients 
because this causes different types of problems and is responsible for high health care 
expenses.    
 
Prevalence in the elderly 
When people are ageing the number of chronic conditions increases, so ageing will lead to 
an increase in the use of medicines for chronic diseases. Furthermore, substantial numbers 
of preventive medicines have been developed and they take their places in 
prescription/treatment guidelines. Evidence is increasing that such therapies are also useful 
in the elderly, e.g. statin therapy 25,26, so treatment of chronic diseases in the elderly 
requires an increasing number of drugs. 
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 The prevalence of medication use among the ambulatory population increases 
substantially with advancing age. In the Netherlands the annual number of prescriptions for 
the elderly of 65 or over is almost 3 times higher than that for the Dutch population on 
average, the number of prescriptions delivered for elderly of 75 years or over is even four 
times higher (35.9 prescriptions/year versus 8.9 prescriptions/year). About 80% of all 
prescriptions for the elderly of 65 years or over are repeat prescriptions. On average this 
group uses three different medicines daily27. In Dutch studies considering polypharmacy in 
the elderly in primary care comparable amounts of medicines have been found 28-30. 
 Elderly use relatively cheap medicines, but they do use a high volume, which leads to 
high costs. The elderly of 65 years and older comprise only 14% of the population but are 
responsible for 40 % of medicine costs. For the elderly of 65-74 years the medicine costs 
are about 2,5 times higher than for the Dutch population on average (658 Euro a year 
versus 270 euros), for the elderly of 75 years or over these costs are even 3.3 times as high 
(890 Euros a year versus 270 euros)27. Furthermore ageing of the population will lead to an 
further increase in medicine costs. In 2006 14% of the population in the Netherlands was 
65 years or over, this percentage of elderly is bound to increase to 15% in 2010 and 19% in 
2020 31, leading to a supplemental increase in the costs related to medicines of 26 million 
Euro yearly27.  
 
Polypharmacy and user-related problems 
Polypharmacy increases the risk of confusion about the practical intake of medicines, 
especially in the elderly with deterioration in cognition, vision or coordination. Because of 
decreased muscle strength and problems with coordination elderly can have practical 
problems when taking their medicines. These problems can emerge when using 
complicated dosage forms, like inhalation devices 32-34 or eye drops 35,36. Some other 
studies address problems with breaking tablets 37,38 and handling medicine packages 39.  
 On the other hand managing complicated medication regimens can also lead to 
problems, patients do not know when to take what kind of medicine. Especially when 
cognition is decreasing the management of the increasing number of medicines becomes a 
problem. Even more problems may be expected when medication changes are made by the 
prescriber, when branded medicines are replaced by generic medicines or in case of 
switches between generic labels (leading to tablets with other colours and shapes). Patients 
may get confused and continue the medicine that is supposed to be stopped or take both the 
branded medicine and the generic one. These problems may result in unintentional under- 
or overuse with the consequence that the patient does not receive full benefit of treatment 
or may suffer from side effects.  
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 Numerous studies address non-adherence 40-44, which can be divided into intentional and 
unintentional non-adherence. These kinds of non-adherence are two very distinctive 
problem areas that should be handled by means of different types of interventions. To 
reduce intentional non-adherence motivational interventions can be offered, whereas 
interventions aimed at education and training can be offered to reduce unintentional non 
adherence.    
 
Polypharmacy and prescribing 
The recognition that most common conditions regularly have to be treated with more than 
one agent (e.g. diabetes mellitus, angina pectoris) has led to obligatory or rational 
polypharmacy. This concept has shifted the focus on polypharmacy in recent years from 
reducing the number of medicines to optimizing pharmacotherapy45. Although 
polypharmacy increases a number of risks, like the occurrence of adverse drug reactions 
and hospitalisation, medicines that are necessary for optimal treatment of the conditions the 
patient suffers from should be considered. The risk of unavoidable adverse drug reactions 
should be weighed against the knowledge that dose-related failure of existing therapy to 
manage the condition may be one of the most important drug-related reasons for admission 
of the elderly to hospital 46,47. Therefore the benefit-risk ratio should be assessed more 
thoroughly in the elderly using higher numbers of medicines than in younger patients using 
no co-medication.  
 Nowadays more and more attention is paid to disease management programs. In these 
the presence of singular co-morbidities is often indicated but the presence of multiple 
morbidities, as frequently seen in the elderly, is mostly not addressed. When blindly 
following treatment guidelines conflicting recommendations and drug-drug or drug-disease 
interactions can emerge. Especially when a number of chronic conditions are present, 
healthcare professionals should balance and prioritize medication use, and an individual 
health-care program should be made for each geriatric patient with multimorbidity 48.  
 Patients with a short life expectancy will not benefit from the preventive effects of 
medicines like statins. Holmes has proposed a model that includes four components that 
can be used to balance the pros and cons of prescribing (or discontinuing) medications in 
the elderly. The components included in this model are remaining life expectancy, time 
until benefit, goals of care and treatment target 49.  
 
Polypharmacy as a risk factor 
The incidence of adverse drug reactions increases with the number of medications taken 50-
52
. The link between polypharmacy and the risk of drug-related hospitalisation seems clear 
when considering that polypharmacy increases non-adherence, adverse drug reactions and 
 Introduction 11 
drug-drug interactions. Some studies have shown that this is associated with the number of 
drugs used 5,51-54. In a number of studies higher age was also related to an increased risk of 
drug-induced hospital admission 5,6,52,55. In a literature review evaluating the incidence of 
adverse patient outcomes due to drug-drug interactions it was found that interactions were 
held responsible for 4.8% of the hospital admissions for the elderly (> 65 years), while this 
percentage in the whole population was only 0.57%56. 
 A number of studies have shown that only a small number of drug classes are 
responsible for a high proportion of drug-related hospital admissions. A recent systematic 
review found that antiplatelets, diuretics, NSAIDs, and anticoagulants were responsible for 
more than half of all drug-related hospitalisations 54. Other studies also indicate digoxin, 
calcium channel blockers, antidiabetics, corticosteroids and psycholeptica, cytostatics and 
immunosuppressives5,6,52,55,56. These drugs associated with high proportions of drug-related 
problems are drugs that are commonly used by the elderly.   
 
Medication review 
Periodical review of pharmacotherapy 
In The Netherlands all prescriptions for outpatients are checked in daily routine by the 
pharmacy computer. When a medicine is added that leads to a direct problem a signal will 
warn the pharmacy-assistant (for example in case of drug-drug interactions, drug-disease 
interactions, dose-changes etc). In some instances no direct problems will emerge when 
delivering a medicine although it is not the most elegant solution of the problems as 
presented to the GP (e.g. prescribing a second medicine for treatment of a side effect 
instead of changing the medicine causing the problem, if possible), in other instances no 
signals are generated by pharmacy-systems yet (e.g. geriatric dosages or duration of 
therapy). Other problems can be identified more easily by looking at a graphical 
representation of the whole pharmacy record and may remain undetected in daily routine 
(for example a medicine that is stopped without a logical substitute).  
 By means of a periodical review of complete pharmacotherapy of a specific patient, 
problems that otherwise would go unnoticed, can be identified and feedback can be given 
to the GP. In these reviews a pharmacist searches for problems or improvements needed, 
e.g. are all diseases treated following guidelines, do all medicines used have a proper 
indication, are the medicines suitable for this specific patient (considering age, and 
possible other diseases). Literature has shown that reviewing the complete 
pharmacotherapy results in positive effects, such as a decrease in inappropriate prescribing 
score, higher percentages of problems solved or more medication changes in the 
intervention group compared to the control group 22,57-59. 
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 Periodical reviews can be performed based on explicit or implicit criteria. An example 
of explicit criteria for treatment review concerning the elderly are the Beers criteria 13. 
Explicit criteria can be used by less experienced persons, they only have to keep in mind 
the list of medicines that should not be used by the elderly or not used by the elderly 
suffering from certain conditions. These criteria can also be used to build a computerised 
screening tool.  
 Implicit criteria, on the other hand, are based on the clinical judgement of the reviewing 
healthcare professional. Specific information about the health condition of the patient 
should be used to weigh up the pros and cons of certain drug therapies. As explicit and 
implicit criteria have their own benefits and limitations, a combined application may offer 
a more thorough assessment than each approach separately60.  
 
Private pharmaceutical consultations 
Medication reviews involving direct contact with the patient (also known as private 
pharmaceutical consultations, medicines consultations etc) can be used to solve (or 
prevent) user-related and prescription-related pharmaceutical care issues. The patient is 
either asked to visit the pharmacy or general practice with all medicines he/she uses, or the 
medication review is performed at the home of the patient. Firstly, the patient is asked 
whether he/she has problems with the use of medicines, and whether side effects are 
experienced. Subsequently a number of questions are asked for each medicine (about daily 
dosage regimen, the reason for using the medicine, what to do if a dosage is missed etc.). 
Furthermore, the patient is asked which non-prescription drugs are used to check whether 
they can be taken in combination with the prescription medicines.  
 Studies have shown that the number of user-related pharmaceutical care issues decreases 
after such reviews58,61,62. Although not all studies indicate an effect at adherence, some 
studies have shown improved knowledge and adherence to pharmacotherapy 63. In the  
patient interviews, gaps in the knowledge of the patient concerning pharmacotherapy can 
be detected and solutions for problems can be shared with the patient. During these 
consultations other services can also be offered, for example synchronising all repeat 
prescriptions. For patients having even more problems managing medicines themselves, 
the pharmacist should offer to deliver medicines in week organisers.  
 
Levels of medication review described in the UK ‘Medicines Partnership’ model 
The Medicine partnership in the United Kingdom has defined three different levels of 
medication review (textbox 1)64. In Dutch pharmacies prescription reviews (level 1) 
probably routinely performed in daily practice. Treatment reviews (level 2), in which 
pharmacotherapy is screened by a pharmacist and feedback is given to a GP, are 
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increasingly popular , but not yet standard practice in many pharmacies. Dutch pharmacies 
also perform private pharmaceutical consultations but their frequency is still low 65. The 
combined form of treatment review and medicine consultations, clinical medication 
reviews (level 3) is not yet regularly being performed in the Netherlands. 
 
Textbox 1. Different levels of medication review as described in the UK ‘Medicines Partnership’ model.  
  
Level 1. Prescription 
review 
Technical review of list of patient’s medicines 
Prescription reviews can be helpful in identifying anomalies and highlighting patients 
who may need clinical medication reviews. 
As a stand-alone tool their benefits are relatively limited as they do not normally allow 
for a full discussion with the patient. 
Level 2. Treatment 
review 
Review of medicines with patient’s full notes  
Treatment reviews normally take place under the direction of a doctor, nurse or 
pharmacist, but often without the patient, for instance, removal of unwanted items 
from the repeat medicines list, and dose adjustments. This may arise from a review of 
patients with a particular condition such as asthma or taking a group of drugs such as 
proton pump inhibitors. The review may include the complete repeat prescription or 
focus on one therapeutic area (eg hypertension), drug (eg lithium) or group of drugs 
(eg NSAIDs). Recommendations may be passed to the prescriber for implementation. 
Level 3. Clinical 
medication review 
Face-to-face review of medicines and condition 
Clinical medication reviews require access to the patient’s notes, full record of 
prescriptions and non drug care and results from laboratory tests etc. The review 
should include the complete repeat prescription as well as over-the-counter and 
complementary remedies. In clinical medication reviews, medicines would not be 
examined in isolation but considered in the context of the patient’s condition and the 
way they live their lives. Clinical medication review should therefore involve the 
patient as a full partner. This means listening to the patient’s views and beliefs about 
their medicines, reaching an honest understanding of their medicine taking behaviour, 
and taking full account of their preferences in any decisions about treatment. This is 
more than what currently happens for most patients when they visit their GP for a 
renewal of a repeat prescription item. The invitation to a review of an individual 
patient’s medication (ie a type 3 review) should include both the patient and (when 
appropriate) the carer. 
 
Outline of the thesis 
Our research project followed the cycle of implementation. First we looked analytically at 
the types of problems associated with elderly and medication safety (part 1), in the second 
part of the thesis we tried to improve prescribing for the elderly. Textbox 2 gives an 
overview of the different chapters and types of research as described in the chapters 
mentioned. 
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Textbox 2.  Overview of the chapters and types of research used  
 
 Objectives Method 
1. Introduction - - 
Part 1. Problems associated with elderly and use of medicines 
2. User-related pharmaceutical 
care problems and factors 
affecting them: the importance 
of clinical relevance 
To investigate the type, number and clinical 
relevance of user related pharmaceutical care 
problems. 
To develop a risk model for detecting elderly drug-
users at risk of user related pharmaceutical care 
problems 
Interview study 
3. Analysis of polypharmacy in 
older patients in primary care 
using a multidisciplinary expert 
panel 
To determine the nature, volume and clinical 
relevance of prescription related point of attention 
in the elderly 
Consensus method 
4. Composite screening tool for 
medication reviews of 
outpatients  
To examine prominent existing tools for medication 
review  
Present a new composite tool for medication review 
Literature review 
5. Drug induced hypoglycaemia 
in elderly users of anti-
diabetics; incidence and risk 
factors 
To determine the incidence rate of drug induced 
hypoglycaemia for the different groups of users of 
hypoglycaemic agents 
To determine risk factors for drug induced 
hypoglycaemia 
Prospective cohort 
study 
Part 2. Improving medication safety in the elderly 
6. Cluster controlled trial 
comparing two procedures for 
treatment reviews concerning 
elderly people on polypharmacy 
in primary care  
To determine which procedure for treatment 
reviews (case conferences versus written feedback) 
results in more medication changes. 
To determine costs and savings related to such an 
intervention. 
Cluster controlled 
trial 
7. Comparison of two methods 
for performing treatment 
reviews by pharmacists and 
general practitioners for home-
dwelling elderly people 
To describe feasibility of two methods for treatment 
review 
To determine whether the process of treatment 
review can be improved, and by what manner. 
Process evaluations 
by questionnaires, 
interviews and 
analysis of various 
features of treatment 
reviews  
8. General discussion - - 
 
Research questions 
Part 1 Problems associated with elderly and use of medicines 
During the preparation of our study we saw that little research has been performed on the 
whole range of user-related problems, we could only find studies focusing on specific 
types of user-related problems and studies regarding adherence to pharmacotherapy. So 
firstly we examined actual medication use by the elderly living in their own homes. Do 
elderly take their medicines as prescribed? What problems do elderly experience when 
taking their medicines? This was studied by means of home-interviews for 300 elderly. 
The results of this study are described in chapter 2.  
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 We saw that internationally much research has been performed concerning inappropriate 
prescribing for the elderly living in the community. However, most of these studies have 
been performed with the Beers criteria, these criteria are aimed at the situation in the USA. 
Some of the medicines as indicated on the list are not used in the Netherlands, while other 
medicines used in the Netherlands considered to be inappropriate for use in the elderly are 
not on the list because they are not regularly used in the USA. Furthermore only one aspect 
of prescribing is included in most of these studies, whereas mostly different types of 
problems can be indicated when prescribing for the elderly is reviewed. So we performed 
an in-depth-analysis of the pharmacotherapy of 100 elderly drug users from our interview 
study. What did the GPs prescribe for the elderly, and what improvements could be made? 
This was studied by means of a multidisciplinary panel consisting of eight experts, 
individually scoring points of attention in the medication of our participants and sharing 
these during consensus-meetings. The results of this in-depth analysis of polypharmacy in 
the elderly are described in chapter 3. 
 Although we had a relatively high number of patients included in our in-depth analysis 
of polypharmacy, some types of prescribing problems, especially those that occur rarely, 
could have been missed or underrepresented. So we additionally searched the literature to 
acquire a good overview of all types of problems associated with elderly and 
pharmacotherapy. Out of the wealth of literature concerning prescribing for the elderly and 
our own studies we could identify a number of problem categories. By means of these 
categories we constructed a new tool for performing medications reviews in daily practice. 
What categories of points of attention should be kept in mind when performing treatment 
reviews? In this literature study different categories of problems are described, liberally 
provided with examples (chapter 4). 
 Furthermore, we saw that the majority of drug-related hospital admissions are related to 
a limited number of drug-classes. So, in one of our studies we looked at one of these 
medicine classes; hypoglycaemic agents. Some blood glucose-lowering medicines and 
combinations of medicines are associated with a higher risk at hypoglycaemic events, 
thereby increasing the risk of hospital admission. We looked for risk factors to identify 
users of hypoglycaemic agents at increased risk for hypoglycaemic events in a prospective 
cohort study in the Rotterdam-study database 66 (chapter 5).    
 
Part 2 Improving medication safety in the elderly 
For the second part of our research project we first identified which types of problems were 
most in need of a solution and we developed an intervention for improvement. From the 
studies in part 1 we concluded that there were high percentages of prescription-related 
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problems and the problems were of direct clinical relevance in higher proportions of 
patients than the user-related pharmaceutical care problems.  
 Although no randomised trial had been performed concerning this subject in the 
Netherlands, there was enough evidence from other countries that performing treatment 
reviews is useful. In our study we investigated the best method for performing  treatment 
reviews in daily practice. From the scientific literature it is known that personal feedback 
(case-conferences) is more effective than written feedback when influencing prescribing 
behaviour. In our study we wanted to determine whether this is also the case for treatment 
reviews and whether extra costs caused by extra time expenses can be covered by 
supplemental savings on medication costs. We studied this by means of a cluster controlled 
trial. The results of this intervention-study are described in chapter 6. 
 To study feasibility in day-to-day primary care and to study whether improvements in 
the process could be made we also performed a process evaluation. We used written 
questionnaires, structured interviews and process parameters as gathered during the 
intervention study. The results of this process evaluation are described in chapter 7. 
 Chapter 8 concludes the thesis with a general discussion, the results of the different 
studies are discussed and recommendations for further research and for improving the 
performance of treatment reviews in daily practice are given.      
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Abstract 
Background and objectives: Many studies determined the number and nature of user-
related Pharmaceutical Care Problems (PCP) and factors affecting them, but none 
considered the inclusion of clinical relevance.The aims of this study are (i) to investigate 
the type, number and clinical relevance of user-related PCP self-reported by home dwelling 
elderly on polypharmacy and (ii) to develop a risk-model for detecting elderly drug-users 
at risk of user-related PCP. 
Methods: The study was a cross-sectional study conducted among 286 home dwelling 
elderly on polypharmacy (≥ 75 years, ≥ 4 medicines) in the Netherlands. The user-related 
PCP found were divided into problem categories and subsequently a pharmacist and a 
general practitioner classified the problems into those with low and those with (potential) 
clinical relevance. Factors possibly associated with PCP (both for all and relevant 
problems) were identified, and subsequently tested in multivariate models using logistic 
regression.  
Results: Three hundred and ninety-eight user-related PCP were observed in 189 patients 
(66% of all participants). After classification of user-related PCP only 26% appeared to be 
of potential clinical relevance (26% of all participants). When including clinical relevance 
a shift in predominantly present problem categories is observed. Furthermore, the risk 
model for problems with potential clinical relevance contains more factors than the model 
which considered all problems. Factors associated with clinically relevant PCP are 
emotional or physical problems interfering with social life, communication skills (vision 
and hearing), using tablets that have to be divided, using inhaled medicines, and the 
number of medicines used. This risk-model has a specificity of 92% and a sensitivity of 
32%. 
Conclusions: Although user-related PCP were seen in about two-thirds of the participants, 
in only one out of four participants was the PCP considered to be of potential clinical 
relevance. With inclusion of clinical relevance, other problem categories become more 
dominant. A specific risk model is designed to select elderly patients that are most likely to 
have PCP in need of more urgent intervention. Unfortunately higher specificity is 
accompanied by low sensitivity in the present model. 
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Introduction 
Pharmacists aspire to reduce drug-related problems by monitoring and advising elderly 
patients as well as their physicians1. To further this ambition, our study analysed user-
related and prescription-related pharmaceutical care problems (PCP) and their determinants 
in home-dwelling drug-users who were at least 75 years old and who were taking at least 
four medications chronically. The study concerning user-related problems is described 
here, whereas details of the prescription-related problems will be reported elsewhere. 
 Unlike previous studies, we not only evaluate the nature and prevalence of user-related 
problems, but also estimated their potential clinical relevance. In other words we assessed 
whether the solving of these user-related problems could actually lead to an improvement 
in the health status of the particular patient. Furthermore, we measured various 
characteristics of users that have been described as potential determinants of user-related 
problems. Besides social and demographic characteristics (e.g. age, socio-economic status, 
educational level, living conditions), we recorded the number and nature of prescription 
medicines, the use of non-prescription medicines, the number and medical specialisation of 
the physicians seen, and the frequency of doctor visits2–7. We also assessed cognitive 
function and emotional wellbeing, because impairments in these domains have been 
repeatedly associated with non-adherence2,3,8–12. We hoped that the evaluation of these 
factors would allow us to develop a reliable risk model that would help community 
pharmacists to detect elderly drug-users at increased risk of clinically relevant user-related 
problems. These would more likely require urgent pharmaceutical care services. 
 
Methods 
Study design 
The study was a cross-sectional study conducted among 286 home dwelling elderly in the 
Southern part of the Netherlands, with data collected from November 2001 to February 
2003. 
 
Study population 
The participants were selected from the pharmacy records of a convenience sample of nine 
pharmacies in the Southern part of the Netherlands. The pharmacies were located in 
villages, small towns and medium-sized cities. Eligible patients were those who were (i) 75 
years or over, (ii) living at home and (iii) taking four or more medications on a regular 
basis. Elderly patients who were terminally ill, lived in a nursing home or in a home for the 
elderly were excluded from the study. Signed consent was obtained from participants 
before the onset of data-collection. Non-responders were reminded by telephone after 
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several weeks. Patients who refused participation were asked for their reasons, age and the 
number of medications they were currently taking. 
 
Variables and instruments 
USER-RELATED PHARMACEUTICAL CARE PROBLEMS 
User-related PCP were defined as: 
1. Non-adherence to prescribed treatment (e.g. underuse, overuse, deviation from the 
dosage schedule), which has been reported to occur in 14–56% of the patients, depending 
on the definition of non-adherence and on study populations2, 3, 5, 13–16. 
2. Problems with correct self-administration of medications, such as difficulties with 
dividing tablets17,18, opening packages3,19,20, or using eye drops21,22, inhalation devices or 
other special dosage forms. In one study, 41% of elderly inpatients were unable to perform 
one or more tasks that were needed when using their medications, such as opening 
containers or strips and dividing tablets23. In other studies, 41–44% of all elderly patients 
using inhalation medicines had problems with the correct use of these devices24–26. 
3. Inappropriate medicine-taking habits, such as taking medicines that are out of date, or 
lending prescribed medicines to others. These habits have been reported in 6 and 7% of 
participants respectively20.  
 
CLINICAL RELEVANCE OF USER-RELATED PHARMACEUTICAL CARE PROBLEMS 
A pharmacist and a general practitioner classified problems into PCP with low clinical 
relevance and PCP with potential or high clinical relevance; this was based on the most 
likely reason for use. 
Problems were considered as having clinical relevance, if they had a potential harmful 
effect on the general health status of the patient. Each problem was discussed until the 
physician and pharmacist reached consensus. 
 
FACTORS POSSIBLY ASSOCIATED WITH USER-RELATED PHARMACEUTICAL CARE PROBLEMS 
− Socio-demographic characteristics: age, sex, marital state, income, living situation, 
general practitioner and dispensing pharmacy. 
− General health measured by the COOP/ 
− WONCA charts on physical fitness, feelings, daily activities, social activities, change 
in health and overall health27. For analysis, the five point-scales were dichotomized, 
by grouping the positive and negative answers. 
− Impairment of activities of daily living was measured by the Groningen Activity 
Restriction Scale (GARS, ADL-scale)28. The total score on the GARS-ADL was used 
in analysis. 
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− Mental health measured by the Hospital Anxiety and Depression Scale (HADS)29,30. 
The total score and the total scores on the anxiety and the depression sub-scales were 
used for analysis. 
− Cognitive impairment, measured by the Mini Mental State Examination31. The 
maximum total score of the original instrument is 30. As our questionnaire lacked one 
question in the area of orientation, participants could score a maximum of 29. 
− We also probed whether the participant knew the indications for all medicines as a 
measure for cognition. 
− Medical consumption: number of medicines taken, number of prescribing physicians, 
hospital admission in the last 3 months, number of physician and pharmacy visits in 
the last 3 months. 
− Receiving help with managing medication. 
− Drug administering characteristics: having problems with reading and understanding 
instructions on medicine-labels, having problems with opening packages, strips or 
with using administration aids, having problems with subdividing tablets or with 
using adherence aids. 
− Medicine-taking characteristics: using prescription and OTC medicines which were 
classified according to the Anatomical Therapeutic Chemical Classification of the 
WHO Collaborating Centre for Drug Statistic Methodology32. 
− Communication problems: having difficulties in conversing with one other person or 
a group of three people, having problems with reading newspapers or in recognizing 
people. 
 
Data collection 
Data were collected from the registration records at the pharmacies, by self-administered 
questionnaires, and by face-to-face interviews with participants.  
Data on prescribed medications of participants were obtained from the registration records 
of the nine participating pharmacies. The researcher (pharmacist) used these data to point 
out potential user-related PCP that needed to be probed on during the interview. 
Subsequently, participants received self-administered questionnaires to be completed 
before the face-to-face interview took place. The questionnaires included questions on 
patient characteristics that were believed to be determinants, such as age, sex, education, 
income, and the scales that measured depression, anxiety, general health and functional 
validity. The face-to-face interview was used to probe actual use and administration of 
medicines and to probe on topics not covered by the written questionnaire, such as 
cognition, OTC drug use, use of adherence aids and drug administration devices. During 
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the interview, participants were asked to present all medications they were regularly taking 
and to indicate for each medicine the purpose of the medicine, the dosage schedule and 
skipped doses. If the reported dosage schedule differed from the schedule recorded at the 
pharmacy, the participant was asked for the reason.  
The interviews took place at the participant’s homes and were conducted by trained 
interviewers with a background in health sciences (medical students), pharmacy (pharmacy 
assistants) or general practice (practice assistants). 
 
Data analysis 
Interview data were entered in a MS-ACCESS database and analysed using SPSS 11 
(SPSS Inc, Chicago, IL, USA).  
User-related PCP were counted and classified into those with low clinical relevance and 
those with potential clinical relevance by a pharmacist and a general practitioner. 
Potential determinants were analysed by making comparisons between: 
− Participants having at least one user-related PCP and participants having no PCP at 
all. 
− Participants having at least one (potentially) clinically relevant PCP and participants 
having only non-relevant or no PCP at all.  
Comparisons were made on factors that are possibly associated with PCP. The significance 
of bivariate associations was determined by t-tests (for numeric values), a chi-square-test 
(for count data), and Mann–Whitney U-tests when data had been measured at the ordinal 
level. Factors that were significantly associated at the bivariate level, were tested in 
multivariate models using logistic regression. The dependent variables in logistic 
regressions were (i) having at least one user-related problem or (ii) having at least one 
user-related problem of (potential) clinical relevance. As the HADS and its subscales for 
depression and anxiety were highly correlated, only the subscales were tested at the 
multivariate level. 
 
Results 
Participants 
A flowchart of the response of the patients is presented in Fig. 1, showing that out of the 
487 eligible patients, 333 agreed to participate. Of these 333 participants, 35 dropped out, 
resulting in a total of 298 interviews. During analysis, another 12 patients had to be 
excluded because they did not meet the inclusion criteria. All analyses were conducted on 
the remaining 286 patients (net response 59%). 
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Figure 1:  Flowchart of response of participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The characteristics of the 286 participants are described in Table 1. 
A non-response analysis comparing participants with non-responders by age and number of 
medicines taken showed that responders used more medicines (P < 0.01); on average 6.6 as 
compared with 6.0 by non-participants. 
 
Table 1.  Characteristics of participants (n=286) 
 
 Participants (n=286) 
Age, mean (SD) 80.3 (3.7) 
Mean no. of prescribed medicine (SD) 6.6 (2.2) 
Sex (% of participants being male) 36 
Living situation (% of participants living alone) 53 
Level of education (% of participants with only primary education) 30 
Hospitalisation (% of participants which was hospitalised last 3 months) 4 
Prescriptions (% of participants which gets prescriptions only by one physician)  46 
Adherence aids (% of participants using a medicine box)  24 
Help with medication (% of participants which gets help with managing medication) 55 
 
Total sample  
487 (100%) 
Total response  
333 patients ( 68%) 
Drop out before interview: 
Health problems (n=3) 
Deceased (n=4)  
Miscellaneous (n=21) 
Lost to follow up (n=7) 
Non response  
154 persons (32%)  
Reached by 
telephone 
115 (24%)  
Not reached 
by telephone  
39 (8%) 
Total number of interviews: 
298 (61%) 
Excluded: 
<4 medicine (n=10) 
Help from nursing home 
(n=2)  
Total number of patients in 
analysis: 
286 (59%) 
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Number of user-related pharmaceutical care problems and their clinical relevance  
A total of 398 user-related PCP were observed in 189 patients, implying that 66% of all 
participants reported at least one user-related problem and that participants usually had 
more than one user-related problem. Table 2 shows the distribution of PCP’s over the 
different types of problems. The most common user-related PCP, seen in 45% of patients, 
was using less medication than prescribed. This was followed by problems with breaking 
tablets (seen in 16% of all participants and 36% of all participants who had to divide 
tablets) and discrepancies in dosing schedule, seen in 11% of all participants. 
 
Table 2. Distribution (in percentages) of PCP over the various problem categories categorised by seriousness 
of user related PCP  
 
Nature of problem All PCP  
 
 
 
(n=398) 
PCP with 
minimal 
clinical 
relevance  
(n=295) 
PCP with 
potential 
clinical 
relevance  
(n=103) 
Example of PCP with 
minimal clinical 
relevance 
Example of PCP with 
potential clinical 
relevance 
Using less than 
prescribed 
53 62 27 Hypnotic not used daily Hydralazine used 2 
times daily instead of 3 
times daily  
Problems with dividing 
tablets  
11 13 6 Problem with dividing 
tablets of 
antihypertensives 
Problem with dividing 
amiodarone tablets 
Deviation in dosage 
schedule (total daily 
dose is as prescribed) 
9 9 8 Tolbutamide taken as 2 
tablets in the morning 
and 1 in the evening 
instead of 1 tablet 3 
times daily  
Simvastatin taken am 
instead of pm 
Problems with using eye 
drops  
9 4 22 Problem with eye drops 
without 
pharmacologically 
active ingredient 
Problem with ocular 
beta-sympathicolytics 
for use in glaucoma 
Using more than 
prescribed 
 
6 4 12 Lactulose syrup taken 
twice daily instead of 
once daily 
Additional tablet of 
zopiclone taken during 
night when waking up 
(almost every night)  
Use of former prescribed 
medicine  
3 3 3 Temazepam Mefenoxalon 
Lends medicine to 
another person  
3 3 2 Paracetamol Diazepam 
Prescription medicine 
discontinued on 
patient’s own initiative  
2 1 5 Discontinuation of 
acetylcysteine 
Discontinuation of 
theophylline 
Has problems by using 
inhalation medicine 
2 - 6 - Flixotide  
Miscellaneous 4 2 10 Patient tries sometimes 
if lactulose can be 
stopped for a while 
Patient forgets often to 
take the patch with 
transdermal nitro-
glycerine off at 
evening.  
PCP= pharmaceutical care problems 
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After classification of user-related PCP into problems with minimal/no clinical relevance 
and problems with potential clinical relevance, it appeared that only 26% of all PCP could 
be considered as having a potential clinical relevance. Similar figures are seen at the level 
of the participants, with 58% of the total number of participants only having user-related 
PCP that were likely of no or minimal clinical relevance, 73 participants (26%) showed at 
least one PCP with potential clinical relevance. 
 Furthermore, when clinical relevance was included, other problem categories became 
more prominent. Using less than prescribed amounts of medication is also in the category 
of clinical relevant problems the problem seen most (seen in 9% of all participants). This is 
followed by having problems using eye drops (seen in 5% of all participants) and using 
more than prescribed amounts (seen in 4% of all participants) (Table 2). 
 
Risk model for user-related pharmaceutical care problems 
A comparison of participants with user-related problems to participants without problems, 
showed that, at the bivariate level, significant factors (P < 0.05) were using a higher 
number of medicines, using tablets that had to be divided, using at least one medicine out 
of the ATC-groups A or N and having problems with reading and understanding the 
instructions on the labels. At the multivariate level, three factors remained significant: a 
higher number of medicines, using tablets that had to be divided, and problems with 
understanding the instructions on the labels (Table 3). 
 
Table 3.  Logistic regression model for PCP and for PCP with potential clinical relevance 
 
 All PCP PCP with potential clinical relevance 
 B Exp (B) 95% CI B Exp (B) 95% CI 
Number of medicines taken (for each 
suppl. medicine) 
0.306 1.358** 1.172-1.573 0.177 1.194* 1.036-1.377 
Participant has to divide tablets 0.584 1.793* 1.038-3.095 0.959 2.609** 1.373-4.960 
Participant has problems understanding 
instructions on the medicine label 
1.223 3.397 0.959-12.033 - - - 
Interference of emotional or physical 
problems with social life 
- - - 0.798 2.221* 1.061-4.648 
Participant has problems with talking to 
another person 
- - - 0.883 2.417* 1.121-5.214 
Participant has problems in recognising 
people  
- - - 0.734 2.083* 1.058-4.103 
Participant uses inhalation medicines - - - 1.425 4.159** 2.048-8.446 
*   p<0.05 
** p<0.01 
PCP= pharmaceutical care problems 
 
Comparing participants with at least one potentially clinically relevant problem to 
participants with only problems of low clinical relevance or no problems at all showed 
significant bivariate associations (P < 0.05) with a higher number of medicines taken, 
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using tablets that have to be divided, worse general health of participants, and participants 
having problems with hearing and vision. In addition, mental health (feeling anxious or 
depressed, experiencing emotional problems and feeling that emotional or physical 
problems interfered with social life) and the usage of special dosage forms (inhalation 
devices and eye drops) increased the likelihood of having problems that were potentially of 
clinical relevance. As Table 3 indicates, six factors remained significant at the multivariate 
level: using a higher number of medicines, using tablets that have to be divided, 
interference of emotional or physical problems with social life, problems with talking to 
another person, problems in recognizing people and using inhalation medicines. 
 The predictive values of both models showed that the model for having PCP (relevant 
and nonrelevant) had a reasonable sensitivity, as it could select 85% of all participants who 
are at risk for having user-related PCP, although the specificity (excluding those who are 
not at risk) was only 26%. 
 The specificity of the second model was high (93%), but the sensitivity was still low at 
32%. 
 
Discussion 
User-related PCP were reported by two-thirds of home-dwelling drug users, who were at 
least 75 years old and who were taking at least four medications chronically. The most 
common types of problems were underuse, difficulties with dividing tablets, deviations 
from the prescribed dosage schedule without changing the total daily dose, problems with 
the application of eye drops and overuse. Use of formerly prescribed medicines, lending 
medicines to others, or discontinuation of prescribed medicines without consulting the 
prescriber were only sporadically recorded. Our data on under-use and over-use (observed 
in 53% of all participants, if taken together, with patients often being non-adherent to more 
than one medicine) correspond fairly well with the findings of others, who observed that 
14–56% of their patients did not comply for at least one prescribed medicine2,3,5,13–16. The 
difficulties identified, concerning the dividing of tablets, the use of eye drops or inhaling 
medicines have also been described previously17–19,22–26. McElnay et al.16 found that 
inhaled bronchodilator medicines are related to non-adherence and that patients are likely 
to adapt the required doses of inhaled medicines to their physical condition, which is 
consistent with the findings of our study. The strong association between using inhaled 
medicines and user-related PCP is probably mainly due to non-adherence and to a lesser 
extent to self-reported administration problems. 
 Unlike previous studies, we assessed the potential clinical relevance of the reported 
problems. This revealed that the majority of user-related PCP was unlikely to cause 
clinically significant problems and that other types of problems became more prominent. 
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 For instance, 14% of the cases concerning under-use involved the reduced intake of 
benzodiazepines compared to the prescription, which is certainly not a change for the 
worse. Only one-fourth of all PCP could be considered as being of potential clinical 
relevance (Table 2). This implies that studies which do not take the degree of clinical 
relevance into consideration focus too much on problems that do not really matter.  
 Paying attention to problems of potential clinical relevance is also important in the 
development of a predictive risk model for helping community pharmacists to identify 
elderly drug users at increased risk of user-related PCP. When clinical relevance was not 
taken into account, only the (higher) number of medicines taken, the ability to understand 
the instructions on the labels and having to divide tablets emerged as principal risk factors. 
When potential clinical relevance was considered, however, other risk factors besides the 
number of medicines taken and having to divide tablets became prominent, namely using 
inhalation-medicines, the capability to recognize people, to have a conversation, and the 
extent to which patients felt that emotional problems and physical disabilities limited their 
social functioning. Although others have sometimes reported these determinants2–4,6–11,13,15, 
33–35
 this is the first time that their importance for the occurrence of clinically relevant 
problems has been demonstrated. 
 Our study is not without limitations. First, we relied on self-reports of problems, which 
may lead to an underestimation, e.g. of non-adherence problems. Our interviewers 
occasionally observed that participants could not provide a satisfactory explanation, when 
the interviewers confronted them with an interruption in the dispensing pattern of their 
chronic medicines (as established by consulting their pharmacy records). They still stated 
that they had taken the medicine as prescribed. This problem may also arise in daily 
pharmacy practice, and is just as difficult to solve as in our research setting. A second 
limitation is that nonresponders differed from responders by using fewer medicines, which 
may have led to a slight overestimation of the PCP per patient. Furthermore, the 
pharmacists and general practitioners who took part in the study were a convenience 
sample and we do not know to what extent a selection bias may have occurred. This 
selection bias may also be seen in the response of the invited participants. Participants 
familiar with noncompliance are likely to be less inclined to take part in a study concerning 
drug-taking habits. Finally, our study did not comprise highly urbanized areas. This may 
have led to an under representation of immigrant drug users, who might have different 
types of PCP compared with our study population. 
 The risk model we developed to predict the detection of PCP with potential clinical 
relevance had a high specificity (93%) but unfortunately a low sensitivity (32%). This has 
also been found by another research group, who developed a risk model for non-adherence 
in elderly patients prior to hospitalization16. The practical implication is that the 
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determinants found with our model can support community pharmacists in achieving early 
successes. They can start with intensifying their care for elderly patients, by asking three 
simple questions on health and the communication ability of the user, supplemented with 
information on the total number of medicines used and dosage form of each medication. 
This information can also be easily extracted from the pharmacy dispensing record. The 
model is not suitable, however, for the identification of all elderly patients who are at 
higher risk and have an increased need of pharmaceutical care services. For that purpose, 
further research will be necessary with our model providing a potentially useful starting 
point. 
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Abstract 
Background: Many older patients suffer from chronic diseases for which medicines should 
be used. Because of the higher number of medicines used and decline in hepatic and renal 
function, older patients are more prone to problems caused by these medicines. 
 Therefore, it is important to review pharmacotherapy concerning older patients in 
primary care in a reliable way. 
Aim: To determine the nature, volume and clinical relevance of prescription-related points 
of attention in the elderly. 
Design of study: Analysis of pharmacotherapy by a multidisciplinary expert panel 
consisting of GPs, geriatric specialists, clinical pharmacists and community pharmacists. 
Setting: Pharmacotherapy of 102 home-dwelling older patients on polypharmacy (≥75 
years, using ≥4 medicines continually) living in the Netherlands. 
Method: The analysis of medication-profiles was based on a two-round consensus method. 
Results: When performing medication reviews for older people it seemed that for almost 
all (98%) improvement in pharmacotherapy could be made. For 94% of all patients points 
of attention could be identified in prescribed medicines, of which 30% was considered to 
be of direct clinical relevance. In 61% of all patients a medicine could be added to improve 
pharmacotherapy, 25% of these prescribing omissions were considered to be of direct 
clinical relevance. 
Conclusion: The regular performance of medication reviews should be part of routine in 
primary care as it yields significant numbers of prescription-related points of attention. 
Although they were not all considered to be of direct clinical relevance, all points of 
attention do ask for a signal to the prescribing physician. This paper is not implying poor 
practice or poor reviewing practice but documenting the need for performing regular 
medication reviews. 
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Introduction 
In the Netherlands 14% of the population consists of older people (≥ 65 years old). This 
proportion of the population is responsible for as much as 39% of all expenses on 
medicines as delivered by community pharmacies. People aged 65 years or over use three 
times as many medicines as compared to the whole population in the Netherlands (three 
medicines daily on average). People of 75 years or over use on average as many as four 
medicines daily.1 Older people use many medicines because they suffer from more chronic 
conditions that need treatment by means of pharmacotherapy. However, older people are 
more prone to adverse drug reactions, resulting from age-related factors such as changes in 
drug distribution, metabolism and excretion, and in receptor sensitivity as well as from 
drug–drug interactions and drug–disease interactions caused by prescribing of multiple 
drugs.2–5 In other words, prescribing in older patients involves balancing conflicting 
demands, and the benefit:risk ratio should be considered when deciding whether to initiate 
pharmacotherapy. 
 Although it is not possible to prevent all prescription-related problems in older people, 
several studies have shown that it is possible to reduce the occurrence of prescription-
related problems by means of a medication review.6–9 In such a medication review, 
complete pharmacotherapy of an individual patient is assessed by a trained professional 
(GP and/or pharmacist). In the UK regular medication reviews for older people on long-
term medication were recommended by the Department of Health to maximise therapeutic 
benefit and minimise potential harm,10 and this practice has been included in the 
Community Pharmacy Contractual Framework for all patients on long-term medication in 
the UK.11 
 In this article we describe the occurrence and clinical relevance of prescription-related 
points of attention found in older patients when use is made of an in depth and 
comprehensive approach with medication reviews performed by both prescribers and 
pharmacists. The occurrence of user-related pharmaceutical care problems in the same 
group of older patients had been determined in a previous study,12 creating insight in to 
whether it appears more effective to focus quality improvement interventions on 
prescribers (in particular GPs), or on the users of medicines. 
 This study is the first in-depth analysis by a large expert panel and focuses on a wider 
and more comprehensive set of prescription-related points of attention than previous 
studies have done.13–21 It therefore provides a more complete and accurate picture of the 
size and types of prescription-related points of attention faced by older patients as well as 
the clinical relevance of them. Whether or not precautions were taken by the prescribing 
physician (such as regularly checking potassium levels) to prevent these potential problems 
is not included in this study. However, the results of this study should give some insight in 
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to the process of medication review that can be used for setting up better and more reliable 
medication reviews in the future. 
 
Method 
Study design and population 
An analysis was performed of pharmacotherapy of 107 older people living in the 
community in the southeast of the Netherlands. Pharmacy dispensing data were collected 
from November 2001 to December 2002. The assessment of pharmacotherapy by the 
expert panel was based on a consensus method.  
 Patients were selected from the participants of a study on user-related problems12 with 
298 homedwelling participants of ≥ 75 years old who were being prescribed four or more 
medicines chronically, and were living in the south of the Netherlands. In the previous 
study, nine pharmacies were included (convenience sample). These pharmacies each 
contacted one to three GPs. The pharmacists and GPs invited eligible patients to participate 
in the study: patients were included if they returned the application form, including their 
informed consent. For each GP participating in this study (n = 18), six patients were picked 
at random, resulting in a total of 107 patients (for one GP only five eligible patients could 
be pointed obtained). 
 
Variables and instruments 
Types of prescription-related points of attention. Inappropriate prescribing was assessed 
based on the aspects described in Table 1.  
 
Table 1. Aspects of inappropriate prescribing including examples for each aspect 
 
 Example Description of the problem 
1. Medicine not useful (no indication, no proven 
effectiveness or better/safer alternatives available) 
Prescribing clofibrate, for which much safer and more 
effective alternatives exist 
2. Medicine inappropriate for use in older patients Prescribing diazepam, which has a long half-life time 
3. Prolonged prescribing of hypnotics  Medicine is not taken for a correct duration 
4. Dosage exceeds the suitable dosage for older patients Prescribing flurazepam in a dosage exceeding 15 mg daily 
5. Unnecessary therapeutic duplication Prescribing cylcobarbital and a benzodiazepine 
6. Contraindication known (drug-disease interaction) Prescribing indometacin to a patient suffering from heart 
failure 
7. Medicine used for treatment of a side-effect caused 
by another medicine 
Omeprazole for treatment of stomach problems probably 
caused by ketoprofen (NSAID) 
8. Interaction with another medicine (drug-drug 
interaction). 
Prescribing cotrimoxazol to a patient using acenocoumarol 
(coumarin-derivative) that causes problems in managing 
INR 
9. Omission of drug therapy that is indicated for the 
treatment or prevention of a condition 
Lack of prescribing a laxative to a patient 
10. Medicine used in/provided by unsuitable 
administration aids for older people 
Prescribing different types of inhalation devices to one 
patient  
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Clinical relevance of prescription-related points of attention. Panel members rated the 
clinical relevance of points of attention and prescribing omissions by means of a score 
from zero to three. Points of attention were considered as having clinical relevance if they 
could lead to a deterioration in general health status of the patient (see Table 2). 
 
Table 2. Levels of clinical relevance for prescription related pharmaceutical care problems, including 
examples for each score of clinical relevance 
 
Score Description Example 
0 Aspect is not applicable - 
1 Aspect is applicable, but not clinically relevant Use of vitamin C preparations without an indication 
known 
2 Aspect is applicable and potentially clinically 
relevant; extra information is needed to determine 
the relevancy of these points of attention (such as 
blood pressure, other measurements or clinical 
condition of the patient) 
Drug-drug interaction between digoxin and diuretics, 
when potassium levels are regularly checked this 
interaction will not cause any problems.   
3 Aspect is applicable and clinically relevant; these 
aspects are of clinical relevance in all instances 
Prescribing glibenclamid, which is not suitable for use in 
older patients because it can cause prolonged 
hypoglycaemia 
 
Procedures 
Expert panel. The expert panel consisted of two GPs, two community pharmacists, two 
olderpatient specialised internal medical specialists and two clinical pharmacists. Panel 
members were selected on the basis of their nationally recognised expertise in 
pharmacology and/or clinical older patient pharmacology. 
 
Individual scoring. For each of the 107 participating older patients the panel members 
received a pharmacy record, a graphic medication record, the reasons for prescribing the 
medicines (provided by the GP), and a scoring form, containing all medicines regularly 
taken as determined by pharmacy records and the previously named aspects (see Table 
1).10 The scoring forms were completed and sent back to the researcher by individual panel 
members. Before the consensus meetings, panel members received overviews in which 
their own scores were reflected in the light of the scores of the other panel members. 
 
Consensus meeting. During the consensus meetings aspects of medicines were discussed 
that indicated a lack of consensus or were of clinical relevance. The researcher (a 
pharmacist) selected the points of attention that needed further discussion, including all 
items that had a score of at least six (when taking scores of all experts together) and all 
items that had scored at least a single three (clinically relevant item). An independent 
chairperson led the meeting. Panel members were invited to raise any additional topic that 
they considered of concern.  
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In case panel members were not able to join the meeting the researcher held an individual 
interview with the panel members to discuss his/her scores, and brought it into the 
discussion during the group meetings. 
After the panel meeting, reports of the meeting, made by the researcher, were sent by email 
to all panel members, so that they could give their comments. Issues that remained unclear 
and comments of panel members were discussed again during the next consensus meeting, 
until consensus was reached. 
 
Data analysis. After the panel discussions the scored points of attention (consensus) were 
analysed with SPSS 11 (SPSS Inc. Chicago, Illinois, US), and an inventory of all 
prescription-related points of attention was made. During the panel discussions it seemed 
that a score of 1 was not always used consequently; when an aspect was not relevant it was 
not scored at all. Therefore, in the results, only points of attention with a score of 2 
(potential clinical relevant) or 3 (clinically relevant) are included. 
 
Results 
Consensus meetings 
In total, five panel discussions (four on telephone and one in person) took place during 
which the medications of 107 patients were discussed. On average, there were more than 
six panel members present during the panel discussions (one time, all experts were present, 
one time only five experts were able to participate, for two discussions six panel members 
participated and in one instance seven panel members were present).  
On average, the total panel consensus contained more (and other) points of attention than 
the individual scoring lists. It appeared that each panel member had his/her own area of 
expertise. The individual written score κ value showed a variation for each item and each 
panel member (range 0.01–0.88). The average κ value after the round in writing for all 
items and all panel members was 0.34 (slight agreement). The discussion sometimes 
yielded additional points of attention because of the interaction between panel members of 
different professions. During the consensus meetings, however, consensus was reached for 
all items. 
 
Patients 
In the panel discussion the medications of 107 elderly patients were discussed. After an 
evaluation of medicine use, five older patients were excluded because they used fewer than 
four medicines. The included patients were on average 81 years of age, were almost two-
thirds female (62%), and used on average 6.8 medicines chronically. Forty-one per cent of 
the included patients got their prescriptions only from one physician.  
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In total, 102 older patients used 755 medicines. Medicines for cardiovascular diseases were 
prescribed most frequently (36% of the total number of medicines used), followed by 
medicines for the central nervous system (13%), the alimentary tract and metabolism 
(12%), and blood and blood-forming organs (10%).  
In the medication records of 98% of all patients, points of attention were identified. In 4% 
of these medication profiles the expert panel had no comments on the medicines currently 
used, but one or more medicines could possibly or should be added to improve 
pharmacotherapy. 
 
Number, type and clinical relevance of prescription-related points of attention 
Panel members rated 457 points of attention considering prescribed medicines used by 96 
older patients. Thirty per cent of these recommendations were considered to be of direct 
clinical relevance, the remaining 70% was considered to be of potential clinical relevance. 
The latter category of problems can possibly partly be solved by reviewing the medical 
records (such as measures of potassium or blood pressure), but whether or not these 
measures were regularly performed by the GP was not registered in our study. 
Table 3 shows the distribution of the points of attention by various problem categories.  
Medicines considered as being not useful are reported most frequently, seen in anatomical 
therapeutic classification (ATC) group N (medicines for the nervous system, 21%) and C 
(medicines for the cardiovascular system, 20%). The problem category seen second most 
frequently is prescribing medicines for an incorrect period of time, almost exclusively 
(88%) seen in ATC group N, and prescribing medicines in a dose not appropriate for older 
people, seen in group C (56%) and N (40%). Drug–drug interactions are also reported 
frequently, drug–drug interactions are mainly (57%) caused by medicines from ATC group 
C, medicines for the cardiovascular system. 
 
Table 3  Number and types of prescription-related points of attention (including points of attention with 
potential clinical relevance and points of attention with direct clinical relevance) 
 
Type of prescription related point of attention Number of prescription-related points of attention  
(% of total number of prescription-related points of attention) 
Medicine not useful (no indication, no proven 
effectiveness or better alternatives available)  
76 (19) 
Dose not appropriate for > 75 years 57 (14) 
Incorrect period  57 (14) 
Medicine interaction  55 (13) 
Medicine inappropriate for > 75 years 51 (13) 
Inappropriate administration form or aids 48 (12) 
Medicine used for treatment of side effects of another 
medicine 
27 (7) 
Contraindication known 19 (5) 
Unnecessary therapeutic duplication 18 (4) 
Total 408 (100) 
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Table 4 shows the percentages of medicines out of main ATC groups having at least one 
prescription-related point of attention of potential clinical relevance. The main ATC group 
R (medicines for the respiratory system) is the group with the highest number (relatively); 
this is mainly caused by concerns of panel members about the suitability of the inhalation 
devices for elderly patients, but also about the use of mucolytics. There is some doubt 
whether these preparations are effective. At the time of our study, the leading Dutch Drug 
Compendium (Farmacotherapeutisch Kompas) discouraged the use of oral mucolytics, this 
discouragement is still present in the 2006 edition.22 The panel felt that their use should, at 
the very least, be carefully considered.  
 
Table 4.  Number of recipes within a main anatomical therapeutic classification (ATC)-groupa  
 
Main ATC-Group Number of recipes 
with at least one 
prescription-related 
point of attention (% 
in main ATC-group) 
Total 
number of 
recipes in 
main ATC-
group 
Type of prescription related point of attention seen 
most within the particular main ATC-group 
(percentage in main ATC-group)  
A. Alimentary tract and 
metabolism 
30 (32.3) 93 Medicine for treatment side-effect of other medicine 
(20.5) 
Medicine not useful  (8.7)  
B. Blood and blood 
forming organs 
19 (24.4) 78 Medicine not useful (15.4) 
Drug-drug interaction (8.9) 
C. Cardiovascular 
system 
97 (35.7) 272 Drug-drug interaction (18.0) 
Dose not correct for > 75 years (11.8)  
G. Genitourinary system 
and sex hormones 
8  (66.7) 12 Medicine not useful (41.6) 
Medicine not suitable for  > 75 years (33.3) 
H. Systemical hormonal 
preparations (excl. sex 
hormones and insulin) 
6  (31.6) 19 Unnecessary therapeutic duplication (15.8) 
Medicine not useful (10.6)  
J. Anti-infectives for 
systemic use 
3  (42.9) 7 Length of prescription (28.6) 
Drug-drug interaction (14.3) 
M. Musculoskeletal 
system  
28 (73.7) 38 Drug-drug interaction (26.4) 
Medicine not suitable for > 75 years (26.3) 
N. Central nervous 
system 
65 (65.0) 100 Length of prescription (50.0) 
Medicine not suitable for  > 75 years (27.0)   
R. Respiratory system 58 (90.6) 64 Administration form not suitable for > 75 years (73.4) 
Medicine not useful (20.4) 
S. Sensory organs 4  ( 9.5) 42 Medicine for treatment side-effect of other medicine 
(4.8) 
Length of prescription (4.8) 
a
 with at least one point of attention (including points of attention with potential clinical relevance and points of 
attention with direct clinical relevance), total number of recipes in main ATC-group and a description of the type 
of points of attention seen most (percentage of all points of attention in the main ATC-group) 
 
Main ATC group M (medicines for the musculoskeletal system) is the group with the 
second highest number of points of attention, mainly caused by drug–drug interactions 
caused by NSAIDs (26%), use of hydroquinine or NSAIDs being less appropriate for the 
elderly (26%), and use of NSAIDs when other analgesics are indicated (18%). 
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 In the main ATC group G (medicines for the genitourinary system and sex hormones) 
recommendations were related to medicines for incontinence with a marginally proven 
effectiveness (while leading to side effects) for which alternatives exist causing fewer side 
effects (42%) and inappropriateness for older people because of anticholinergic side-
effects (33%). In group N (medicines for the nervous system) points of attention were 
mainly related to prolonged prescribing of benzodiazepines (50%). Points of attention in 
this group were aimed at prescribing long-acting benzodiazepines that are less suitable for 
use in the elderly (27%) and prescribing drugs —mainly benzodiazepines— in dosages 
exceeding the geriatric daily dose (23%). 
 In some ATC groups, high percentages of prescriptions have at least one 
recommendation. These recommendations can be categorised into specific groups of points 
of attention, more than half of all points of attention can be identified by looking at these 
specific medicines or groups of medicines. 
 
Prescribing omissions 
By reviewing the complete medication profiles, it appeared that 101 medicines might have 
been needed to improve the quality of medication therapy in 62 patients (61% of all older 
patients). Score 2 (a medicine might be added to improve pharmacotherapy depending on 
the general condition of the patient) was scored in 76% of all cases and seen in 52% of all 
older patients. Twentyfive per cent of the omitted medicines had a score of 3, meaning that 
according to prescription guidelines a medicine should be added to improve 
pharmacotherapy. These prescribing omissions were seen in 23% of all elderly patients. 
More than half of all prescribing omissions (60%) were found in main ATC group C 
(medicines for the cardiovascular system), for example, the need of adding an ACE-
inhibitor to pharmacotherapy of an elderly patient with heart failure. Twenty-two per cent 
of the prescribing omissions could be categorised in main ATC group B (blood and blood 
forming organs), such as adding a thrombocyteaggregation- inhibitor to the 
pharmacotherapy of an older patient with angina pectoris. Ten per cent of all omitted 
medicines belonged to main ATC group R (respiratory system); a medicine should 
probably be added to optimise ATSMA/COPD treatment, such as rescue-medication 
(short-acting β2-sympathicomemetica) for the treatment of a patient only using long-acting 
β2-sympathicomimetica. 
 
Discussion 
Summary of main findings 
In this study, prescription-related points of attention of potential clinical relevance were 
found in pharmacotherapy of almost all included patients. One-third of the points of 
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attention found in prescribed medicines were considered to be of direct clinical relevance, 
implying that these prescriptions should be changed unconditionally. The remaining two-
thirds were potentially relevant, meaning that adjustment would depend on clinical 
measurements or specific clinical parameters of the patient, whether or not these 
precautions were taken by the physician was not registered in our study. In addition, the 
panel determined that a relevant medication was missing or potentially missing in almost 
two-thirds of the patients. 
 
Strengths and the limitations of the study 
This study is the first in-depth analysis by a large expert panel and focuses on a wide and 
comprehensive set of prescription-related points of attention. It provides a complete and 
accurate picture of the number and types of prescriptionrelated points of attention faced by 
older patients as well as the clinical relevance of these problems. 
 Our study is not without limitations. First, the patients in our study consisted of a limited 
sample. Although their number was quite high for such a comprehensive method of 
evaluation, some types of prescribing problems — in particular those that occur rarely — 
may be underrepresented. Second, consensus approaches always entail a risk that some 
panel members are more influential than others. Third, our expert panel has identified 
points of attention on the basis of a medication record and the indications for the medicines 
as given by the physician. Our panel had no medical records at their disposal. In most 
instances, regular checks and measurements will be performed by the physician and in 
some instances a second choice medicine will be optimal treatment because other 
medicines will not be tolerated by the particular patient. Our study does indicate a high 
number of points of attention in daily practice. However, a part of these points of attention 
will be dealt with already by means of regular checks. This paper is not implying poor 
practice or poor reviewing practice but documenting the need for regular medication 
reviews. 
 
Comparison with existing literature 
Recommendations were mainly seen in the medicines for the respiratory system, the 
cardiovascular system and the nervous system. Points of attention regarding medicines for 
the cardiovascular system were mainly caused by drug–drug interactions, which were in 
most instances not of direct clinical relevance. In daily practice, high numbers of drug–
drug interactions are seen within this group, and many problems caused by these 
interactions will be prevented by regularly measurements (such as potassium levels or 
blood pressure).23–24 
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 Recommendations regarding medicines for the respiratory tract were mainly aimed at 
the suitability of inhalation devices used for older patients. This is consistent with other 
studies that also found that older patients frequently have problems taking inhaled 
medication,25,12 therefore such a signal to the physician may be relevant. 
 Most points of attention of direct clinical relevance were seen in the group of medicines 
for the central nervous system, which were in particular related to benzodiazepine use. 
Problems included the use for an incorrect period, in dosages exceeding the geriatric daily 
dosage and use of substances with a long half-life time that are not suitable for use in older 
patients. Prolonged use of hypnotics, particularly in the elderly, is a widespread problem, 
as numerous studies concerning inappropriate prescribing for the elderly have 
shown.13,14,20,26 
 In almost two thirds of the patients, prescribing omissions were identified, of which one 
out of four were of direct clinical relevance. Prescribing omissions are only scarcely 
described in studies concerning inappropriate prescribing for the elderly,27 in spite of studies 
that prove that a substantial number of older patients is not receiving omitted but necessary 
pharmacotherapy for established diagnosis.28–31 Prescribing omissions may place older 
patients at higher risk for preventable adverse consequences. Hence, medication reviews 
should point at the quality of complete medication profiles and not only at the quantity of 
drugs prescribed. 
 
Implications for future research or clinical practice 
Over half of detected points of attention recurred in only a handful of drug classes, 
suggesting that medication reviews of older outpatients on polypharmacy may benefit from 
a computerised screening tool. Although such a computerised screening tool could detect a 
large proportion of potential problems, the detection of various other problems in our 
analysis shows that such a tool should be supplemented with a more implicit method of 
assessment. The professional judgement of a complete medication profile by an 
experienced healthcare provider can detect problems that would go unnoticed if one would 
rely solely on computerised screening. The overall κ-value indicated slight agreement after 
the round in writing. All panel members seemed to have their own speciality. During the 
consensus meetings, however, consensus about all aspects was reached. In some instances 
panel members had to make out their case, in other instances consensus was reached 
quickly because other panel members realised they had overlooked a particular problem. 
Another interesting observation (data not shown) was that about 15% of the points of 
attention could only be detected because the panel was not only supplied with the 
medications prescribed but also with the reasons for prescribing them. Together these 
findings raise the possibility that medication reviews ideally should be performed by more 
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than one healthcare professional, ideally of different professions, with the medical record 
at their disposal. Further research is needed to confirm these assumptions. 
 All in all, we conclude that it appears advisable to perform medication reviews for 
home-dwelling older patients by GPs, community pharmacists and other specialists. It 
yields significant numbers of relevant prescription-related points of attention and a 
potential for quality improvement of prescriptions for older patients living in the 
community. 
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Abstract 
The regular performance of medication reviews is prominent among the methods that are 
advocated to reduce the extent and seriousness of drug-related problems, such as adverse 
drug reactions, drug-disease interactions, drug-drug interactions, drug ineffectiveness and 
cost-ineffectiveness. Several screening tools have been developed to guide practising 
healthcare professionals and researchers in reviewing the medication patterns of elderly 
patients, but each of these tools has its own limitations. This review offers a wide range of 
presciption-related, treatment-related and patient-related issues that should be taken into 
account in the implicit reviewing of medication patterns. A broad selection of concrete 
examples and references that can be used as basis for the explicit screening of medication 
patterns in outpatients is also offered.  
 Patients on repeat prescriptions are at risk of experiencing adverse drug reactions, drug-
disease interactions, drug-drug interactions and ineffectiveness, particularly when they are 
elderly. This is due to factors such as polypharmacy, suboptimal monitoring, 
nonadherence, and pathological or age-related physiological changes. The regular 
performance of pharmacy-initiated medication reviews is prominent among the methods 
that are advocated to reduce the extent and seriousness of such problems.1-3 Drug 
treatments should be periodically reconsidered in terms of their adverse effects. 
Randomized controlled trials have partially confirmed that pharmacy-initiated medication 
reviews may have economic as well as clinical benefits, if designed and executed 
appropriately.1;2;4-10 
 In several countries, pharmacists can now claim a fee for conducting medication reviews 
of outpatients. Australian community pharmacists are compensated for home medicines 
reviews under an agreement between the government and the pharmacy guild. In 
cooperation with a general practitioner (who refers the patient), the pharmacist visits the 
patient at home, reviews his or her medications, and provides the general practitioner with 
a report. The general practitioner and patient then agree on a medication management plan. 
The pharmacist’s responsibilities vary, depending on whether he of she is accredited to 
conduct medication reviews.11 In The Netherlands, private health insurance companies 
have recently started to pay a fee to community pharmacists for conducting medication 
reviews of outpatients on polypharmacy.12;13  
 In the UK, The UK Task Force on Medicines Partnership distinguishes four different 
levels of medication reviews (Table 1). Pharmacists in this country are allowed to claim 
payment for so-called medicines use reviews, which aim at improvement of the patient’s 
knowledge and use of drugs by in particular: (a) establishing the patient’s actual use, 
understanding and experience of taking drugs; (b) identifying, discussing and resolving 
poor or ineffective use of drugs by the patient; (c) identifying side effects and drug 
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interactions that may affect the patient’s compliance with instructions given to him by a 
health care professional for the taking of drugs; and (d) improving the clinical and cost 
effectiveness of drugs prescribed to patients thereby reducing the wastage of such drugs.15  
 
1. Objectives 
The growing importance of medication reviews increases the need for adequate guidance 
on how to perform such reviews, particularly in elderly patients with complicated drug 
regimens. The present paper examines prominent existing tools for medication reviewing 
and then presents a new composite tool which supplies: 
1. various general issues that should be taken into account in the implicit reviewing of 
medication patterns;  
2. a broad range of concrete examples and detailed references to examples that can be 
used for the explicit reviewing of medication patterns.  
 
2. Methods 
Our initial search strategy for finding pertinent articles was a free text search on 
“medication review” OR “medication reviews” in Medline through on-line consultation of 
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed; entrez date up to 
Dec 31 2006). We resorted to this free text approach, because Pubmed did not provide a 
specific MeSH term for medication review. Only 141 references were retrieved, many of 
which were judged (on the basis of their title and/or abstract) to be less useful for our 
purposes. More importantly, the search failed to unearth various relevant articles that we 
had uncovered in the course of an earlier literature review on repeat prescribing in 
ambulatory care patients2 and two original studies of prescriber-related and user-related 
drug-related problems in elderly outpatients on polypharmacy.16;17 We therefore 
supplemented our initial Medline search with an incremental search strategy that 
comprised the following elements: 
1. Manual searching of the literature that had already been collected or consulted for our 
earlier studies.2;16;17 As these studies had focused on ambulatory care patients, we 
decided to give our new study the same focus.  
2. On-line searching for additional papers of the research groups that turned out to be 
prominent in the field of medication reviews and related issues.  
3. Manual searching of the bibliography of every useful reference retrieved for additional 
references and iterating this procedure until no more useful references emerged.  
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3. Existing screening tools 
Several implicit and/or explicit screening tools have been developed to guide practising 
healthcare professionals as well as drug utilization researchers in reviewing the medication 
patterns of elderly patients, but each of them has its own benefits and limitations. This will 
be illustrated by discussing some prominent examples below. Generally speaking, implicit 
screening criteria allow a full and flexible clinical judgement of individual drug treatments, 
which can also detect problems that are not prespecified. However, implicit screening 
methods depend heavily on the knowledge, experience and skills of the individual 
reviewer. They may be relatively time-consuming and it can be difficult to apply them 
consistently and to measure outcomes in a valid and reliable way. In contrast, explicit 
screening criteria have the advantages that they can be reliably based on literature review 
and expert consensus, that they can identify and prioritize problems in a consistent way, 
and that they can be easily incorporated in practice computer systems. However, explicit 
screening methods have the disadvantage of an inflexible approach, which leaves 
insufficient room for individual differences between patients and can thereby lead to false 
positive signals (i.e., the signaling that a drug-related problem exists whereas in reality it 
does not exist). Furthermore, explicit screening methods will miss any drug-related 
problem that has not been prespecified and will therefore fail to provide a full assessment 
of the patient. All in all, the combination of implicit and explicit methods can be expected 
to offer a more thorough assessment than each approach separately. The only caveat is that 
such a combined application can be more time-consuming and care should therefore be 
taken to keep this approach sufficiently feasible in daily practice.18 
 
3.1. Beers criteria 
A widely advocated explicit screening tool was introduced in 1991 by Beers and 
associates.19 It was first developed to be used in nursing home patients and consists of a list 
of concrete drugs and drug classes which should generally be avoided in elderly patients. 
These so-called Beers criteria have been very useful for assessing medication 
appropriateness in elderly populations, and they have been widely used for this purpose.20-
23
 When interpreting such data, one should realise that some drugs on the Beers list are 
appropriate for specific patients in certain circumstances.24;25 Furthermore, the original 
Beers criteria focused entirely on the appropriateness of medications in elderly patients 
without addressing other important categories of drug-related problems. In 2003, an 
additional Beers list was introduced that specified certain drug-disease combinations which 
should also generally be avoided in elderly patients.26 While this broadened the scope of 
the Beers criteria, it certainly did not result in a complete set for medication reviewing.  
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3.2. Medication Appropriateness Index 
A well-known example of an implicit screening tool for reviewing medication patterns in 
elderly patients is the so-called Medication Appropriateness Index.27-29 The first version 
was published in 1992 by Hanlon and co-workers30 and a modified version was presented 
by the same group in 1997.31 The Index raises a number of important issues that are not or 
incompletely considered by the Beers criteria: has each medication an indication; is it 
expected to be effective for the patient’s condition; is each dosage correct; are the 
directions for use correct and practical; are there any clinically significant drug-drug 
interactions or drug-disease interactions; is there any unnecessary duplication with other 
drugs; is the duration of therapy acceptable; and is each medication the least expensive 
alternative compared with others of equal utility. Contrary to the Beers criteria, the 
Medication Appropriateness Index does not specify, which drug therapies or drug 
combinations are of primary concern in these domains. Furthermore, even the Medication 
Appropriateness Index does not cover all relevant categories of drug-related problems. For 
instance, it does not address such important issues as adherence to each medication 
regimen7 or the risk that the patient is not receiving a required medication.32;33  
 
3.3. ACOVE indicators 
The so-called ACOVE indicators for Assessing Care Of Vulnerable Elders offer a mix of 
explicit and implicit screening criteria. In 2001, a series of consensus-based sets of 
ACOVE indicators were published as a special issue of the Annals of Internal Medicine. A 
few years later, the results of applying these indicators to assess the quality of medical care 
and pharmacological care for vulnerable elders were presented in the same journal.34;35 
One of the ACOVE sets of indicators focuses on appropriate medication use. It consists of 
12 different indicators, which range from very specific topics (e.g., avoid barbiturates, if 
they are not needed to control seizures; check electrolytes within 1 week of initiating 
therapy with a thiazide or loop diuretic and at least annually thereafter) to very broad 
recommendations (e.g., every new drug should have a clearly defined indication; the 
patient or caregiver should receive education for every new drug about its purpose, how to 
take it, and expected side effects; every vulnerable elder should have a drug regimen 
review at least annually – sic!).32 In addition, various drug therapy-related indicators occur 
in the other ACOVE sets of indicators.36 An example are recommendations in the set for 
the management of osteoarthritis to use acetaminophen as the first drug and to give this 
drug in a maximum dose (considering age and comorbidity) before switching to another 
agent.37 
 Although the ACOVE indicators point out some important aspects of drug therapy in the 
elderly that are neither covered by the Beers criteria nor the Medication Appropriateness 
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Index (e.g., the risk of underprescribing and the need to monitor certain drug therapies 
carefully), neither their range of general drug-related topics nor their selection of drug-
specific indicators provide an exhaustive enumeration.  
 
4. General issues in implicit screening 
Based on our earlier review of the quality management of repeat prescriptions,2 two 
original studies of user-related and prescriber-related problems in elderly outpatients on 
polypharmacy,16;17 and various other papers about general aspects to be considered when 
reviewing medications,3;14;18;26;31;32;36;38-44 we identified a large number of issues that should 
be taken into account in the implicit screening of medication patterns in outpatients.  
 Following the classification of medication reviews by the UK Task Force on Medicines 
Partnership (Table 1), we divided these issues into presciption issues, treatment issues and 
patient issues (Table 2). The next sections will outline these categories one by one, identify 
the general issues in each category, and supplement each general issue with concrete 
examples and/or detailed references to concrete examples.  
 
Table 1 Levels of medication review distinguished by the UK Task Force on Medicines Partnership 
(reproduced with permission from its 2002 report Room for Review14) 
 
Level Description 
0 Ad-hoc 
review 
Unstructured, opportunistic review of a patient’s medication 
E.g., an isolated question to a patient from a receptionist in the surgery or from a pharmacist in the 
community pharmacy. 
1 Presciption 
review 
Technical review of list of patient’s medicines 
This can be helpful in identifying anomalies and highlighting patients who may need clinical 
medication reviews, but as a stand-alone tool its benefits are relatively limited as it does not normally 
allow for a full discussion with the patient. Examples of interventions: include dose and pack 
optimisation, resolving quantity problems, drug presentation issues, and brand to generic switches.  
2 Treatment 
review 
Review of medicines with patient’s full notes  
This normally takes place under the direction of a doctor, nurse or pharmacist, but often without the 
patient – e.g., removal of unwanted items from the repeat medicines list, and dose adjustments. It 
may include the complete repeat prescription or focus on one therapeutic area (eg hypertension), 
drug (eg lithium) or group of drugs (eg NSAIDs). Recommendations may be passed to the prescriber 
for implementation. Examples of outcomes: reducing the number of items, modifying doses. 
3 Clinical 
medication 
review 
Face-to-face review of medicines and condition 
This requires access to the patient’s notes, full record of prescriptions and non-drug care and results 
from laboratory tests etc. It should include the complete repeat prescription as well as over-the-
counter and complementary remedies. In a clinical medication review, medicines are not examined in 
isolation but considered in the context of the patient’s condition and the way they live their lives. The 
review should involve the patient as a full partner (i.e., listening to the patient’s views and beliefs 
about his medicines, reaching an honest understanding of his medicine taking behaviour, and taking 
full account of his preferences in any decisions about treatment. The invitation to a review should 
include both the patient and (when appropriate) the carer. 
A level 3 review involves evaluating the therapeutic efficacy of each drug, identifying and 
addressing unmet therapeutic need, monitoring the progress of the conditions being treated, together 
with purposeful discussion about specific aspects of the patient’s medication to facilitate a 
concordant approach to medicine taking. Clinical medication review may take place in a variety of 
settings including the patient’s home. 
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5. Perscription issues 
Prescription issues often focus on cost reduction. While cost effectiveness is a legitimate 
objective of medication review, it should always be subordinate to improved care and 
safety.14 
 
5.1. Generic substitution 
Consider the possibility that medications may be substituted by cheaper generic 
equivalents  
Generic substitution, which involves the substitution of a medication by a cheaper 
medication with the same active ingredient(s), drug strength(s) and dosage form, can offer 
substantial economic benefits.45;46 It can usually be performed safely, if sufficient attention 
is paid to the following caveats:47-49 
− The risk of inequivalence is smaller, when drug licensing authorities verify 
systematically and rigorously that generic products are bioequivalent to original brand 
products and to each other and it is larger, when this is not the case.48 
− The risk of inequivalence depends on the specific dosage form and specific drug 
substance. Caution is especially needed when the dosage form has controlled-release 
properties50-52 and when the drug substance has a narrow therapeutic index (e.g., 
anticonvulsants, warfarin.53;54 
− Alertness to the occasional possibility that an individual patient is confused by 
differences in outward appearance (e.g., colour, shape, packaging) or in content of the 
package insert.55 A particular concern is the risk of confusion between original brands 
and parallel imported equivalents with different brand names. 
 
5.2. Therapeutic substitution 
Consider the possibility that medications may be substituted by cheaper therapeutic 
equivalents  
A step beyond generic substitution is class substitution, in which medications are replaced 
by cheaper medications with another substance from the same drug class. This type of 
substitution is a pillar under many drug formularies and reference pricing systems, and the 
potential cost savings often seem larger than what can be achieved by generic 
substitution.56;57 However, the pharmacotherapeutic caveats that should be respected to 
guarantee therapeutic equivalence are also of a different order. Drug substances with the 
same mechanism of action may still be different with respect to ancillary pharmacological 
properties, safety profile and/or the risk of drug-drug interactions, which may lead to 
differences in effectiveness, safety, or applicability.58;59;60 For instance, there is substantial 
evidence to suggest that beta-blocking agents are not always equal with respect to their 
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effectiveness61-63 and that the classical NSAIDs show notable variation in their adverse 
reaction profiles.64;65 An additional concern is that studies on clinical endpoints are usually 
not available for all drug substances belonging to the same cardiovascular drug class. Even 
if one assumes that the effects on cardiovascular endpoints are class effects, it may be 
difficult to ascertain which dose levels are appropriate for those substances which have not 
been evaluated in endpoint trials. This is especially a problem, when monitoring on the 
basis of a pharmacological effect (e.g., on cholesterol level or blood pressure) is either 
impossible or inadequately executed.60;66 
 
6. Treatment issues 
The reason for prescribing should be known to the medication reviewer 
A general point with respect to treatment issues is that medication reviewers may identify 
and evaluate certain types of problems only or much easier, when they do not only have 
access to the pharmacy record but also to the medical record. In a recent UK evaluation of 
pharmacist-led medication reviews in patients over 65, the pharmacists detected 18% of the 
drug-related problems by reviewing medical notes (in addition to 52% by looking at 
perscription records and 29% by interviewing patients at home).67 Evidence that the quality 
of a pharmacist-conducted medication review increases, as access to complete patient 
information increases, also comes from a US study of paper cases.68 
 
6.1. Potentially superfluous medications 
Consider discontinuation of medications without well-established effectiveness 
Examples of medications with marginal or questionable effectiveness include: 
1) hydergine and piracetam for dementia or cognitive impairment69;70;  
2) betahistine for Meniere's disease71; most oral vasodilators for intermittent 
claudication72;73;  
3) antispasmodic or anticholinergic agents in irritable bowel syndrome74;  
1) expectorants for acute bronchitis75;76; 
2) long-term use of low-dose oral corticosteroids for stable chronic obstructive pulmonary 
disease (COPD)77;  
3) most phytotherapeutic agents for most indications78;79 and homeopathic agents for any 
indication.80;81  
 
Consider discontinuation of medications without effectiveness and/or valid reason for use 
in the particular patient under review 
Many medications may be stopped in elderly outpatients without the occurrence of an 
adverse drug withdrawal event. However, such withdrawal events are known to occur, and 
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if they do, they result in substantial health care utilization. One should therefore be vigilant 
for disease recurrence, when drug therapy is discontinued in the elderly.82;83 A concrete list 
of drugs that qualify for careful consideration of their discontinuation in the elderly has 
been drawn up by Woodward.41 Well-known examples include: 
1. Loop diuretics. In a study evaluating their use in Dutch community-dwelling patients 
aged 75 years or older, general practitioners considered their continuation unnecessary 
in 19.5% of the patients. The reason for their use was unknown in 8% of the patients, 
and they were used for the controversial indication of ankle edema in another 8%.84  
2. H2-antagonists and proton pump inhibitors. Studies in general populations have shown 
that these acid suppressants are not always used for a valid reason85;86 and that an 
appreciable proportion of chronic users is able to discontinue these drugs.87;88 A recent 
epidemiological study suggests that use of proton pump inhibitors for more than a year 
is associated with an increased risk of hip fracture in elderly users, possibly by 
interference with calcium absorption.89 
3. Cholinesterase inhibitors and memantine. As these agents produce clinically relevant 
effects only in a minority of patients with Alzheimer’s disease,90;91 it is important to 
assess after initiation of therapy which patients respond and which patients do not.92 
4. Anticholinergic medications for the treatment of overactive bladder,41 because their 
clinical benefits may be of questionable significance in many patients.93  
5. Antihypertensive medications in very old patients. The benefits and risks of these agents 
in patients over 80 years of age are still insufficiently clear.94-96 Preliminary results of a 
controlled trial in this age group suggest that the risk of stroke may be reduced but that 
this gain may be offset by extra non-stroke deaths.97 Trials to withdraw or lower the 
dosage of antihypertensive medications in elderly outpatients have shown that this may 
be successful in up to 40% of the patients, when combined with salt restriction and 
weight loss.94 
6. Oral mucolytics. A recent review suggests that treatment with these agents is not cost-
effective in all patients with chronic bronchitis or COPD and that it should be restricted 
to patients with more frequent and severe exacerbations.98 
 
Consider the possibility of potentially inappropriate duplication of drug treatment 
Unnecessary duplications of drug treatment (different brands of the same drug or different 
drug substances from the same therapeutic class) should be avoided.99;100 For instance, the 
concurrent use more than one nonsteroidal anti-inflammatory drug (NSAID) may increase 
the risk of gastroduodenal toxicity.101  
 A particular risk of unnecessary duplication may occur, when drug substances or 
preparations with the same pharmacological effects are applied for different therapeutic 
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reasons, e.g., alpha-blocking agents for hypertension and benign prostatic hyperplasia, or 
norepinephrine/serotonin reuptake inhibitors for depression and urinary incontinence.102 A 
particular risk moment for drug duplication is the period immediately after discharge of 
patients from hospital.103 
 
Consider the possibility that one or more medications may have been added to an existing 
drug therapy to combat an adverse effect of one or more medications already taken 
A new medication may be added to an existing drug regimen to combat an adverse drug 
reaction. This so-called “prescribing cascade” may place the patient at risk of developing 
additional adverse effects relating to this potentially unnecessary treatment. Examples 
include the addition of:104;105 
− An antihypertensive to NSAID therapy (because of a rise in blood pressure);  
− Levodopa to metoclopramide treatment (because of parkinsonian symptoms); 
− An acid suppressant drug to a nitrate or calcium channel blocker (because these latter 
drugs may precipitate gastroesophageal reflux by decreasing lower esophageal sphincter 
pressure);106  
− A cough suppressant to treatment with an ACE inhibitor (because of a dry persistent 
cough107); 
− A cholinesterase inhibitor to drug treatment capable of impairing cognition;108 
− An anticholinergic drug to medications which are capable of inducing urinary 
incontinence,109;110 such as cholinesterase inhibitors for the treatment of dementia.111;112 
The possibility that drug-induced urinary incontinence may have triggered the addition 
of an absorbent incontinence product should also be considered.113 
− A drug for benign prostatic hyperplasia to anticholinergic medications (to combat 
urinary hesitation114). 
In such cases, it should be evaluated whether the causative drug can be withdrawn or 
substituted with another medication that does not have the same adverse effect. 
In the past, the addition of an antigout agent to a thiazide diuretic was also commonly 
listed as an example, but a recent study has cast doubt on the validity of the underlying 
assumption that thiazide diuretics actually increase the risk of gout.115 
 
6.2. Potentially inappropriate medications 
Consider elimination of medications that are potentially inappropriate for the patient 
under review (e.g. because of the patient’s age or because a side effect has developed) 
Since adverse drug effects can have profound clinical and economic consequences for 
elderly patients, Beers and associates have identified a large number of drugs and drug 
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classes that should generally be avoided in the elderly (cf. paragraph 3.1).19;116 The reader 
is referred to Table 1 in the 2003 update of these soc-alled Beers criteria for the most 
recent version.26 A few comments are in order. Firstly, the reasons for including 
nitrofurantoin (potential for renal impairment and  availability of safer alternatives) are 
incorrect.117 It is only true that nitrofurantoin should not be given to patients with renal 
impairment, since antibacterial concentrations in the urine might not be attained, whereas 
the risk of toxicity (peripheral neuropathy, hepatic reactions) is increased.102;118;119 
Secondly, the Beers criteria should not be applied indiscriminately, because there may be 
acceptable reasons, why some of the listed medications are prescribed to elderly patients 
(e.g., low-dose amitriptyline in neuropathic pain.120) Thirdly, the Beers listing is not 
without omissions, if only because it focuses on the medications that are available in the 
United States. Prominent examples of medications that are excluded but should 
nevertheless be considered as potentially inappropriate for the elderly are:  
1) glibenclamide, because its long duration of action can result in prolonged and recurrent 
hypoglycemia in elderly patients121-123; 
2) theophylline (unless its plasma levels can be closely monitored), because it has a 
narrow therapeutic index and because its plasma level is sensitive to reduced clearance, 
underlying diseases and drug-drug interactions124-126;  
3) quinine and hydroquinine, especially when used longer than a few weeks, because their 
modest and variable effects on restless legs or nocturnal muscle cramps are outweighed 
by the risk of adverse reactions, such as cinchonism, thrombocytopenia and 
hemianopsia.102;127-129 
4) Atypical antipsychotics in higher doses, which entail a risk of serious adverse reactions 
in the elderly and in certain conditions (e.g., Parkinson’s disease, dementia).130-132 
 
6.3. Potentially inappropriate dosages 
Consider whether the dosage of each medication is still appropriate 
Compared to the young, elderly patients show a more marked variability in hepatic and 
renal function, and this may be accentuated by differences in intake of food, co-
medications and pharmacogenetic influences. Furthermore, elderly patients may have 
altered sensitivity to anticoagulants, cardiovascular drugs, and psychotropic drugs at the 
pharmacodynamic level.133-136 As a result, individual elderly patients may need reduced 
dose levels so that an initially correct dosage may become less appropriate.25;137;138 
 The need to explore lower doses is particularly relevant for medications with a narrow 
therapeutic index, such as lithium,139 digoxin,140 theophylline,141 metoclopramide,142 
tricyclic antidepressants,143 antipsychotic agents144 sulphonylurea agents,121 dopaminergic 
antiparkinson agents, sedating antiepileptics, opioid analgesics and verapamil.145;146 
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Adjustment of drug dosages to an appropriate geriatric level can also be relevant in the 
absence of a narrow therapeutic index. It has been repeatedly observed, for instance, that 
high dose levels of benzodiazepines in elderly users are associated with an increased risk 
of hip fractures.147;148  
 When low-dose therapy is considered in elderly patients, care should be taken to avoid 
that concerns about side effects lead to an inappropriately low dosage.133;149 This risk is 
illustrated by a North American study, which evaluated patterns of prescription of warfarin 
in frail older people with atrial fibrillation and found that INR levels were maintained 
below the established therapeutic range in 45% of the patients.150 
 When prescribing and dispensing specific geriatric dosages, it should be realized that 
elderly patients may find it difficult to split tablets into two equal halves, even when these 
tablets are provided with a score line. Tablets that already provide the lower dose without 
splitting are therefore preferable.151;152 
 
6.4. Potentially inappropriate duration of treatment 
Consider whether medications are prescribed for an inappropriately long period 
Repeat prescribing without direct doctor-patient contact entails the risk that there is no 
longer adequate control that every repeat prescription is still appropriate, effective and 
well-tolerated, and that it is still being viewed upon and taken by the patient as intended.2 
In a recent US study, excessive duration of drug therapy was one of the five top reasons for 
interventions by pharmacists, which accounted for almost 10% of all interventions.153 A 
special problem with repeat prescribing is that general practitioners (GPs) frequently 
continue drug therapies which have been initiated by medical specialists. Although GPs 
often indicate that this particular part of their prescribing behaviour cannot be changed, 
they have their own responsibility, when repeating specialist-initiated prescriptions.2  
 Prolonged use of antibacterials can be justified for certain indications (e.g., tuberculosis 
or long-term prophylaxis of urinary tract infections), but it may be unadvisable in other 
situations. For instance, repeating antibiotic prescriptions for a lower respiratory tract 
infection should be the exception rather than the rule in general practice.154 Likewise, the 
suggested duration of treatment with an oral anticoagulant after venous thromboembolism 
varies from 5 weeks to indefinite, depending on the type of event and patient-bound risk 
factors.155 
 The Beers criteria advise against the long-term use of stimulant laxatives (e.g., 
bisacodyl, cascara sagrada), except in the presence of an opioid analgesic, and against the 
long-term use of a fully dosed non-selective NSAID with a longer half-life (e.g., naproxen, 
oxaprozin, piroxicam).26 
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 Long-term anxiolytic or hypnotic use of benzodiazepines and related substances is 
limited by serious problems of dependence. Continuation of such use without any attempt 
of drug withdrawal or dose reduction should generally be discouraged.156;157 Strategies for 
discontinuation can be divided into gradual discontinuation programs and minimal 
interventions. The former may be successful in two-thirds of patients from general 
populations, but they are labour-intensive, as they involve gradual tapering of dosage to 
minimize the risk of withdrawal symptoms.158;159 Minimal intervention strategies invite 
patients to stop on their own or to come around for an evaluation consultation (e.g. by a 
letter making them aware of the risks involved). This type of intervention is much less 
labour-intensive, and it is successful in about one fifth or one quarter of patients from 
general populations.158;160  
 
Consider whether medications have been prescribed for an inappropriately short period 
The prescription period of medications should not be too short either. For instance, patients 
with major depression should receive antidepressant treatment for at least 3-6 months after 
an initial response to decrease the risk of relapse or recurrence.161;162 It should be realized, 
however, that a medication review is not an optimal method for assuring an adequate 
minimal treatment period, since it can only identify cases retrospectively, after the use has 
already been discontinued.  
 See also the comments on drug persistence in the paragraph 7.2. 
 
6.5. Drug-disease interactions 
Consider the risk of potentially inappropriate drug-disease interactions 
For listings of drug-disease interactions that are potentially harmful for elderly patients, the 
reader is refererred to McLeod et al.163 and Fick et al.26 The occurrence of such drug-
disease interactions in elderly patients in the US has been studied by Lindblad et al.164 and 
Zhan et al.165 A particular concern in this domain is that strict adherence to current clinical 
practice guidelines (CPGs) may have undesirable effects, when caring for elderly patients 
with several comorbidities. Boyd et al.166 constructed a hypothetical 79-year-old woman 
with five chronic diseases (osteoporosis, osteoarthritis, type 2 diabetes mellitus, 
hypertension, and chronic obstructive pulmonary disease) and discovered that concurrent 
adherence to all five CPGs for these diseases in the US resulted in potential interactions 
between a medication and a disease other than the target disease, between medications for 
different diseases, and between food and medications. They also found that 
recommendations could also contradict one another. If the hypothetical osteoporotic, 
diabetic patient would have had peripheral neuropathy, the osteoporosis CPG 
recommended that she perform weight-bearing exercise, while the diabetes CPG cautioned 
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that some patients with advanced peripheral neuropathy should avoid weight-bearing 
exercise.  
 When clinical information is not available, concurrently used medications may serve as 
more or less suitable surrogate markers of disease states, e.g. insulin for diabetes 
mellitus,167 nitrate prescriptions for ischaemic heart disease,168 and digoxin or amiodarone 
for atrial fibrillation.40  
 Medication reviewers should bear in mind that contraindications may arise long after a 
chronic drug therapy has been established.169 One reason is that the health status of the 
patient can change over time, e.g. because new co-morbidity develops or because the 
patient has grown much older than he was at the start of the treatment. For a US list of 
specific drug-disease combinations that should generally be avoided in the elderly, the 
reader is referred to Table 2 in the most recent version of the Beers criteria.26  
 
Table 2.  General issues in the implicit screening of medication patterns in outpatients 
 
Prescription issues 
- Consider the possibility that medications may be substituted by cheaper generic equivalents 
- Consider the possibility that medications may be substituted by cheaper therapeutic equivalents 
Treatment issues  
- The reason for prescribing should be known to the medication reviewer 
- Consider discontinuation of medications without well-established effectiveness 
- Consider discontinuation of medications without effectiveness and/or valid reason for use in the particular patient 
under review 
- Consider the possibility of potentially inappropriate duplication of drug treatment 
- Consider the possibility that one or more medications may have been added to an existing drug therapy to combat 
an adverse effect of one or more medications already taken 
- Consider elimination of medications that are potentially inappropriate for the patient under review (e.g. because of 
the patient’s age or because a side effect has developed) 
- Consider whether the dosage of each medication is still appropriate 
- Consider whether medications are prescribed for an inappropriately long period 
- Consider whether medications have been prescribed for an inappropriately short period 
- Consider the risk of potentially inappropriate drug-disease interactions 
- Consider the risk of potentially inappropriate drug-drug interactions 
- Consider the risk of potentially inappropriate duplication of adverse effects 
- Consider the possibility that a required medication is inappropriately missing 
- Consider the appropriateness of drug treatment in the light of organ functions, such as renal and hepatic function 
- Consider the appropriateness of drug treatment in the light of electrolyte levels 
- Consider the appropriateness of drug treatment in the light of pharmacogenetic test results 
Patient issues 
- Direct contact between reviewer and patient (or caregiver) offers essential advantages 
- Ask the patient what he knows about his medications and condition(s), which medications he actually takes and 
how he takes them, which beneficial and unwanted effects he experiences, and which queries the patient has 
himself 
- Make adequate room for the patient perspective 
- Consider the possibility that the patient is taking less of the medication(s) than prescribed 
- Consider the possibility that the patient is taking more of the medication(s) than prescribed 
- Consider earlier patient experiences with drugs 
- Consider special patient characteristics and habits 
- Consider the need of special packaging  
- Consider whether the patient is able to self-administer dosage forms that require special skills 
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A new contraindication may also develop when a drug turns out to be less safe than it was 
initially assumed to be. For instance, it has recently become clear that COX-2 inhibitors 
carry such cardiovascular risks that they should not be used in patients with established 
ischaemic heart disease, cerebrovascular disease, or peripheral arterial disease, and that 
caution should be exercised when prescribing these agents to patients with risk factors for 
heart disease, such as hypertension, hyperlipidaemia, diabetes and smoking.170 
 Medication reviewers should pay special attention to the asssessment of relative 
contraindications, which are not strictly forbidden but require careful follow-up to avoid 
unnecessary adverse consequences. A medication review also offers the opportunity to 
check whether any contraindicated drug-disease combination that should already have been 
avoided before the patient started the therapy may nevertheless have been allowed to pass.  
 
6.6. Drug-drug interactions 
Consider the risk of potentially inappropriate drug-drug interactions 
For general background information, the reader is referred to textbooks in this domain.171-
173
 Medication reviewers should be aware that pharmacists have a tendency to assess the 
risk of a drug-drug interaction most thoroughly, before that combination is dispensed for 
the first time.174 There are also drug-drug interactions, however, that do not require strict 
avoidance but should be carefully monitored to prevent adverse consequences (see Table 3 
for a selection).  
 Medication reviewers may also check whether any drug-drug combination has been 
allowed to pass, which should have been intercepted before it was started. Malone et al. 
carefully developed a list of 25 clinically important drug-drug interactions that are likely to 
occur in outpatients and should be avoided as much as possible.176 Application of this 
selection to a large US prescription claims database revealed that 0.8% of the patients had 
been exposed to a drug-drug interaction on the list. The highest prevalence (278.56 per 
100,000 persons) and highest case-exposure rate (242.7 per 1,000 warfarin recipients) was 
found for warfarin plus a nonsteroidal antiinflammatory drug.177 Other publications also 
highlight the need for checking on contraindicated drug combinations163;165;178-180 as well as 
the reasons why they are not always prevented in daily practice.181;182  
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Table 3.  Examples of drug-drug combinations that do not require strict avoidance but should be followed up 
carefully to prevent adverse consequences (after De Gier 2006)175 
 
Drug-drug combination Potential risk Follow-up required 
Digoxine + Loop diuretics or 
thiazide diuretics 
Increased toxicity of digoxin Monitoring of potassium level  
Sulphonylurea derivatives  + 
chloramphenicol 
Increased effect of sulphonylurea 
derivative 
Monitoring of glucose levels 
 
Methotrexate + salicylates or 
NSAIDs 
Increased level of methotrexate and 
risk of decreasing renal function  
Monitoring of renal function, hepatic 
function and blood picture  
Potassium-sparing diuretics + 
potassium supplements   
Increased plasma level of potassium  Monitoring of potassium level 
Hypoglycaemics + isoniazid Decreased glucose tolerance Monitoring of glucose levels 
NSAIDs + ACE inhibitors or 
angiotensin II receptor 
antagonists 
Decreased effect of ACE inhibitor or 
angiotensin II receptor antagonist; in 
patients with heart failure, addition of 
an NSAID may lead to deterioration 
of renal function and an increased 
potassium level  
Depending on indication of ACE inhibitor 
or angiotensin II receptor antagonist:  
- hypertension: monitoring of blood 
pressure  
- heart failure: monitoring of symptoms 
(also by patient)  
Beta-blocking agents + NSAIDs Decreased antihypertensive effects of 
beta-blocking agent 
Monitoring of blood pressure (if NSAID 
is used for longer period) 
Loop diuretics + NSAIDs Decreased effect of loop diuretic  In heart failure: monitoring of symptoms 
(also by patient), renal function and 
potassium level 
ACE inhibitors or angiotensin II 
receptor antagonists + 
potassium-sparing diuretics or 
potassium supplements 
Increased plasma level of potassium  Monitoring of potassium level 
HMG-CoA-reductase inhibitors 
+ ciclosporin, tacrolimus or 
fibrates 
Risk of myopathy and rhabdomyolysis Combined use only under strict 
specialistic monitoring   
Corticosteroids + enzyme 
inductors  
Decreased plasma level of  
corticosteroid   
Adjustment of corticosteroid dosage 
based on clinical picture  
 
Consider the risk of potentially inappropriate duplication of adverse effects 
Drugs from different drug classes may potentiate each other, particularly in the elderly, 
when they have similar adverse effects: 
1. Renal impairment; ACE inhibitors, NSAIDs and diuretics can all impair renal function. 
The demonstrated advantages of these medications should therefore be carefully 
balanced against the risk of inducing renal failure by combining them.183-186;187 Such 
caution is also warranted with respect to angiotensin receptor antagonists187 and Cox-2 
inhibitors.188;189 
2. QT-interval prolongation;190;191 
3. Anticholinergic effects;111;192;193 significant serum anticholinergic activity has also been 
reported for drugs, for which this was not expected, such as theophylline, prednisolone, 
and cimetidine;194  
4. Dizziness, drowsiness, and the risk of falls.195-197 Recent studies suggest that certain 
drugs increase the risk of falls in a modifiable way that is independent of 
comorbidity.198;199 Centrally active drugs which have been associated with an increased 
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risk of falls in the elderly include: anxiolytics, sedatives/hypnotics, antipsychotics, 
antidepressants, and anticonvulsants.197;200;201 Short half-life benzodiazepines are not 
safer in this respect than long half-life benzodiazepines.197;201;202 An important 
cardiovascular drug class which has been associated with falls in the elderly is the class 
of type Ia antiarrhythmics,203 and the risk that diuretics can cause dizziness as a 
consequence of orthostatic hypotension should also be taken into account.198 
5. Confusion or delirium;204;205  
6. Constipation.114;206  
 
6.7. Undertreatment 
Consider the possibility that a required medication is inappropriately missing  
Even when patients are already on polypharmacy, they do not always receive all the drugs 
that are indicated in their condition.16;33;207-209 Examples of missing drugs include: 
1. Acetylsalicylic acid should always be considered in patients with angina pectoris;210;211 
2. Patients on high daily doses of corticosteroids often need a bisphosphonate to protect 
them against osteoporosis;212;213 
3. Laxative therapy is often needed to treat or prevent opioid-induced constipation;214  
4. Elderly users of NSAIDs may need gastroprotective agents, if the NSAID cannot be 
ceased.215-217 
5. Elderly and demented patients with chronic pain may need opioids.218;219 
6. Insulin therapy is not only a treatment option for younger patients with type 2 diabetes 
but also for elderly patients with this disease.220 
There is increasing evidence that elderly populations may benefit as much from certain 
cardiovascular drug therapies as younger adults do, which increases the range of 
medications which may be missing. Relevant examples include: 
1. Not only middle-aged patients but also patients over 70 years of age can benefit from 
statin treatment;221;222 
2. ACE inhibitor use was associated with a significant survival benefit in a retrospective 
study of hospitalized older heart failure patients with perceived contraindications 
(hypotension, renal insufficiency, hyperkalemia, aortic stenosis);223 
3. Warfarin treatment should not be withheld from elderly patients with atrial fibrillation 
who are at high risk of a stroke;224;225 
When patients have several unrelated diseases concurrently, a particular concern is that one 
of these problems may consume attention at the expense of the other problems. There has 
been a Canadian study, for instance, which suggested that patients with diabetes mellitus 
are less likely to receive estrogen-replacement therapy, whereas patients with pulmonary 
emphysema are less likely to receive lipid-lowering medications.226 
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6.8. Use of laboratory test results 
Increasing technological possibilities are making it more and more feasible for healthcare 
providers to access not only their own data file about a patient but also data about that 
specific patient which have been filed by other healthcare professionals. A particularly 
promising development in this field is better linkage between the pharmacy and the 
laboratory.227 Pharmacy-initiated medication reviews are certainly among the 
pharmaceutical services which will benefit from an increased availability of laboratory test 
results. Clinical pharmacists have much experience, of course, with laboratory 
measurements of drug levels for therapeutic drug monitoring and establishing adherence. 
However, other types of laboratory data (e.g., blood lipid levels) can further improve the 
assessment of drug effectiveness and patient adherence. In addition, results from organ 
function tests, blood cell counts, electrolyte and enzyme determinations, etc., will greatly 
advance the evaluation of the drug safety issues that were raised in the preceding sections. 
For instance, concerns about the safety of digoxin in an elderly patient can be substantially 
mitigated by information about renal function.228 
 
Consider the appropriateness of drug treatment in the light of organ functions, such as 
renal and hepatic function 
As medication reviews are often performed in elderly patients, it is important that 
physiological changes in drug metabolism and excretion occur with ageing. Remarkably, 
the metabolic differences with younger adults are not characterized by a similar shift in all 
elderly people but with a sharp increase in the variation between individual patients.134;229 
A quantitative estimate of renal function can be readily obtained by calculating creatinine 
clearance on the basis of serum creatinine, age, gender and weight of the patient. This 
calculated clearance can then be used to adjust the dosage or dosing interval of various 
renally cleared medications.230;231 One should be aware that older patients may have 
impaired renal function despite normal serum creatinine levels and are therefore exposed to 
an increased risk of adverse reactions to hydrosoluble drugs.232 There is evidence to 
suggest that, even when renal function data are available, they are not yet systematically 
applied for establishing the most appropriate dosage regimen.227;233;234 Guidance for this 
type of adjustment can be found in package inserts and pharmacotherapeutic textbooks, but 
an important caveat is that such sources are not yet sufficiently evidence-based.235;236 
 Liver disease can also modify the kinetics of many drugs to an extent that dosage 
adjustment is required. While an analogous method for the simple and reliable 
quantification of hepatic clearance in daily practice is not available, high bilirubin level, or 
low albumin levels can provide qualitative evidence that a dose reduction for hepatically 
cleared medications is necessary.227;237;238 
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 As the kidney and liver are important sites of drug toxicity,189;239;240 renal and hepatic 
function data can also be applied to prevent the injudicious continuation of a nephrotoxic 
or hepatotoxic medication in patients with renal or hepatic impairment.  
 Besides renal and hepatic impairment, there are also other organ dysfunctions that can 
be recognised on the basis of laboratory test results and that can affect drug efficacy and 
drug safety.241;242 For instance, it has been recognised for many years that thyroid disorders 
affect the pharmacokinetics of propranolol and can alter the sensitivity to digoxin, 
anticoagulants and sedatives.243;244  
 
Consider the appropriateness of drug treatment in the light of electrolyte levels 
Certain drug-related risks are substantially magnified by electrolyte abnormalities. For 
instance, hypokalemia predisposes for adverse reactions to digoxin102 and the induction of 
torsade de pointes by such drugs as sotalol and psychotropic agents.245;246 Conversely, 
many drugs are capable of inducing abnormal levels of sodium, potassium, calcium, 
magnesium, or phosphorus.247-250 In recent years, there have been particular concerns about 
drug-induced hyponatremia250;251 and hyperkalemia.252;253 It has been demonstrated, for 
instance, that the addition of spironolactone to an ACE-inhibitor for heart failure entails a 
serious risk of life-threatening hyperkalemia, if potassium level and renal function are not 
closely monitored.254  
 
Consider the appropriateness of drug treatment in the light of pharmacogenetic test results 
Pharmacogenetic test data are likely to become more and more important for assessing and 
predicting drug efficacy and toxicity. This field started with a focus on polymorphisms of 
drug metabolism,255;256 and it is precisely in this domain that practical possibilities to 
improve the dosing of certain drugs (phenytoin, antidepressants, mercaptopurine and 
azathioprine) are emerging or have already emerged.257-261 Pharmacogenetics is rapidly 
expanding, however, to encompass a wide spectrum of genetic variations in 
pharmacokinetic and pharmacodynamic patient profiles.262-264 While the practical 
application of this knowledge still largely lies in the future,265;266 the moment that such data 
will become applicable within the framework of a medication review is coming more and 
more near. It is therefore important to design new systems for improving the availability of 
laboratory data to medication reviewers in such a way that pharmacogenetic test results can 
be taken into account. 
 In this development, pharmacogenetic parameters will only rarely represent a review 
issue in themselves (e.g., factor V Leiden mutation as a contraindication for the use of oral 
hormonal contraceptives267). More often, they will act as risk modifier in an already 
existing review issue, such as the appropriateness of: 
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− Drug choice (e.g., there is increasing evidence that the reponse to SSRIs is partially 
dependent on serotonin transporter promoter (SERTPR) polymorphism268 and that 
antidepressant responses may also vary with other pharmacodynamic polymorphisms269; 
while it would be quite premature to determine such parameters in daily practice to 
predict clinical response, one day this might become a feasible reality);  
− Dose regimen (see the examples given earlier in this paragraph); 
− Drug-drug combination (e.g., allelic variants of CYP2C9 magnify the risk of an 
interaction between oral anticoagulants and NSAIDs270); 
− Drug-herb combination (e.g., St. John’s wort produces a significant increase in 
CYP2C19 activity in extensive CYP2C19 metabolizers but not in poor metabolizers271). 
 
7. Patient issues 
Direct contact between reviewer and patient (or caregiver) offers essential advantages 
For a proper assessment of user-related issues, it is essential to combine the review of 
prescription records and/or medical records with an interview of the patient or caregiver to 
elucidate such aspects as actual medication taking behaviour and experiences of adverse 
effects.2 In a UK intervention including a patient interview, such direct contact was 
considered most influential; potential changes were discussed with the patient to find out 
whether the patient would be intolerant of change. Agreeing suggested changes with the 
patient made implementation less time-consuming for the GP.272 In a US study, 73% of the 
identified problems were recognized only through a patient interview.273 In another US 
study, the longer the contact was between the reviewing pharmacist and patient, the more 
problems were identified and resolved; personal contacts identified and resolved more 
problems than contacts by telephone.274  
 
7.1. Basic issues 
Ask the patient what he knows about his medications and condition(s), which medications 
he actually takes and how he takes them, which beneficial and unwanted effects he 
experiences, and which queries the patient has himself 
Important issues to be raised during the patient consultation include: does the patient know 
what the medications are for; does he remember the dosage of each medication; is he still 
taking each medication as prescribed; is he taking any other medications (including any 
complementary medicines); does he notice any benefits or side effects; and does the patient 
have any queries himself.38 As outlined in the next paragraph, the last issue is certainly not 
the least important one. 
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Make adequate room for the patient perspective 
Medication reviewers assessing the appropriateness of drug therapy should not restrict 
themselves to medical and pharmacological points of view, but should also incorporate the 
patient’s perspective on appropriateness in their evaluation.275;276 For instance, a physician 
prescribing drugs for an elderly patient may be primarily occupied with treating medically 
diagnosed diseases, whereas the patient is more interested in treatment that will reduce 
functional decline and disabilities.277;278 
 According to qualitative research of the patient perspective on medication reviews, 
patients and carers want to tell the reviewer about their personal beliefs, preferences and 
concerns, and they want to verify if they are taking the best medicines for their problems. 
To assure enough room for these needs, they would like to have time specifically set aside 
for the interview; someone to listen carefully to their questions; clear explanations in 
simple language; an open interaction where they could be honest about what they were 
actually taking; and the reviewer’s honesty about the consequences of taking (or not 
taking) their medications.279 Research has also shown that patients can get the most out of 
their medication review if they know in advance why they are coming, what to expect, and 
how to prepare. It is therefore advisable to provide patients who are invited for a 
medication review (or who are eligible for such a review) with education materials about 
these aspects.280 
 Ideally, the patient interview should reflect a good rapport between patient and 
professional reviewer, in which the latter does not consider the interview as an opportunity 
to reinforce instructions around treatment (compliance), but as a space where the expertise 
of patient and professional are pooled to arrive at mutually agreed goals 
(concordance).281;282 It cannot yet be expected that every patient interview turns into such a 
concordant discussion, if only because this depends on the approach and skills of the 
individual reviewer. It is important, however, that each interview is concluded with a 
summary of the agreement with the patient about the treatment and an explanation of what 
will happen next.14 
 
7.2. Non-adherence 
Consider the possibility that the patient is taking less of the medication(s) than prescribed 
Non-adherence to prescribed drug regimens is a common and important problem. 
Depending on definition, detection method and user characteristics, non-adherence has 
been reported to range from 14% to 70%.283-285 Self-determined drug discontinuance 
(which could be conceived as the most drastic form of non-adherence) may occur up to 
40% of the time.286 Recent studies indicate that this non-persistence is a major problem for 
a diversity of drug classes intended for chronic use.287-291 Among the factors that have been 
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associated, at one time or another, with non-adherence are the number of medications, the 
type of drug being taken, prescriptions from more than one doctor, independence when 
taking medicines, impaired cognitive function, probability of dementia, depression, cost of 
medications, insurance coverage, and physician-patient communication.284;285;292-294  
 Non-adherence can be either untentional (the patient cannot manage his medications) or 
intentional (the patient does not want to manage them as prescribed). In the latter case, the 
beliefs of the patient (or caregiver) about illness and drug treatment play a crucial 
role.295;296 A recent synthesis of qualitative research into the main reasons why people do 
not take their medications as prescribed identified a number of important lay themes 
around medication taking.297 According to this analysis, people evaluate their medications 
in their own way and encounter difficulties, when weighing up the benefits of taking their 
medications against the costs of doing so. They place hope in their medications, but a key 
concern is worries about adverse effects. Another concern is about whether a prescribed 
regimen fits in with the patient’s daily life. People may place more faith in their own 
observations and/or in alternative sources of information (e.g., peers, books, internet) than 
in their doctor’s advice. They may find it confusing, if objective indicators show 
improvement while they do not feel any better, or feel worse. They may also find it 
difficult to assess the long-term impact of preventive medications, which makes some of 
them uncertain about whether the medication is really necessary (e.g., antihypertensives). 
Some people have difficulty distinguishing undesirable effects of the medication from the 
symptoms of their disease. There are also worries about medications that lay testing and 
evaluation cannot resolve, such as fears about dependence, tolerance and addiction, about 
masking more serious symptoms, or about the potential harm from taking medications on a 
long-term basis. Another reason why people may not take their medications as prescribed 
is that they do not accept their illness and/or regard medications as an unwelcome reminder 
of that illness. Such people are unlikely to accept their drug treatment as prescribed. For 
instance, some people with asthma downplay its significance, claiming either that they do 
not have real asthma or only a slight form. Such patients may leave their preventive 
medications and only take reliever medications, particularly in social or public situations. 
For certain drug classes (HIV agents, psychotropic drugs) and in certain age groups 
(children), people may fear that disclosing their drug use to others will mark them out as 
being different from their peers, which will lead to stigmatisation or discrimination.297 
As a result of these considerations and concerns, many people alter the way in which they 
take their medications, and they may do so without discussing this with their doctors. They 
may decide not to initiate drug treatment, or to stop taking their medications alltogether. 
They may also start to self-experiment with their prescribed regimens by taking their 
medications symptomatically or strategically, or by adjusting doses to minimise unwanted 
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consequences or to make a regimen more acceptable. Many of these modifications reflect a 
desire to take as little medications as possible, and sometimes this is also evident from 
decisions to supplement or replace drug therapies with alternative or non-pharmacological 
treatments.297 
 An obvious method to assess adherence to drug therapy in daily practice is to look at 
specific clinical effects (e.g. on cholesterol levels or blood pressure). This is by no means a 
feasible option for all drug therapies, however, and measurements performed during 
scheduled patient’s visits do not necessarily provide an accurate picture of the intake 
between visits. Alternatively, it is possible to ask questions to the patient, evaluate 
prescription refill patterns and/or perform pill counts. All of these methods may help to 
detect non-adherence to a certain degree, but they are all prone to a risk of overestimating 
adherence, and their effectiveness varies with the way in which they are executed (e.g., 
whether or not questions are asked in an open-ended, non-judgmental way).298-301 A more 
objective method is direct monitoring of the effects of the treatment (e.g. by measuring 
blood pressure, cholesterol levels, or peak flow), but this is not a viable option for all types 
of chronic medications. Another possibility is electronic monitoring of drug intake by 
providing the medication in a pill bottle with an electronic caps that registers the time of 
each bottle opening. This approach can not only detect different patterns of nonadherence, 
but the mere fact that the patient knows that he is being monitored can stimulate him to 
become more adherent.302;303 This electronic method is not fool-proof, however, as patients 
may take out more than one dose at a time or open the bottle without taking the 
medication.304 Furthermore, experience with such monitoring electronic devices outside the 
strict setting of research studies still is rather limited.305  
 General reviews of interventions to improve medication adherence in chronic patients 
conclude that currently investigated methods are mostly complex, labor-intensive, and not 
predictably effective and that more studies of innovative approaches are still needed.306-308 
Pending the results of more and better studies, it is important in daily practice to tailor 
actions for the prevention and reduction of non-adherence as much as possible to the type 
of non-adherence that is expected or observed: unintentional or intentional. In the latter 
case, the most important prerequisite is that discussions are based on a good rapport 
between patient and interviewer (see the previous paragraph). In cases of unintentional 
non-adherence, the following possibilities should also be considered, depending on the 
specific problem(s) of the individual patient:  
1. Educating patients who are not yet sufficiently aware of the necessity to adhere to their 
prescribed medication regimens  
2. Educating patients about practical ways to improve adherence. For instance, it can be 
rewarding to help patients in selecting cues that will assist them in remembering to take 
74 Chapter 4 
doses (time of day, meal-time, or other daily rituals). If this is ineffective, the 
possibility of providing a compliance aid (such as an auditory or visual alarm) may be 
contemplated.309 
3. Simplifying prescribed dosage regimens, e.g. once-daily or twice-daily instead of  3 to 
4-times-daily310 and fixed-dose combination products instead of separate products for 
each drug substance.311-313 
4. Weekly dispensing in a multi-compartment medication box or other time-specific 
packing.314;315 Concrete evidence that this really increases correct use is still 
meagre,309;316;317 but it has considerable face validity.  
If meaningful, these options can also be combined with each other. In a recent randomized 
controlled trial in the US, a pharmaceutical care program consisting of standardized 
medication education, regular follow-up by pharmacists, and the dispensing of medications 
in time-specific packs increased medication adherence, medication persistence, and 
clinically meaningful reductions in blood pressure.318 
 
Consider the possibility that the patient is taking more of the medication(s) than prescribed 
Besides the risk of underuse, the possibility of overuse must be considered for certain drug 
classes, such as inhaled beta-agoists,319 benzodiazepines,320 opioid cough suppressants,321 
laxatives,322 and triptan derivatives.323 
 
7.3. Patient experiences and habits   
Consider earlier patient experiences with drugs 
Earlier experiences of an individual patient with a particular drug or drug class can be quite 
relevant, when evaluating the appropriatenes of his use of medications. When a certain 
drug has been ineffective or toxic in the past, it is important to prevent injudicious 
reexposure to that particular drug or a closely related one. For example, a previous episode 
of gastrointestinal bleeding or ulcer is a relevant determinant of NSAID-associated 
gastrointestinal toxicity.216;217;324 In other words, when a patient has suffered from an 
NSAID-related gastrointestinal complication, it is not acceptable to restart this NSAID 
under the same circumstances.324;325 Likewise, benzodiazepines should not be restarted in 
ambulant elderly patients with a history of falls.40;156 
 A recent Dutch study identified elderly drug users in whom drug regimens had been 
stopped during their hospital stay at a geriatric ward because of adverse reactions. These 
patients were subsequently followed after their discharge to see whether the stopped drug 
regimens would be reintroduced outside the hospital. The represcription rate was 27% 
within the first six months after discharge. Represcription rates were not markedly different 
for serious or nonserious adverse drug reactions or for adverse drug reactions mentioned or 
 A composite screening tool 75 
not mentioned on the discharge letter.326 It must therefore become easier to exchange and 
record patient experiences in a standardized way so that they can be systemically taken into 
account in computerised medication surveillance systems and medication reviews. 
 
Consider special patient characteristics and habits 
It can also be relevant to document diverse patient characteristics that may affect drug 
effects or drug intake, e.g., tobacco smoking,327 a predilection for natural remedies,78;328 
religious beliefs that stand in the way of using porcine derived drug products,329 strict 
adherence to the Ramadan rule of abstaining from any food, beverage, or oral drug from 
dawn to sunset,330;331 and so on.  
 A patient characteristic which particularly deserves more attention than it has received 
so far is nutritional status, since nutritional deficiencies entail a risk of serious food-drug 
interactions. Frail elderly people are especially at risk, because they may accrue several 
risk factors, such as malnutrition, anorexia, alcoholism, chronic disease, and 
polypharmacy.133 On the one hand, impairment of nutritional status can have a major 
impact on the pharmacology of many drugs in the frail elderly, devolving from the 
physiological alterations it generates. On the other hand, drugs often have, directly and 
indirectly, a deleterious effect on the nutritional status of the elderly.332 A list of 
medications which can be associated with undesired weight loss in older adults has been 
compiled by Golden et al.333 
 
7.4. Dosage forms and packaging 
Consider the need of special packaging  
It should be recognized that some patients may have difficulty opening foil-wrapped or 
plastic-wrapped dose units, for instance because they have a rheumatic disorder.334;335 
When a patient seems to be unable to cope with the complexity of his drug-taking 
regimens, weekly dispensing in a multi-compartment medication box may be contemplated 
(cf. paragraph 7.2). 
 
Consider whether the patient is able to self-administer dosage forms that require special 
skills  
Many patients find it difficult to split tablets into two equal halves, even if the tablets are 
provided with a score line.151;152  
 Patients may also lack adequate skills to self-administer certain dosage forms accurately 
due to age-related or disease-related deficits in cognitive skills, memory or physical 
dexterity. A good example is the difficulties that elderly patients may have in using their 
inhaler device correctly.336 As their perception of their own inhaler skills may not correlate 
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with actual performance, it is important to ask patients to demonstrate the appropriateness 
of their inhaler technique.337 In one study, failure to shake the device, poor coordination of 
actuation and inhalation and absence of breath holding were the most common errors.338 In 
another study, major errors were more common with breath-actuated devices.337 
Unrecognized cognitive impairment or dyspraxia may render elderly patients unable to 
learn to use an inhaler, and patients with dementia are almost invariably unable to use any 
form of inhaler.339 Another concern is that many patients with asthma or COPD are treated 
with two or three different types of inhalation devices, which may complicate their 
competence to use each device correctly.340 
 Patients may also experience difficulties with the application of their eye drops, even to 
the point that self-administered drops may not fall into the conjunctival sac. There are 
appliances that can help to improve instillation, but care should be taken to select a device 
that links up with the problem area of the individual user (e.g., alignment or 
squeezability).341-343 In addition, it should be checked whether chronic patients continue to 
use the appliance when their eye drop bottle is replaced by a newly dispensed bottle.344 
A third potentially worrisome dosage form is the insulin injection.315 Many elderly patients 
with diabetes cannot perform self-administration of insulin, because of their poor dexterity, 
vision or cognitive skills.345 In addition, users of NPH insulin run a risk that they do not 
mix this suspension adequately.346;347 
 
8. Concluding remarks 
We collected various general issues for the implicit screening of medication patterns and 
grouped them into prescription issues, treatment issues, and patient issues (Table 2). These 
groups parallel the ongoing development of the pharmaceutical profession from a drug 
product orientation through drug therapy orientation to drug user orientation.348 
 We provided the general issues with numerous explicit examples and detailed references 
to other explicit examples, not only to facilitate the education of professional medication 
reviewers, but also to spark further research into the clinical, humanistic and economic 
aspects of current drug utilization patterns. We incorporated recent technological 
developments, such as better linkage between the pharmacy and the laboratory and the 
increasing range of pharmacogenetic testing possibilities. We also argued, however, that 
medication reviewers should not restrict themselves to a clinical perspective, but should 
also side with the patient so that his perspective at drug-related problems is also taken into 
account adequately. Because at the end of the day, it is the patient who has to cope with his 
drug therapy, and it is the patient who is in the driver’s seat, when decisions are made 
whether or not medications are taken as directed. 
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 One final point to be raised here is the need for more studies of medication reviews 
looking at relevant outcomes. Studies that actually document clinical and humanistic 
improvements after a medication reviews are still scarce.1;2;349-352 Some studies have shown 
favourable trends9 or significantly positive results,5;353 but other studies have found no 
influence on quality of life or rehospitalization,2;10;354 and even a negative effect on the rate 
of hospital admissions has been reported.10 Further well-designed studies are needed to 
explain such counterintuitive findings, and they should also identify which specific 
methods of medication review are the most effective and cost-effective. 
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Abstract 
Background: More strict control of blood glucose can decrease or delay the onset of 
microvascular complications of diabetes mellitus. A potential consequence of this more 
vigorous treatment is an increased risk of hypoglycaemia.  
Aim: To study the incidence of and risk factors for hypoglycaemia during antidiabetic drug 
therapy in an elderly population. 
Design and setting: Prospective cohort study in a sample of the Rotterdam Study, a 
population-based cohort study of 7,983 elderly people. 
Method: All users of antidiabetic medicines were followed until they experienced a 
hypoglycaemic event (hospital admission or blood glucose of 3.5 mmol/ml in GP 
laboratory testing), died, left the study, or reached the end of the study period. For each 
treatment group (only oral antidiabetics, only insulin or a combination of oral antidiabetics 
and insulin) incidence rates of hypoglycaemia were determined.  
 The influence of the co-factors age, sex, renal function, body mass index (BMI), type of 
hypoglycaemic agent, polypharmacy, use of selective or non-selective beta-blocking 
agents, medicines acting on the renin-angiotensin system or medicines influencing 
CYP2C9 was determined for the total group of users and for users of sulfonylurea 
derivatives. Subsequently, cofactors with a univariable association were entered into a 
multivariable model in which a forward selection of significant cofactors was performed. 
Results: Hypoglycaemic events are seen in 1 out of 12 patients during the study period. 
The risk was four times higher in insulin users with or without oral agents (39.1 and 39.0 
per 1000 person years) than in users using only oral antidiabetics (9.9 per 1000 person 
years).   
 Renal impairment, higher age, polypharmacy, and use of insulin were significantly 
associated with an increased risk of hypoglycaemia in the total group of antidiabetic users, 
whereas use of tolbutamide was associated with a decreased risk in this group.  
 Use of higher numbers of medicines, use of glibenclamide, and use of medicines having 
an influence on CYP2C9 were associated with an increased risk at hypoglycaemic events 
for users of sulfonylurea derivatives, whereas tolbutamide appeared to be associated with a 
decreased risk.  
 In the multivariable analyses use of insulin and renal impairment remained significant 
for all users of hypoglycaemic agents. Use of tolbutamide and use of medicines having an 
influence on CYP2C9 remained significant for users of sulfonylurea derivatives.  
Conclusion: Elderly users of antidiabetic medicines are at risk of developing 
hypoglycaemia. As this risk is greater in insulin users than in users of oral antidiabetic 
drugs, it seems particularly relevant that elderly insulin users can adequately recognize and 
rectify upcoming hypoglycaemic events. As the risk of hypoglycaemia is also greater in 
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elderly users of glibenclamide than in users of tolbutamide, the latter sulfonylurea 
derivative is the drug of choice in this drug class. Finally, more attention should be paid to 
interactions between sulfonylurea derivatives and CYP2C9 modifying drugs (such as co-
trimoxazole). 
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Introduction 
Diabetes mellitus is a disease in which treatment is shifting. Large trials have shown that 
more strict control of blood glucose can decrease or delay the onset of micro-vascular 
complications associated with diabetes mellitus 1,2. The practice guideline for treatment of 
type II diabetes mellitus of the Dutch College of General Practitioners starts drug treatment 
with oral antidiabetics (preferably metformin), when blood glucose levels do not decrease 
to an acceptable level a combination of oral antidiabetics is prescribed (addition of a 
sulfonylurea derivative). When blood glucose levels are still too high or when the disease 
is progressing, insulin is added to the therapy 3-5. A potential consequence of this more 
vigorous treatment of diabetes mellitus is an increased occurrence of hypoglycaemic 
events. Recent studies in the Netherlands and elsewhere have shown that hypoglycaemic 
events during antidiabetic drug therapy are among the important causes for drug-related 
hospital admissions 6-8. 
 In the literature a number of risk factors for hypoglycaemic events have been described, 
such as age 9-11, recent hospital discharge 9, duration of diabetes 12-14, renal impairment 10, 
infection 10, polypharmacy 9,14, smoking habits 15, decreased food intake 10,16, drugs 
interacting with hypoglycaemic agents 10,15-17, and type of hypoglycaemic drug 9,10,14.  
Sulfonylurea derivatives are metabolised by CYP2C9 18-21, and users with a variant 
genotype may be at increased risk for hypoglycaemia 22. A recent study has shown that 
patients who are carriers of a CYP2C9*3 allele require lower doses of tolbutamide to 
regulate their serum glucose levels than patients with the wild-type genotype 17. At the 
same time, medicines inhibiting CYP2C9 can increase the effect of sulfonylurea 
derivatives 23, probably leading to hypoglycaemia.  
 Because data from the literature are conflicting, we studied the incidence of and risk 
factors for hypoglycaemia during antidiabetic drug therapy in a large prospective cohort 
study of elderly users of hypoglycaemic agents. 
 
Methods 
Setting 
This study was conducted as a part of the Rotterdam study 24, a prospective population-
based cohort study on the occurrence and determinants of disease and disability in elderly 
people. In 1990, all inhabitants of Ommoord, a suburb of Rotterdam in the Netherlands, 
who were 55 years or over and who had lived in the district for at least 1 year were invited 
to participate in the study. Of the 10,275 eligible persons 78% participated. Participants 
gave informed consent and permission to retrieve information from medical and 
pharmaceutical records. Base-line examination was performed between 1990 and 1993. At 
baseline, trained interviewers administered an extensive questionnaire during a home 
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interview covering socio-economic background and medical history, among other topics. 
During subsequent visits to the study centre, additional interviewing, laboratory 
assessments, and clinical examinations were performed. Follow-up examinations are 
carried-out periodically (every 5 years). Data on hospital admissions are obtained by record 
linkage with Prismant, an organisation which collects admission data from all general and 
academic hospitals in the Netherlands. For every admission, one discharge diagnosis 
(mandatory) and up to 9 auxiliary diagnoses (optional) are given based on the ICD9-CM 
classification 25. Information on vital status is obtained at regular time intervals from the 
municipal authorities in Rotterdam. Since January 1st, 1997, data from the General 
Practitioners laboratory, where all laboratory testing for the GPs in the region is performed, 
have also been linked to the Rotterdam study database.  
 The medical ethics committee of the Erasmus Medical Center, Rotterdam, the 
Netherlands, approved the Rotterdam study.  
 In the research area there are 7 fully computerised pharmacies linked to one network. 
During the study, all participants filled 98% of their prescriptions in 1 of these 7 
pharmacies. From the moment a participant enters the Rotterdam study data on all drug 
prescriptions dispensed by automated pharmacies are routinely stored in a database. The 
data include the date of prescribing, the prescribed daily number of units, Anatomical 
Therapeutic Chemical Classification (ATC) code 26, and product name.  
 
Cohort definition 
For the present study, we enrolled all participants of the Rotterdam Study who were on one 
or more antidiabetic drugs at the start date of our study period (1 January 1997) as well as 
incident users who received their first prescription of an antidiabetic after this date. All 
users were followed from the start date of the study or from the date of their first 
prescription of an antidiabetic drug during the study period until they experienced a 
hypoglycaemic event, died, left the study, or reached the end of the study period at 30 June 
2005, whichever came first.  
 
Case definition  
Patients with a first diagnosis of hypoglycaemia during the study period were defined as 
cases. Hypoglycaemia was defined as a blood glucose level of 3.5 mmol/ml or less as 
assessed by the GP’s laboratory, or as a hospital admission with the ICD-code 251.0 
(hypoglycaemic coma) or 251.2 (hypoglycaemia).The day of the first diagnosis of 
hypoglycaemia was defined as the index date. 
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Cofactors 
Apart from age and sex, we studied the role of renal function, body mass index (BMI), type 
of hypoglycaemic agent, and concurrent drugs as potentially important confounders or risk 
modifiers. Renal function of the included patients was determined by means of serum 
creatinine levels according to Cockcroft and Gault 27, renal impairment was defined as a 
creatinine clearance of less than 60 ml/min, including moderate, severe and complete renal 
failure of the guidelines of the (American) National Kidney foundation (K/DOQI) 28,29. 
Body mass index (BMI, weight of a person related to the square length of this person) was 
categorised as BMI< 25 versus BMI> 25.  
 Drug use was defined as current if the index date fell within the prescription length of 
that drug. Hereto, the prescription length of each drug was calculated as the number of 
filled tablets/capsules divided by the prescribed daily number. Because the following drugs 
are associated with an increased risk at hypoglycaemia, we recorded whether they were 
used in the period of 90 days before the index-date: selective or non-selective beta-
blocking agents 30,31, medicines acting on the renin-angiotensin system (ACE-inhibitors or 
AII-antagonists) 32,33. Because for some of the medicines an increased risk has been 
observed at the start of therapy, we distinguished between starters (<30 days current use), 
recently started users (30-90 days current use) and long-term users (> 90 days current use). 
The number of prescriptions for any drug in the period of 90 days before the index date 
was recorded. For each index date, this was categorised by patients having less than 10 
prescriptions and patients having 10 or more prescriptions dispensed in the period of 90 
days before the index date.  
 Because sulfonylurea derivatives are metabolised by CYP2C9 18,20,21 we studied the 
effect of CYP2C9 genotype of the study participants, in which individuals with genotypes 
CYP2C9/2*3 and CYP2C9/3*3 were categorised as slow metabolisers 19.  
 To study the specific effects of medicines influencing CYP2C9, we also studied the use 
of CYP2C9 inhibitors and other substrates for CYP2C9 23 in the period of 90 days before 
the index-date: nateglinide (A10BX03), rosiglitazone (A10BG02), amiodarone 
(C01BD01), losartan (C09CA01), irbesartan (C09CA04), fluvastatin (C10AA04), co-
trimoxazole (J01EE), fluconazole (J02AC01), voriconazole (J02AC03), isoniazid 
(J04AC01), tamoxifen (L02BA01), phenylbutazone (M01AA01), diclofenac (M01AB05), 
piroxicam (M01AC01), meloxicam (M01AC06), ibuprofen (M01AE01), naproxen 
(M01AE02), celecoxib (M01AH01), probenicid (M04AB01), phenytoine (N03AB02), 
amitriptyline (N06AA09), fluvoxamin (N06AB08), sertraline (N06AB06) and fluoxetine 
(N06AB03). Analyses were performed for use of the individual drugs in this group and for 
use of any medicine influencing CYP2C9 in the period of 90 days before the index date.   
 
 Drug-induced hypoglycaemia in elderly users of antidiabetic agents 97 
Statistical analysis 
The incidence rate of hypoglycaemic events was determined separately for subjects using 
only oral antidiabetics, for users of insulin alone, and those who were using both on the 
index date. The incidence rate was calculated by dividing the number of hypoglycaemic 
events in the particular treatment group during follow-up by the cumulative amount of 
person years treatment in the particular groups on the index date. Incidence rates were 
converted as numbers per 1000 person years treatment. We calculated the hazard ratio 
(95% confidence intervals) of each cofactor as described above, both for the total group of 
users and for users of sulfonylurea derivatives, in a Cox proportional hazards model (SPSS 
12.0 software ltd). In our analyses calendar time in days was used as the time axis.  
 For all cofactors we studied whether there was a univariable association with 
hypoglycaemia in an age- and sex-adjusted model. Risk factors that were based on 3 
exposed cases or less were discarded as being insufficiently reliable. Effect modification 
was studied with interaction terms in a multivariable model. If statistically significant, 
analyses were stratified on the effect modifier. Subsequently, cofactors with a univariable 
association were entered into a multivariable model in which a forward selection of 
significant cofactors was performed (p=0.05).  
 
Results    
Study population at baseline 
In the database 784 users of antidiabetics could be identified. Their mean age was almost 
74 years and 59.7 per cent of the patients were women. About 22 per cent of this 
population was suffering from renal impairment, and about 80 per cent of the population 
had a body mass index of 25 or more. 
 There were 447 individuals with the wild type (*1/*1) of CYP2C9 (66.9%). The 
remainder had either one or two *2 or *3 variant alleles. Twelve patients (1,8%) were 
identified as slow metabolisers for CYP2C9 having the CYP2C9 genotypes *3/*3 or 
*2/*3. 
 At baseline almost 83 per cent of the included subjects was treated with oral 
antidiabetics only, 13.5 % of the population was treated with insulin only and almost four 
per cent of the population was treated with a combination of insulin and oral 
hypoglycaemic agents (Table 1). 
 For 66 of the 784 included subjects, a hypoglycaemic event was registered during the 
study period (8.4%). Ten of these subjects were admitted to a hospital because of 
hypoglycaemia, the remaining 56 cases had a blood glucose level of 3.5 mmol/ml or less 
during GP laboratory testing.  
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Table 1.  Characteristics of the study population at baseline  
 
Variable Number of patients (%) 
Age at base-line (mean + SD) in years 73.82 (7.84) 
Female gender 468 (59.69) 
Body mass index (mean + SD) in kg/m2   (n=710) 28.24 (3.93) 
Body mass index < 25 in  kg/m2  (n=710) 136 (19.2) 
Renal impairment (creatinine clearance < 60 ml/min) (n=533)  117 (21.95) 
> 10 prescriptions dispensed in 90 days before baseline 108 (13.78) 
CYP2C9 2*3 or 3*3 genotypes (slow metabolisers) (n=668) 12 (1.80) 
Any use of any medicine influencing CYP2C9 during study period 425 (54.21) 
Any use of tolbutamide during study period 255 (32.53) 
Any use of glibenclamide during study period 173 (22.07) 
Any use of glimepiride during study period 165 (21.05) 
Any use of gliclazide during study period 80 (10.20) 
Antidiabetic use 
- Only oral antidiabetics 
- Using insulin  
- Using insulin and oral antidiabetics 
 
647 (82.53) 
106 (13.52) 
31 (3.95) 
 
Table 2 shows that the highest incidences of hypoglycaemia occurred in the groups of 
patients using insulin with or without oral hypoglycaemic agents (39.1 and 39.0 per 1000 
person years, respectively). The incidence for subjects using only oral antidiabetics was 
about one fourth of that of insulin users (9.9 per 1000 person years), a statistically 
significant difference (HR 3.9 [95%CI: 2.3-6.6]). 
 
Table 2. Incidence of hypoglycaemia for all users of antidiabetics and for the subgroups 
  
 Person years 
of treatment 
Total number 
hypoglycaemic 
events (cases) 
Incidence 
(per 1000 person 
years) 
95% confidence 
interval 
Total group  3729.2 66 17.7 13.8-22.3 
Using only oral antidiabetics 2730.7 27 9.9 6.6-14.2 
Using insulin 768.4 30 39.0 26.9-55.0 
Both insulin and oral antidiabetics 230.1 9 39.1 19.3-71.4 
 
Influence of cofactors   
Table 3 shows an increased incidence of hypoglycaemic events in antidiabetic users with 
higher age, renal impairment, polypharmacy and use of insulin. In contrast, the use of 
tolbutamide was associated with a decreased risk of hypglycaemia (ORadj 0.16; CI95% 
0.04-0.66). Significant effects were seen for use of use of amitriptyline and sertraline, 
because of the low number of cases (3 cases and 1 case respectively) these cofactors were 
discarded as being insufficiently reliable. 
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Table 3  Factors associated with the risk at hypoglycaemic events for the total group of users of antidiabetics. 
All co-factors (see methods) were tested, only results with significant results and with a sufficient 
number of cases were included in the table 
 
Risk factor No. of cases Odds Ratio 
(95% CI) 
Adjusted Odds Ratio* 
(95% CI) 
Age 75 years or over 
- No 
- Yes 
 
15 
51 
 
Reference 
1.952 (1.096-3.477) 
 
n.a. 
Renal impairment (n=533) 
- no 
- yes 
 
28 
15 
 
reference 
1.964 (1.045-3.689) 
 
Reference 
2.005 (1.008-3.989) 
> 10 prescriptions dispensed in 
period 90 days before index date 
- No  
- Yes 
 
 
46 
20 
 
 
Reference 
2.195 (1.297-3.716) 
 
 
Reference 
2.129 (1.257-3.606) 
Use of insulin 
- No 
- Yes 
 
27 
39 
 
Reference 
2.504 (1.527-4.105) 
 
Reference 
3.083 (1.846-5.148) 
Use of tolbutamide 
- No 
- Yes 
 
64 
2 
 
Reference 
0.169 (0.0410.692) 
 
Reference 
0.160 (0.039-0.657) 
*  sex and age adjusted 
 
Factors that were significantly associated with hypoglycaemia in users of sulfonylurea 
derivatives are presented in Table 4. Renal impairment, which was associated with 
hypoglycaemia in all users of antidiabetics did no longer show a significant association in 
users of sulfonylurea derivatives. On the other hand, having 10 or more prescription in the 
period of 90 days before the index date was also associated with an increased risk of 
hypoglycaemia in these users. Use of glibenclamide, a long acting sulfonylurea derivative, 
appeared to increase the risk of hypoglycaemic events, as did the use of medicines having 
an influence on CYP2C9. On the contrary, use of tolbutamide appeared to be associated 
with a decreased risk at hypoglycaemia. Significant effect modification was seen for use of 
glibenclamide and use of medicines having an influence on CYP2C9, so odds ratios were 
adjusted for this interaction effect. 
 Significant effects were seen for use of cotrimoxazole (2 cases), amitrityline (2 cases),  
sertraline (1 case) and recent start (< 30 days current use) of ace-inhibitors (3 cases), 
because of the low number of cases these cofactors were discarded as being insufficiently 
reliable. 
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Table 4  Factors associated with the risk of hypoglycaemic events in sulfonylurea derivative users. All co-
factors (see methods) were tested, only associations with significant and a sufficient number of cases 
were included in the table. 
 
Risk factor No. of cases Odds Ratio 
(95% CI) 
Adjusted Odds Ratioa 
(95% CI) 
> 10 prescriptions in period 90 days before index date 
- No 
- Yes 
 
19 
10 
 
Reference 
2.250 (1.089-5.072) 
 
Reference 
2.315 (1.055-5.079) 
Use of tolbutamide 
- No 
- Yes 
 
27 
2 
 
Reference 
0.153 (0.037-0.650) 
 
Reference 
0.148 (0.035-0.625) 
Use of glibenclamid 
- No 
- Yes 
 
11 
18 
 
Reference 
2.434 (1.141-5.192) 
 
Reference 
2.347 (1.093-5.041)  
Use of  medicines having an influence on CYP2C9  
- No 
- Yes b 
 
19 
10 
 
Reference 
2.790 (1.294-6.015) 
 
Reference 
2.662 (1.230-5.759)  
a
 sex and age adjusted 
b medicines having an influence on CYP2C9; cotrimoxazole two cases, ibuprofen two cases, amitriptylin two 
cases, rosiglitazone one case, sertralin one case, losartan one case, amiodarone one case   
 
Table 5 shows the factors that remained significant in multivariable analyses. For all users 
of antidiabetics use of insulin and renal impairment remained significant in the multivariate 
model, both factors leading to an more than two-fold increase in the risk at hypoglycaemic 
events. For users of sulfonylurea derivatives use of tolbutamide and use of medicines 
having an influence on CYP2C9 both remained significant. Tolbutamide gave a decreased 
risk at hypoglycaemic events whereas use of medicines having an influence on CYP2C9 
increased this risk. 
 
Table 5  Factors associated with risk at hypoglycaemic events at multivariate level. All cofactors that were 
significant in univariable analyses were included in the analyses, selection of cofactors was performed 
in a forward and backward procedure 
 
All users of antidiabetics Users of sulfonylurea derivatives Risk factor 
No. of cases Odds Ratio 
(95% CI) 
No. of cases Odds Ratio 
(95% CI) 
Renal impairment (n=533) 
- no 
- yes 
 
28 
15 
 
reference 
2.090 (1.112-3.931) 
 
- 
 
- 
Use of insulin 
- No 
- Yes 
 
19 
24 
 
Reference 
2.438 (1.329-4.474) 
 
- 
 
- 
Use of tolbutamide 
- No 
- Yes 
 
- 
 
- 
 
27 
2 
 
Reference 
0.155 (0.037-0.653) 
Use of medicines having an 
influence on CYP2C9  
- No 
- Yes 
 
- 
 
- 
 
 
19 
10 
 
 
Reference 
2.774 (1.286-5.986) 
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Discussion 
Summary of main results 
The current study shows that hypoglycaemic events can be seen in a relatively high 
proportion of patients treated with antidiabetics, namely in 1 out of 12 users of 
antidiabetics, with an incidence of 17.7 per 1000 person years (table 2). The risk was four 
times higher in insulin users, with or without oral agents (39.1 and 39.0 per 1000 person 
years) than in users using only oral antidiabetics (9.9 per 1000 person years).   
 Of the risk factors that were associated with an increased risk of hypoglycaemia in the 
univariable analyses, use of insulin and renal impairment remained significant in the 
multivariable analyses for all users of hypoglycaemic agents. For users of sulfonylurea 
derivatives the increased risk associated with the use of medicines having an influence on 
CYP2C9 remained significant. In contrast, tolbutamide remained associated with an 
decreased risk of hypoglycaemia.  
  
Comparison with literature 
The incidence of hypoglycaemic events has been studied before by others. In a study by 
van Staa et al. in which a first diagnosis of hypoglycaemia in a GP database was the 
endpoint, a higher incidence was found for users of sulfonylurea derivatives (17.77 per 
1000 person years). Subjects using insulin as co-medication were also included in this 
group of patients, which may explain that the incidence of hypogylcaemia was higher than 
that in our study 34. 
 In a study by Stahl et al. a much lower incidence was found (0.92 per 1000 person 
years) for users of sulfonylurea derivatives. In this study, however, only cases of severe 
hypoglycaemia leading to hospital admissions had been included 16.    
 A study performed by Shorr et al. observed incidence rates comparable to the ones we 
found (12.3 for sulfonylurea-users, 27.6 for insulin users and 33.8 for users of both 
sulfonylurea derivatives and insulin)9,35. However, this study also used serious 
hypoglycaemia (defined by hospitalization, emergency department admission, or death 
associated with hypoglycaemic symptoms) as endpoint.  
 Like us, others have found that higher age9-11 and renal impairment10 are associated with 
an increased risk at hypoglycaemic events. However, in our analyses renal impairment no 
longer had a significant effect when we looked specifically at users of sulfonylurea 
derivatives.  
 We confirmed previous findings that the use of higher numbers of medicines is a risk 
factor 9,14. When we specifically looked at use of medicines influencing CYP2C9 by users 
of sulfonylurea derivatives, we also saw an increased risk at hypoglycaemia. This was also 
found by others, Juurlink found that elderly patients using glibenclamide who were 
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admitted with a diagnosis of hypoglycemia were more than 6 times as likely to have been 
treated with co-trimoxazole in the previous week (adjusted odds ratio, 6.6; 95% confidence 
interval, 4.5-9.7) 36. An increased risk of hypoglycaemia in users of sulfonylurea 
derivatives taking sulfonylurea-potentiating drugs has also been observed in other studies 
14,34
.  
 We confirmed that hypoglycaemia is more common in patients using glibenclamide than 
in patients using shorter acting sulfonylurea derivatives 14,16,35,37-39. This increased risk for 
glibenclamide is caused by its metabolites which have blood glucose lowering properties 
and have long half-life times 37-39.  
 Twelve subjects (1.8%) in our study were identified as slow metabolizers for CYP2C9. 
This percentage falls in the range of 1-3% poor CYP2C9 metabolizers that has been found 
for Caucasian populations in previous studies 22,23. In the present study we could not 
identify an increased risk of hypoglycaemia for CYP2C9 poor metabolizers. Possibly, this 
was caused by the rather small group of subjects in combination with the fact that 
genotyping was not performed for all subjects included in the study. In contrast, another 
study with an even smaller number of cases found a significant association between 
CYP2C9 slow metabolizer genotypes and severe hypoglycaemia 22. In this latter study two 
of the twenty cases (10%) had a CYP2C9 poor metabolizer genotype and five cases (25%) 
were treated with CYP2C9 inhibiting medicines. So more research on the potential effects 
of CYP2C9 poor metabolizer genotype and CYP2C9 inhibiting medicines is warranted. 
 
Limitations of the study  
Although we tried to perform our study as reliably as possible there were some limitations 
to our study. Firstly, not all variables included in our analyses were completed for all 
subjects (e.g. CYP2C9 genotyping and renal impairment), these missing values may have 
influenced the results of our analyses.  
 Secondly the number of cases and included patients were rather small. For some 
cofactors we saw an association, but because of the small number of cases (1-2) and the 
low frequency of some of the cofactors (e.g. use of particular medicines, CYP2C9 slow 
metabolisers) we could not state with certainty that there actually was an association. 
These analyses should be repeated in databases containing larger numbers of diabetic 
patients, using all kinds of medicines. 
 Furthermore, patient characteristics were copied to our database as they had been 
recorded in the Rotterdam study database. These patient characteristics may not have been 
updated systematically during the study period. Yet some of these patient characteristics do 
not necessarily remain constant over a larger period of time (e.g. renal function, BMI etc).  
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Finally, we did not focus our analyses on hospital admissions related to hypoglycaemia but 
also included milder cases (blood glucose values measured in the general practitioners 
laboratory of < 3.5 mmol/ml). Subjects with low blood glucose levels as measured at the 
general practitioners laboratory may not have acute complaints, but they may be at 
increased risk of more serious hypoglycaemic events. In addition, GPs will use portable 
blood glucose measuring equipments in acute situations, these values were not included in 
our study. Furthermore, our study did not take in that more experienced diabetic patients 
may selfadminister a source of glucose to cope with an upcoming hypoglycaemic event. 
Hence, the incidence of hypoglycaemic events as determined in our study is probably an 
underestimation of the total number of hypoglycaemic events in the study population. 
Because these effects concern the whole population of diabetic patients, it is unlikely that 
they have had a large influence on the estimates as determined in our study.    
  
Recommendations for daily practice and further research  
Recent developments aim at more strict control of blood glucose levels and insulin 
treatment in type II diabetes is started easier than a few years ago. We have confirmed that 
elderly users of insulin are at increased risk of hypoglycaemic events. Consequently it 
seems important that these users can adequately recognize and rectify upcoming 
hypoglycaemic events. In the Netherlands, this aspect could be a focus of attention for the 
practice nurses that are nowadays guiding most elderly patients who are starting insulin 
treatment. 
 Renal impairment was associated with an increased risk of hypoglycaemic events, 
although this increased risk lost its significance when we looked specifically at the group 
of sulfonylurea derivative users. For patients with renal impairment lower insulin dosages 
are needed in comparison with patients with a normal renal function 40. In the elderly, in 
general, renal function is diminishing. The average glomerular filtration rate in the elderly 
is declining with age, with a large interindividual variability 41. Furthermore, diabetic 
patients are at risk of developing nephropathy which may further decrease their renal 
function 42.  
 In our study we saw an increased risk at hypoglycaemic events for users of 
glibenclamide (18 cases based on a total of 173 glibenclamide users 10.4%), whereas for 
tolbutamide a much lower risk of hypoglycaemia was observed (2 cases based on a total of  
255 tolbutamide users, 0.78%). Although most guidelines and handbooks mention this risk, 
glibenclamide still was frequently used in our (elderly) study population. Because of the 
lower risk for hypoglycaemia, tolbutamide remains the drug of choice when elderly have to 
be treated with sulfonylurea derivatives.  
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 About a third of all cases in the users of sulfonylurea derivatives appeared to be 
associated with drug drug interactions at the CYP2C9 level. The interaction between 
sulfonylurea derivatives and co-trimoxazole (especially tolbutamide) is routinely 
monitored by only one of the three main medication surveillance systems in Dutch 
community pharmacies. They state the interaction is caused by a combination of CYP2C9 
inhibition and protein displacement. This system advises to dispense an alternative 
antibioticum if possible, but also allows the dispensing of co-trimoxazole provided extra 
precautions are taken. (e.g. inform the patient about symptoms and treatment of 
hypoglycaemia)43. In our study 31 patients were concomitantly using sulfonylurea 
derivatives and co-trimoxazole, of which two were suffering from hypoglycaemia.  
 We also found evidence to suggest that sulfonylurea derivatives may interact with other 
drugs than co-trimoxazole having an influence on CYP2C9 (ibuprofen, amitriptylin, 
rosiglitazone, sertralin, losartan and amiodarone). These other interactions are not yet 
routinely monitored by Dutch medication surveillance systems, so more research in this 
field is warranted.   
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Abstract  
Background: Older people are prone to problems related to use of medicines. As they tend 
to use many different medicines, monitoring pharmacotherapy for older people in primary 
care is important.  
Aim: To determine which procedure for treatment reviews (case conferences versus written 
feedback) results in more medication changes, measured at different moments in time. To 
determine the costs and savings related to such an intervention.  
Designof study: Randomised, controlled trial, randomisation at the level of the community 
pharmacy. 
Setting: Primary care; treatment reviews were performed by 28 pharmacists and 77 general 
practitioners (GPs) concerning 738 older people (>75 years) on polypharmacy (≥ 5 
medicines). 
Methods: In one group, pharmacists and GPs performed case conferences on prescription- 
related problems; in the other group, pharmacists provided results of a treatment review to 
GPs as written feedback. Number of medication changes was counted following clinically- 
relevant recommendations. Costs and savings associated with the intervention at various 
times were calculated. 
Results: In the case-conferences group significantly more medication changes were 
initiated  (42 vs 22, p = 0.02). This difference was also present 6 months after treatment 
reviews (36 vs 19 p = 0.02). Nine months after treatment reviews, the difference was no 
longer significant (33 vs 19 p = 0.07). Additional costs in the case-conferences group seem 
to be covered by the slightly greater savings in this group.  
Conclusions: Performing treatment reviews with case conferences leads to greater uptake 
of clinically-relevant recommendations. Extra costs seem to be covered by related savings. 
The effect of the intervention declines over time, so performing treatment reviews for older 
people should be integrated in the routine collaboration between GPs and pharmacists. 
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Introduction 
Many older people suffer from chronic diseases for which medicines should be used. Older 
patients are more prone to problems related to their medicines because of the higher 
number they use, and because of a decline in cognitive and physical functioning. A 
previous study found that two-thirds of all older people have problems using their 
medicines correctly; and that these problems could lead to a deterioration in clinical 
condition for one of four older patients1. Another study by the current authors found that 
there are prescription-related points of concern, possibly leading to a deterioration in 
clinical condition, in the pharmacotherapy of almost all older patients studied; for example, 
using diazepam, a benzodiazepine with a long half-life and hence unsuitable for use by 
older people. These problems were considered to be of direct clinical relevance in 30% of 
patients2. Th current intervention study focuses on prescribing medicines for older patients, 
rather than on user-related problems.   
 Monitoring pharmacotherapy for older people in primary care is important. One possible 
approach is the use of treatment reviews for individual patients by trained professionals 
(for example general practitioners (GPs), clinical or community pharmacists, or two 
healthcare professionals of different professional backgrounds together). While earlier 
studies have shown that treatment reviews can be useful3-6, supplementary studies are still 
needed to evaluate the comparative effectiveness of various models for treatment reviews7.  
 This study compared two procedures for treatment review by a team consisting of a 
community pharmacist and a GP. In one group (termed the case-conference group) the 
pharmacist and GP personally discussed problems, as identified in the pharmacotherapy of 
the patient through academic detailing or case conferences, and drew up a pharmaceutical 
care plan for each patient. In the other group (termed the written-feedback group) the 
pharmacist passes the results of a treatment review to the GP as written feedback. The 
former procedure may produce more and better results, but also could be more time 
consuming and costly, and require more organisational activity.  
 Effects and cost differences were determined at 6 and 9 months after the intervention. 
Furthermore, yearly savings in medicine costs for each year the medication change 
persisted were determined. The investigators were particularly interested in the medication 
changes made in response to clinically-relevant recommendations made by the pharmacist 
to the GP. 
 
Method 
Study design 
The study was a clustered, randomised, controlled trial. Pharmacists in both intervention 
arms conducted treatment reviews. Written feedback only was given to the GPs in one 
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group. In the other group, the pharmacist and the GP had personal contact in a case 
conference in which a pharmaceutical care plan was drawn up for each patient. Treatment 
reviews were performed between March and May 2004.  
 Randomisation across the intervention arms was at the level of the community 
pharmacy. Each pharmacy included GPs in only one of the intervention groups, so that 
contamination of the effect was prevented. 
 The unit of analysis was the GP (who prescribed the medicines that were evaluated in 
the treatment review). Patients were considered to be nested within general practices. On 
the basis of a power calculation using an intra-cluster correlation coefficient of 0.03 
(deduced from the researchers’ in-depth analysis of polypharmacy for older people2), and 
with the aim to detect a difference of 10% in medication changes following the 
recommendations between the groups 8, an estimated sample of at least 20 pharmacies, 
each associated with 3 GPs with 10 participating patients for each GP, was required.  
 
Study population: participating healthcare professionals and their patients) 
In this intervention study, Service Apotheek Nederland, a franchise organisation 
supporting independent community pharmacies in their professional activities, supported 
this research with their organisational skills. All pharmacies registered with Service 
Apotheek Nederland (N = 120) were invited to participate in the study. Participating 
pharmacies each contacted three GPs (convenience sample). Ten home-dwelling older 
people (aged ≥ 75 years), registered by one GP, who were using at least five prescription 
medicines continuously at the start of the study were selected at random from a large 
database in which community pharmacy dispensing data are collected.  
 Pharmacy codes for these patients were presented on a secure web page that was only 
accessible to the participating pharmacist. The pharmacist had to exclude older patients 
who were terminally ill, deceased, lived in a home for older people, younger than 75 years, 
or used fewer than five medicines continuously; this could be done online. If patients were 
excluded, new patients were presented on the web page as long as these patients met the 
criteria. 
 
Computerised screening tool for detecting suboptimal prescribing for older people 
The Foundation for Pharmaceutical Statistics (SFK) collects pharmacy dispensing data 
from 90% of the community pharmacies in the Netherlands. The SFK gathers these data in 
an anonymous format: only patient codes are recorded to safeguard the privacy of patients. 
This allows the SFK to reconstruct utilisation patterns of individual patients without any 
danger of exposing the patients identities9. 
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 A computerised screening tool was designed to search the SFK records for suboptimal 
prescribing for older people. This computerised screening tool was an aid for participating 
pharmacists: they could obtain the results of these searches (as performed in January 2004) 
on a secured website. Because the pharmacists have to send dispensing files from the 
pharmacy system to the SFK database at the end of a month, the SFK always has a delay in 
the database. The searches were performed in the database including the data of January 
2004. Searches were not updated during the study period. Pharmacists received a graphical 
representation of the pharmacy record of each participant and a list of potential problems 
identified by the computerised screening tool. This information lists the Anatomical 
Therapeutic Chemical  code10 of the medicine(s) causing the problem, a description of the 
problem, and some directions for potential improvement. 
 
Intervention 
All participating pharmacists were invited to attend a training session dealing with 
problems related to medication use in older people and treatment reviews. After this 
training session, pharmacists were randomised and the pharmacists in both intervention 
groups performed treatment reviews with the support of the computerised screening tool. 
They had to decide which of the recommendations highlighted by the computerised 
screening tool should be given to the GP, and whether additional recommendations 
concerning the pharmacotherapy of these patients should be highlighted. 
 The two intervention groups differed in their organisational models (Figure1): 
− Written-feedback group: pharmacists listed all recommendations per patient and 
delivered them to the GP’s office. The pharmacist did not follow up cases.  
− Case-conferences group: the pharmacist and GP discussed all recommendations with 
each other, including other concerns about the patients (if any). The pharmacist and the 
GP together filled in a standardised pharmaceutical care plan, in which they addressed 
who was responsible for the activities in this plan. Three months later the pharmacist 
checked whether these activities had been carried out.  
 
Variables and instruments 
Medication changes following clinically-relevant recommendations  
Researchers determined how many clinically-relevant recommendations were made by the 
pharmacist; and determined the number of medication changes consistent with these 
recommendations that could be detected in the medication records. To verify that 
differences in the number of medication changes were not caused by variation in the 
number of recommendations made, a secondary outcome measure was used that relates the 
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number of recommendations followed to the number of recommendations made: the 
percentage of clinically relevant recommendations leading to medication changes.   
 
Figure 1.  Flow diagram of the intervention study comparing two procedures for medication reviews of older 
people on polypharmacy in primary care 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A copy of the list of recommendations that the pharmacist made for each patient was sent 
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medication changes had been maintained, and whether results of the recommendations as 
proposed could be identified in drug-use profiles and pharmacy records (for example, is the 
drug used for the right indication? Is blood pressure checked regularly?). If the researchers 
could not determine whether action had been taken in response to a recommendation was 
considered to have not been acted on.  
 After 9 months, researchers recorded whether medication changes that were present at 6 
months had been maintained. It could not be assumed that medication changes initiated 
more than 6 months after the treatment reviews were caused by the intervention, so these 
medication changes were not included.  
 
Clinical relevance of recommendations by pharmacists 
Clinical relevance was assessed for all recommendations (as they were identified by the 
computerised screening tool or by pharmacists) that were communicated to GPs.  
Recommendations were classified as:  
− Clinically relevant: recommendation will lead to improvement in the general health of 
the patient. 
− Potentially relevant: for example, relevance depending,on the medical condition of the 
individual patient. 
− Clinically irrelevant: recommendation will not lead to improvement in the general health 
of the patient. 
 
For most of the recommendations identified by the computerised screening tool, clinical 
relevance was based on an earlier in-depth analysis of pharmacotherapy2, while for some 
of the remaining problems it was based on the literature11,12. For the recommendations that 
the pharmacists identified themselves, clinical relevance was based on the previous in-
depth analysis2 or was determined by an expert panel during the present study.  
 The expert panel consisted of a GP, a community pharmacist, a geriatrician, and a 
clinical pharmacist who were chosen because of their experience in geriatric 
pharmacology. The expert panel did not include individual members of the participating 
pharmacies or general practices. Clinical relevance was determined using a consensus 
method. Panel member had to fill in their individual opinions regarding the clinical 
relevance of each recommendation. Panel members received overviews in which their own 
scores were compared with those of the other panel members. During a consensus meeting 
on the telephone, panel members discussed all differences until they reached consensus 
about the clinical relevance of each particular recommendation. 
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Changes in costs of medicines used 
For each medication change, the difference in medication costs at 6 and 9 months after the 
treatment review was determined. Researchers determined the differences in medication 
costs if the medication changes, persisting until 9 months after the intervention, would 
persist for another 12 months. Differences in medicine costs were determined by adding 
the costs of the medicines and the dispensing fees for the pharmacy following legal 
regulations (15-days prescriptions for all new medicines, followed by 3-month 
prescriptions for all medicines, except hypnotics for which the legal maximum prescription 
period is 30 days). Supplemental costs caused by wastage were not included in the 
calculations.  
 
Time consumed by this intervention 
Participating healthcare professionals were asked to keep a separate time log of all 
intervention activities for each patient. This time log was used to calculate the costs of the 
treatment reviews (at an assumed rate of 50 euros per hour for each healthcare 
professional, analogous to another study in the Netherlands13). 
 No reimbursement was given for participation in the study. Participating pharmacists 
were invited to a training session in which medication-related problems and the process of 
treatment reviews concerning older people were dealt with. Pharmacists were offered free 
use of the computerised screening tool.   
 
Data analysis 
Baseline characteristics of the participating healthcare professionals and participants in 
both intervention groups were compared using X2 tests for dichotomous values and 
Student’s t-tests for differences in means of numerous values.  
 The type of problem, directions for improvement, origin (computerised screening tool or 
pharmacist) and clinical relevance for each recommendation passed on to the GP were 
entered into a Microsoft Access database. Whether recommendations were acted on, 
partially acted on, or not acted on at all at the various times of measurement, was also 
recorded in this database. Actual changes in costs associated with the interventions were 
also recorded in this database. The database was analysed using SPSS (version 12.0).  
 Because patients in this study were nested within general practices, researchers analysed 
the number of medication changes following clinically-relevant recommendations at the 
level of GP. For each GP the total number of recommendations acted on was determined. 
Because the number of recommendations followed by the different GPs was not normally 
distributed, differences between groups were determined using X2 statistics at this level. 
Before X2 statistics could be performed, the number of recommendations followed was 
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categorised (zero, one or more than one recommendation followed). Multilevel (mixed 
model) analysis was performed to determine whether differences in costs and in 
percentages of recommendations followed were present. A model with a random intercept 
and all other variables fixed was used. Multilevel analyses were performed using SAS 
(version 8.2)14 .  
 
Results 
Study population 
Of the 120 pharmacies invited, 29 (with 84 accompanying GPs; three pharmacies could 
only find two GPs to take part in the study) were included in the randomisation. Four GPs 
were subsequently excluded for different reasons. During the intervention period, one 
pharmacy in the written-feedback group dropped out (along with three accompanying GPs) 
because they could not find the time to deliver the pharmacy dispensing data of patients to 
the research team.  
 Data for 28 pharmacies were gathered and added to the database (13 written feedback 
and 15 case conferences) accompanied by data for 77 GPs. A total of 738 patients were 
included (351 in the written-feedback group and 387 in the case-conference group).   
 Before the 6-month assessments, but after the treatment review, 37 patients were 
excluded for various reasons (Figure 2). In the period between 6 and 9 months, 16 
participants were excluded. 
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Figure 2.  Inclusion and exclusion of participants and patients in RCT comparing two procedures for 
medication reviews concerning home-dwelling elderly people on polypharmacy in primary care 
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Table 1 shows the characteristics of the participating pharmacists, GPs, and their patients. 
The patient and pharmacy characteristics for the written-feedback group and the case-
conference group were comparable. Of the GP characteristics, only the number of single-
handed practices was unevenly distributed among intervention groups.  
 
Table 1.  Characteristics of  participating patients, GPs, and pharmacies  
 (Student t-test for differences in continuous values and Chi-square statistics for binominal values)   
 
Characteristics Feedback in writing Case conferences 
Pharmacies  13 15 
Pharmacists employed in the pharmacy 2.0 1.9  
Percentage of elderly patients ( >75 years) at the pharmacy 8.9 %  13.4 %  
Percentage of pharmacies with 350 or more prescriptions a day1  58.3 % 71.4 %  
General practitioners 372 403 
Percentage of single-handed practices 59.3 32.4 *  
Number of patients in practice4 3168 3279  
Percentage of patients 75 years or older in general practice 10.6 % 13.5 %  
Patients  351 387 
Age of patients (in years) 81 81  
Percentage of men 34.9 % 40.6 %  
Average number of medicines used by participants (as measured 
by the computerised screening tool) 
7.3 7.1  
* p=<0.05 
1
  Two pharmacists did not answer the question about the daily number of prescriptions, evenly divided over both 
intervention groups 
2 We received 27 questionnaires from GPs in the written feedback group (73% response) 
3 We received 37 questionnaires from GPs in the oral feedback group (93% response) 
4
  Seven GP’s did not answer the question about the number of patients in practice, three in the feedback in writing 
group, four in the group with case conferences 
 
Number and clinical relevance of recommendations as presented to GPs  
Participating pharmacists made a total of 1569 recommendations regarding the  
pharmacotherapy of 624 participating patients; no recommendation was given for 114 
(15.4%) patients. The computerised screening tool identified 62.0% of the 
recommendations that were passed on to the GPs; the pharmacists themselves identified 
38%. Pharmacists in the case-conference group identified significantly more 
recommendations themselves than the pharmacists in the written-feedback group (41.7% 
versus 34.2%, p = 0.003). 
 Table 2 shows the number and types of recommendations presented to GPs. The 
recommendations were categorised by clinical relevance. Some recommendations with 
limited clinical relevance were made (3.4%); for example, prolonged use of vitamin 
preparations without an indication. Many recommendations with potential clinical 
relevance were made (77.3%); for example, performance of regular checks. Most clinically 
relevant recommendations were about prescribing the correct geriatric dosage (104 
recommendations), followed by prescribing medicines considered unsuitable for use by 
older people (99 recommendations), and prescribing omissions (34 recommendations). 
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 The mean number of recommendation per patient made by the pharmacists in the case-
conference group seemed to be higher than that in the group with written feedback; 
however, this difference was not statistically significant (p=0.059). 
 
Table 2.  Numbers, types, and clinical relevance of medication recommendations from the pharmacist to the 
GPs  
 
Feedback in writing 
(percentage within category 
of clinical relevance) 
Case conferences 
(percentage within category of 
clinical relevance) 
Type of 
recommendation 
Not 
clinically 
relevant 
Potentially 
clinically  
relevant 
Clinically 
relevant 
Not 
clinically 
relevant 
Potentially 
clinically  
relevant 
Clinically 
relevant  
Example of clinically relevant 
recommendation 
Dose unsuitable for 
75+ 
1 (4.8) 51 (9.5) 62 (42.2) 0 73 (10.8) 42 (26.9) Use of more than 20 mg of 
temazepam daily 
Medicines not 
suitable for 75+ 
2 (9.5) 18 (3.3) 35 (23.8) 0 14 (2.1) 64 (41.0) Use of glibenclamide, which can 
cause prolonged hypoglycaemia 
Medicine not useful 
at all 
7 (33.3) 27 (5.0) 17 (11.6) 4 (12.5) 32 (4.7) 15 (9.6) Use of meprobamate, for which 
safer alternatives are available 
Prescribing 
omissions 
4 (19.0) 29 (5.4) 16 (10.9) 5 (15.6) 43 (6.4) 18 (11.5) Omitting to prescribe osteoporosis 
prophylaxis for a patient using 
high doses of corticosteroids for a 
long period   
Incorrect duration 
of therapy  
2 (9.5) 10 (1.9) 7 (4.8) 0 6 (0.9) 3 (1.9) Prolonged use of hypnotics 
Unnecessary 
therapeutic 
duplication 
0 39 (7.3) 3 (2.0) 1 (3.1) 40 (5.9) 5 (3.2) Simultaneously use of different 
benzodiazepines 
Form of medication 
not suitable for the 
elderly 
0 12 (2.2) 3 (2.0) 2 (6.3) 16 (2.4) 0 Use of immediate release 
nifedipine capsules 
Suitable for the 
indication? 
0 53 (9.9) 2 (1.4) 0 111 (16.4) 3 (1.9) Patient uses an oestrogen 
preparation regularly used for 
complaints caused by  menopause 
Adherence ( too 
much or too little 
use) 
1 (4.8) 57(10.6) 1 (0.7) 1 (3.1) 74 (10.9) 2 (1.3) Patient uses more oxazepam than 
prescribed 
Contra-indication 
known 
2 (9.5) 9 (1.7) 1 (0.7) 6 (18.8) 12 (1.8) 3 (1.9) Use of amiodarone by patient 
suffering from hypothyreosis 
Drug-drug 
interaction known 
1 (4.8) 60(11.2) 0 0 60 (8.9) 0 - 
Treatment of side 
effect of other 
medicine 
0 84(15.6) 0 2 (6.3) 77 (11.4) 0 - 
Others 1 (4.8) 88(16.4) 0 11 (34.4) 118 (17.5) 1 (0.6) Use of a combination of amlo-
dipine and losartan for a patient 
with oedema. Stop amlodipine and 
increase losartan dosage  
Total 21 (100) 537(100) 147 (100) 32 (100) 676 (100) 156 (100) - 
Number of rec. 
per patient  
0.06 1.53 0.42 0.08 1.75 0.40 - 
Total number  705 864 - 
Number of rec. 
per patient 
 2.01   2.23  p=0.059 
Difference=0.229 
95% CI -0.467-0.009 
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The pharmacy assistants could not determine from the pharmacy records whether 883 of 
the recommendations presented in table 2 (56.3% of all recommendations) had been acted 
on or not. Most problems concerned doubts about the correctness of the indication and 
doubts whether routine checks were performed.  
 In the comparisons that followed, only the 303 recommendations with direct clinical 
relevance were included. For 18 recommendations problems were solved or the particular 
medicine had been discontinued before the intervention started; these recommendations 
were excluded. Another 16 recommendations were excluded from the 6-month 
measurement because the particular patients were excluded from the study. Thus, 269 
recommendations were included in the analysis of the 6-months measurement. A further 
five recommendations were similarly excluded for the 9-months measurement, leaving 264 
recommendations.   
 
Medication changes following clinically-relevant recommendations made by 
pharmacists 
Table 3 presents the number of medication changes following clinically-relevant 
recommendations. Significantly more medication changes were initiated in the case- 
conference group than in the written-feedback group (42 vs 22, p = 0.02). This difference 
is also present in the maintained medication changes at 6 months after the treatment 
reviews (36 vs 19, p = 0.02). For medication changes maintained until 9 months after the 
treatment review, the difference between the groups was no longer significant (33 vs 19, p 
= 0.07).  
 
Table 3.  Number of medication changes following recommendations with clinical relevance  
 
Medication changes Time 
written feedback, n Case conferences, n 
X2 
p-value 
Measurement at 0-6 months and 6-months 128 141 - 
0-6 months after medication reviews (initiated 
medication changes, all attempts, whether or 
not sustained) 
22 42 p=0.016 
6 months after medication review (sustained 
changes) 
19 36 p=0.022 
Measurement at 9-months 126 138 - 
Changes sustained until 9 months after 
medication review 
19  33 p=0.070 
 
Percentage of clinically-relevant recommendations followed was examined as a secondary 
outcome measure. Significantly higher percentages of these recommendations led to 
initiated medication changes in the case-conference-group than in the written-feedback 
group (29.8% vs 17.2%, p = 0.02). This was also seen for the percentage of maintained 
medication changes at 6 months after the treatment reviews (25.5% vs 14.8%, p = 0.03). At 
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the 9-month measurement there was no statistically significant difference (23.9% vs 
15.1%, p = 0.08). 
 
Cost evaluation 
Pharmacists in the case-conference group spent significantly more time on this intervention 
(with accompanying increase in costs) than pharmacists in the written-feedback group. 
This was also true for GPs who kept time logs. Unfortunately only 37% of all GPs kept 
time logs: 42.5% in the case-conference group and 30.5% in the written-feedback group.  
 Changes in patient pharmacy records that were attributed to the treatment review led to 
a modest decrease in medicine costs. Although these benefits were slightly greater in the 
case-conference group, this difference did not reach statistical significance (Table 4). 
 
Table 4.  Costs and savings as caused by the intervention  (multilevel statistics), all recommendations are 
included.  
 
Cost changes per patient, € 1   
written feedback 
(n) 
Case conferences 
(n) 
p-value Difference 
(95% CI) 
Pharmacist 9.69 (350)2 15.03 (387)  p = 0.001 5.27 
(2.21-8.34) 
Costs caused by time 
expenses on the total process 
of medication review GP3 6.22 (97) 8.68 (163)  - - 
Savings due to medication changes at 9 
months after intervention 
-4.33 (320) -7.78 (365)  p = 0.357 3.44 
(-3.89-10.77) 
Yearly savings in medicine costs for each 
year that the medication change persists 
-7.79 (320) -12.24 (365) p = 0.443 4.44 
(-6.90-12.81) 
Net expenses at 9 months after medication 
review (including pharmacy costs and 
savings on medicines) 
5.52 (319) 7.23 (365)  p = 0.655 1.72 
(-5.80-9.23) 
Net expenses at 9 months after medication 
review (including pharmacy and GP costs 
and savings on medicines) 
14.22 (89) 13.71 (153) - - 
1
  Positive number means expenses, negative number means savings  
2  For one patient the time log from the pharmacy got lost, so this patient was excluded from this analysis.  
3
  From GPs, time logs for only 37% of all participants were received. 
 
The expenses and cost benefits of the intervention partially cancelled each other out. The 
extra savings in the case-conference group offset a part of the extra costs due to extra time 
needed by the pharmacists and GPs in this group. There was no significant difference in 
remaining net costs including pharmacy time expenses and savings on medicine costs 
between the two intervention groups. For the remaining net costs including pharmacist 
time expenses, GP time expenses, and savings on medicine costs, no statistical testing was 
performed because of the small number of participants. The results shown in table 4 do not 
seem to indicate differences in remaining costs including pharmacy-time, GP-time and 
savings on medicine costs. 
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Discussion  
Summary of main findings 
In this study, community pharmacists performed treatment reviews for 738 patients and 
feedback was given to GPs. Feedback in personal contact between the pharmacist and the 
GP (case conferences) led to significantly more medication changes following 
recommendations of clinical relevance.  
 Medicine costs were also influenced by the interventions. Both types of intervention 
showed modest savings regarding medicine costs. The slightly greater savings seem to 
cover extra costs caused by pharmacist and GP time expenses in the case-conference 
group.  
 When the effect of the intervention was examined over time, differences between the 
intervention groups were shown to decrease gradually.  
 
Strengths and limitations of the study 
The process of medication reviews was studied in a large sample of pharmacists and GPs 
by means of a cluster controlled trial, and a cost-evaluation was included. Despite these 
strengths, this study was not without limitations. Only medication changes weren taken 
into account; therefore, a considerable number of recommendations with solutions other 
than medication changes were not examined. For example, the effect of some drug-drug 
interactions can be monitored by checking blood pressure or other parameters, but it was 
not checked whether such actions were taken. This loss of data undoubtedly reduced the 
ability to detect differences, and made this analysis fairly conservative. 
 Time logs were received from only 37% of participating GPs, and as the calculations 
that include GP time expenses are based on a small number of patients, they have to be 
interpreted with some reservations. Statistical tests were not performed on these figures. 
 GPs were chosen by the participating pharmacists (convenience sample). It is possible 
that only GPs with whom the pharmacists had the best professional relationships were 
included, which could have led to an over-rating of the effect of these interventions.  
 
Comparison with existing literature 
This study indicates that treatment reviews involving personal contact (case conferences) 
lead to more medication changes than an intervention including only written feedback. 
Studies considering improvement of prescribing practice report similar findings15-18. As the 
extra costs of this approach seem to be covered by the extra savings on medicine costs, the 
case-conference approach is recommended in practice.  
 The persistence of medication changes over time was also investigated. Eighty-six per 
cent of the medication changes were maintained for at least 9 months after the treatment 
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review in the written-feedback group, and 79% in the case-conference group. Other studies 
have shown that 84% 19 and 64% 20of the interventions were maintained until six months 
after the intervention. Another study has shown that 90% of recommendations made by a 
clinical pharmacist remained implemented up to one year after the patient interview21.  
 Savings on medicine costs were also studied. Although older patients included in this 
study were using at least five prescription medicines, prescribing omissions were 
identified. Studies concerning the quality of pharmaceutical care have also observed 
omissions2,22-26. In a number of cases, these prescribing omissions were for newer, more 
expensive medicines (for example, bisphosphonates and proton-pump inhibitors); 
therefore, it is not surprising that the medicine costs did not decrease much. Some studies 
have found differences in costs after medications reviews13,19,27-30, while others have not 
4,31-33
.  
 
Implications for future research  
At the time the study was planned, a number of trials were performed considering the 
effectiveness of treatment reviews. In the trials published at the time, no statistical 
difference in health status or patient satisfaction was found3-6. As a result of the 
information from the literature and because the current study examined the differences 
between two procedures for treatment reviews (case conferences versus written feedback), 
it was decided not to make the study more complicated by measuring health status at 
patient level. However, positive trends in clinical outcomes were found in a later study by 
Sorensen et al.34. 
 In a systematic review some evidence was found that pharmacist-led interventions 
incorporating a medication review are effective in reducing hospital admissions35, and in a 
further study concerning older people living in care homes a reduction in the number of 
falls was found when performing clinical medication review30.  
 Further research is needed to examine the clinical consequences of treatment reviews 
and medication reviews. To measure the clinical consequences, health status, health-related 
patient satisfaction, numbers of falls, hospital admissions, and mortality rates could be 
used. These studies should include large populations of older people because medication is 
just one of the parameters that influences these clinical outcome measures. These kinds of 
studies have already been carried out for home-based interventions after hospital 
admissions to prevent re-admissions36,37 and variable and unexpected results.  
Met opmaak
Verwijderd: 34
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Abstract 
Rationale, Aims and objectives: There is room for improvement in pharmacotherapy for 
elderly outpatients. Studies have shown that collaborating health-care professionals (e.g. 
pharmacists in cooperation with general practitioners) are able to resolve prescription-
related pharmaceutical care issues by means of treatment reviews. The aim of the study 
was to describe the feasibility of two methods for treatment review (results were given to 
the GP either in case-conferences or in written feedback), and to determine if and how the 
process of treatment review can be improved. 
Setting: Local pharmacists and general practitioners (GPs) cooperated in performing 
treatment reviews for outpatients aged 75 years or more who were using five or more 
medicines chronically.  
Method: Written questionnaires, structured telephone interviews, and analysis of various 
features of the treatment reviews that were recorded during the intervention study. 
Results: The pharmacists in the case-conference group made more recommendations to the 
GPs (non significant). Significantly more recommendations were identified by the 
pharmacists themselves in the case conferences group. Health-care professionals accepted 
an intervention with personal contact in case conferences better than an intervention with 
feedback in writing. They were more positive about the process of treatment review 
presented personally, although there were not always as many medication changes as they 
had hoped for. They also had concrete suggestions for improving the intervention, such as 
using a combination of written feedback and case conferences, and reserving the case 
conferences for the most complex cases.  
Conclusions: Treatment reviews for the elderly in normal primary care are feasible. 
Health-care professionals agree that the process for treatment review can be improved.  
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Introduction 
The elderly use more medicines than younger people because they have more chronic 
diseases. In a previous study, we found that almost all pharmacotherapy for the elderly 
needs improvements.1 Performing treatment review would be an aid to making such 
improvements.2-5 These treatment reviews can be performed by primary care professionals, 
e.g. pharmacists in cooperation with general practitioners (GPs).  
 We examined the effects of two methods of treatment review in a cluster controlled trial 
6
 that compared case conferences involving both pharmacists and GPs with written 
feedback from the pharmacist to the GP. We examined the supplemental costs to determine 
whether the savings on medicine costs offset the additional costs of the more time-
consuming case conferences. Our study shows that treatment reviews with case 
conferences lead to better results than treatment reviews with written feedback when taking 
recommendations with direct clinical relevance in to account. Further, the net costs of the  
personal contact model did not seem to be greater than those of the written feedback 
model. It was noted that the effect of the intervention decreased over time. 
 From our and other researchers’ studies, we concluded that performing treatment 
reviews for elderly patients is valuable.3;5;6 In the present in-depth process evaluation, we 
describe the perspectives and experiences of the GPs and pharmacists involved in 
treatment reviews. First, we examine the feasibility of having these health-care 
professionals embed such treatment reviews in daily medical practice. Second, we 
elaborate on opportunities for improvement of the process of treatment reviews. The results 
give rise to recommendations to make treatment reviews more suitable for use in daily 
practice.  
 
Methods 
To study the feasibility of the treatment reviews, we analysed data about the use of 
treatment reviews and asked the opinions of the participants in written questionnaires and 
structured interviews. In this way, both objective and subjective data were used to 
determine feasibility.  
 
Setting 
In a primary care setting, treatment review were performed by 28 pharmacists and 77 GPs 
for 738 elderly people (aged 75 years or more) using 5 or more medicines chronically. 
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Intervention 
In both intervention groups, the pharmacists used our computerized screening tool to 
perform treatment reviews.6 They had to decide which of the recommendations highlighted 
by the computerized screening tool should be given to the GP, and whether additional 
recommendations concerning the pharmacotherapy of these patients should be pointed out. 
 
The organizational models of two intervention groups differed (Figure1): 
 
Figure 1.  Flow diagram of the intervention programme 
 
 
− Feedback in writing  
 The pharmacists listed all recommendations for each patient and delivered them to the 
GP’s office. The pharmacist did not follow up.  
Written feedback 
Computerized screening  
for all included patients 
Professional judgement of the recommendations 
identified by the pharmacist with the computerized 
screening tool. (Pass on to the general practitioner?) 
Professional judgement of the medication record.  
Should other recommendations be made? 
Case conferences 
Pharmacist delivers 
recommendations in writing to 
the general practitioner 
Pharmacist and GP performing    
Case conferences together 
Pharmaceutical care plan 
drawn up for each patient 
(pharmacist and GP together) 
Three months later 
pharmacist checks whether the 
pharmaceutical care plan has 
been implemented 
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− Case conferences 
The pharmacist and the GP discussed all recommendations as well as other concerns 
about the patients (if any). The pharmacist and the GP together drew up a 
pharmaceutical care plan in which they noted who was responsible for the activities in 
the plan. Three months later, the pharmacist checked whether these activities had been 
carried out.  
 
During the intervention study, clinical relevance was assessed for all recommendations that 
were passed on to the GPs. Recommendations were classified as:  
− Clinically relevant: the recommendation leads to improvement in the patient’s general 
health. 
− Potentially relevant: relevance depending, for example, on the medical condition of the 
individual patient. 
− Clinically irrelevant: the recommendation does not lead to improvement of the patient’s 
general health. 
For most of the recommendations identified by our computerized screening tool, clinical 
relevance was judged on the basis of our earlier in-depth analysis of pharmacotherapy,1 or 
on the literature7-10 for some of the remaining problems. For the recommendations that the 
pharmacists identified themselves, clinical relevance was based on our in-depth analysis or 
was determined by an expert panel during the present study.  
 The expert panel consisted of a GP, a community pharmacist, a geriatrician, and a 
clinical pharmacist. Clinical relevance was determined in a consensus method, which 
consisted of a round in writing followed by a round on the telephone. During the consensus 
meeting on the telephone, the experts discussed all differences until they reached 
consensus about the clinical relevance of the particular recommendation.   
 
Variables 
Use of treatment reviews in practice 
− The number of recommendations made for each patient: the average number of 
recommendations for each patient was recorded for each intervention group separately.  
− The number of clinically relevant recommendations: the average number of 
recommendations with direct clinical relevance for each patient was recorded for each 
intervention group separately.  
− Origin of the recommendations passed on to the GP: the overall percentage of 
recommendations identified by the pharmacist themselves was determined within both 
intervention groups.  
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− Time spent in performing treatment reviews: the overall time per patient was determined 
for each intervention group.  
 
Opinions about feasibility of treatment reviews  
Written questionnaires were sent to all participating health-care professionals (pharmacists 
and GPs). Reminders (including a new copy of the questionnaire) were sent after 2 and 5 
months. The questionnaire included questions about:  
− Views and opinions of the results of the treatment review: did the results outweigh the 
time spent? (GPs and pharmacists) 
− Opinion about time spent: did the performance of this intervention cost more or less 
time than expected (GPs).  
− Opinion of health-care professionals about the applicability of this intervention for all 
elderly patients in their practices (GP and pharmacists). 
 
The researcher interviewed by telephone 18 randomly selected pharmacists and 16 
randomly selected GPs, both evenly divided over the intervention groups. In the structured 
interviews, the researcher asked about ways to improve the treatment review method:  
− Stimulating factors for performing treatment reviews (GP and pharmacist) 
− Impeding factors for performing treatment reviews (GP and pharmacist) 
− Difficulties in effecting medication changes (GP) 
− Recommendations to optimize the process of treatment review (GP and pharmacist). 
 
Practice characteristics  
− General practice characteristics (health-care centre or solo practice, number of patients 
in practice, proportion of elderly patients in practice, full-time or part-time employment 
of staff, start of employment in this general practice) 
− Pharmacy characteristics (number of pharmacy assistants employed, number of 
pharmacists employed, proportion of elderly pharmacy, number of prescriptions a day, 
year of graduation of the participating pharmacist). 
 
Analysis 
Types of problems and recommendations were processed manually and entered into an 
MS-ACCESS database. When medication changes took place, the changes were entered in 
the database along with the clinical relevance of the recommendations and their origins6. 
This database was analysed with SPSS 12.0 (SPSS, Illinois).  
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 Results of the written questionnaires were entered into an MS-ACCESS database, which 
was analysed with SPSS 12.0 and used to generate the statistics. Results of the structured 
telephone interviews were literally noted and categorized. 
 
Results 
Analysis of use of treatment reviews 
More recommendations per patient were passed on to the GPs in the case-conference group 
that in the written feedback group, although this difference is not statistically significant. 
The number of recommendations with direct clinical relevance per patient is almost equal 
for both intervention groups (Table 1). 
 Table 1 shows that significantly more recommendations were identified by the 
pharmacists themselves in the case–conference group than in the written feedback group. 
In our intervention study, we saw that this category of problems was solved significantly 
more often than the familiar problems identified by the computerized screening tool.6  
Furthermore, the origins of the recommendations made by the pharmacists within both 
intervention groups varied greatly; this is also true for the clinical relevance of the 
recommendations made.  
 
Table 1. Use of treatment reviews as performed by pharmacists  
 
  
 
Case 
conferences 
Written 
feedback 
Pharmacists n = 15  n = 13  
Chi square 
statistics 
All recommendations 2.23 (387) 2.01 (351)  (p = 0.059) Average number of recommendations 
passed on to the general practitioner per 
patient  (number of patients) 
Clinically relevant 
recommendations 
0.42 (387) 0.40 (351)  (p = 0.753) 
% of recommendations of direct 
clinical relevance 
18.1 (864) 20.9 (705)  (p = 0.165) Sorts of recommendation made by the 
pharmacists (total number of 
recommendations) % of recommendations 
identified by the pharmacists 1 
41.7 (832) 34.2 (682)  (p = 0.003) 
Recommendations of direct 
clinical relevance 
0-36  13-34  - Range in percentages of sorts of 
recommendations  made by the 
pharmacists Recommendations identified by 
the pharmacists 
16-76  1-74  - 
1Recommendations regarding compliance were not included in this comparison 
 
Pharmacists spent more time on the intervention than GPs did. Health-care professionals 
gave more of their time in the case–conference group than in the written feedback group 
(Table 2). However, the sample of GPs was too small to make assumptions about all 
participating GPs and no statistical testing was performed for this group of health care 
professionals. For both groups of health-care professionals, the variability within the 
intervention groups was substantial.  
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Table 2.  Time expenses shown in multilevel statistics 
 
 Case 
conferences 
Written 
feedback 
Multilevel 
statistics 
General practitioners 10.4 (163) 7.46 (97)  - 1 Average time in minutes spent on 
intervention per patient (number of patients 
for which a time log was kept)  
Pharmacists 18.0 (387) 11.6 (350)  p = 0.001 
General practitioners 3.7-18.5 (17) 2.1-16.0 (11) - Range in time expenses in minutes per 
patient (number of professionals that kept 
time logs) 
Pharmacists 10.3-43.0 (15) 3.2-33.1 (13) - 
1 Because of the low number of time logs kept by GPs we did no statistical testing on the time spent by GPs 
 
Written questionnaires and structured interviews 
We received 27 (73% response) completed questionnaires from the GPs in the written 
feedback group and 37 (93% response) from those in the case-conference group. The 
pharmacists returned all the questionnaires (response 100% in both intervention groups). 
General practitioners in the case-conference group were more positive about the results of 
the treatment reviews than the GPs in the written feedback group (Table 3). They found 
that it was useful and that it had a positive impact on the pharmacotherapy. Despite the fact 
that case conferences were more time consuming and took more time than expected, the 
GPs in this group were also more positive about the feasibility of this approach in daily 
practice.  
 
Table 3.  Written questionnaires: general practitioners’ opinions about feasibility of treatment reviews for the 
elderly  
 
 Case 
conferences  
Written 
feedback 
Number of GPs (Percentage of total included in the study ) 37 (93) 27 (73) 
Pharmacotherapy for patients is optimal after this intervention 24.3% 14.8% 
Performing treatment reviews has led to medication changes 54.1% 48.1% 
Performing treatment reviews for the elderly  took more time than expected 11.1% 3.7% 
Implementation of treatment reviews for the elderly in daily practice is impossible 2.7% 7.4% 
Treatment reviews for the elderly can be implemented in daily practice, but a reasonable 
amount of time should be reserved 
56.8% 59.3% 
Treatment reviews for the elderly are only feasible with a financial remuneration 10.8% 11.1% 
If they are spread over the entire year, it is possible to perform treatment reviews for the 
elderly 
24.3% 14.8% 
 
The results for the pharmacists in the case-conference group were similar. The pharmacists 
in general were slightly more positive about feasibility in daily practice. One of the 
participants in the written feedback group thought that it is impossible to implement 
treatment reviews for the elderly in daily practice, but none of the pharmacists in the case-
conference group shared this opinion. Four pharmacists in the case-conferences group 
thought that treatment reviews for the elderly should be possible if they were spread over 
the year. Only two pharmacists in the written feedback group shared this opinion. Most 
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pharmacists, however, thought that implementing treatment reviews in daily practice is 
possible, but a reasonable amount of time should be reserved for them (9 pharmacists in 
the case-conference group and 8 in the written feedback group). Two pharmacists in each 
group thought that this activity could only be implemented in daily practice if it was paid 
for by health-care insurance companies.  
  
Factors influencing the results of the treatment reviews  
Good collaboration and motivation were mentioned as stimulating factors for treatment 
reviews, but some participants thought the personal relationship between GP and 
pharmacist was an interfering factor. Some participants named pharmacotherapy audit 
meetings as a useful tool for starting the process of performing treatment reviews for the 
elderly. The pharmacists liked the input they got from the computerized screening tool.  
There were several difficulties in changing medications for these elderly patients. One was 
the fact that if a medication has been initiated by medical specialists, GPs are not inclined 
to change the prescription. Another difficulty was that the patients are not always 
cooperative, particularly when discontinuation of hypnotics is suggested. A frequently 
mentioned problem is the amount of time needed for treatment reviews, as reported by GPs 
and pharmacists in both intervention groups (Table 4).   
 
Recommendations for introducing this intervention in daily practice 
The participating pharmacists and GPs made the following recommendations during the 
structured interviews. 
• Focus on a selection of patients with relatively many problems, or with many 
medicines, as these patients will benefit most from quality improvement 
interventions.  
• Some types of problems do not require face-to-face contact between pharmacists and 
GPs; they can be solved by feedback in writing (e.g. prolonged use of hypnotics). 
Other types of problems (more complex problems or more complex cases) require 
discussions about indications, etc. In practice, this could lead to a combination of 
both forms, in which only complex cases or problems are discussed, while the 
remaining ones are dealt with in writing.  
• Make it a continuous project in which specific groups of patients (e.g. starting with 
diabetes mellitus patients, followed by rheumatoid arthritis patients, etc.) are included 
in different periods of time. 
• Include patients living in nursing homes and/or homes for the elderly. 
 
 
136 Chapter 7 
 
 
Table 4.  Structured interviews: stimulating and interfering factors for treatment reviews  
 
 Case conferences Written feedback 
Number of GPs 8 8 
Number of pharmacists 9 9 
Stimulating factors (GPs) Good collaboration with pharmacy (1)  
Pharmacotherapy audit meetings (1) 
- (none named) 
Stimulating factors 
(pharmacists) 
Motivation and cooperation of GP (3) 
Pharmacotherapy audit meetings (1) 
Computerised screening tool (1) 
Computerised screening tool (3) 
Participation by whole pharmacotherapy audit 
meeting group (1) 
Participation in research project (1) 
Interfering factors (GPs) Time expenses (2) 
Specialists’ prescriptions(1) 
Organizational factors (1) 
 
Time expenses (2) 
Influence of patients (2) 
Fear of medication changes causing confusion for 
the patient (1) 
Changing medications after years of use seems 
like admitting that prescribing was not always 
optimal (1) 
Interfering factors 
(pharmacists) 
Relationship with general practitioner 
(3) 
Time expenses (1) 
Practical problems linking patients to 
general practitioners (1) 
Practical problems switching between 
computer programmes (1) 
 
Time expenses (2) 
General practitioner’s supposed lack of time (1) 
Lack of knowledge of the indication for 
prescribed medicines (1) 
No response from general practitioner (1) 
Specialists’ prescriptions (1) 
So few spectacular problems found is not 
motivating (1) 
Practical problems linking patients to general 
practitioners (1) 
Practical problems printing data from 
computerized screening tool (1) 
Difficulties in effecting 
proposed medication 
changes (general 
practitioners) 
Influence of patients (2) 
Fear of medication changes causing 
confusion for the patients (1) 
Organizational factors (repeat 
prescribing) (1) 
Specialists’ prescriptions (1) 
Influence of patients (3) 
Specialists’ prescriptions (4) 
 
 
Discussion 
Main findings  
Pharmacists in the case-conference group spent more time on the intervention than 
pharmacists in the written feedback group. The pharmacists in the first group identified 
more recommendations of which more were identified by the pharmacists themselves than 
the pharmacists in the latter group. 
 Pharmacists and GPs were both positive about performing treatment reviews and the 
feasibility of implementing the process in daily practice. Health care professional in the 
case–conference group were generally more favourable to this, although not all of them 
found that the results justified the time spent.  
 Both positive and negative factors influenced the results of the intervention. 
Cooperation and personal relationship between the pharmacist and the GP were said to be 
both positive and negative in performing treatment reviews. The time required and 
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specialists’ prescriptions were named as negative factors influencing the results of the 
intervention.  
 The participating health-care professionals did have several recommendations for 
optimizing treatment reviews. For example, they suggested a combination of written 
feedback and case conferences; they thought it sufficient to discuss only the most complex 
cases and use written feedback for the rest.  
 
Comparison with existing literature 
General practitioners saw the patients themselves as one of the reasons why some 
medications were not changed. Patients were not always inclined to stop using medicines 
that they had used for a long time; this finding is consistent with other studies.(11) This 
problem is well known in regard to hypnotics; it is difficult to stop using benzodiazepines 
without specific interventions.12-14 With regard to changing medication prescriptions 
initiated by specialists,11;15 we believe that, although GPs often say that this particular part 
of their prescribing behaviour cannot be changed, they also have a responsibility when 
specialist-initiated prescriptions are repeated.16 
 
Limitations 
The GP response rates were low for the questionnaires and the time logs, particularly in the 
written feedback group. Perhaps the GPs in this group were not as motivated as the others. 
As it is likely that the non responders had less positive experiences with the interventions, 
the actual differences between the two groups might even be more pronounced than our 
findings show.  
 
Recommendations for daily practice and further research 
In our study, usage of the treatment reviews varied greatly, possibly because of differences 
in the quality of pharmacotherapy at the beginning of the study, as well as the degree of 
dedication and experience in treatment review of the health-care professionals. It seems 
advisable to introduce the process of treatment reviews and pharmacotherapy for the 
elderly in a pharmacotherapy audit meeting to optimize involvement and to inform 
participating health-care professionals.  
 In some instances, GPs reported that the intervention had a spill-over educative effect. 
They learned about optimizing medication prescriptions for the elderly, both in the cases 
discussed and for other cases with similar pharmacotherapy. In some instances, the GPs 
decided not to change the medication, but reported that they would bear the newly acquired 
knowledge in mind when treating other patients. Further research is needed to examine the 
educational effect of such interventions in daily practice. 
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 Adaptations should be made in order to implement such treatment reviews, for example, 
by focusing on specific indications, or on patients using many medicines. Finally, we 
recommend a combined treatment review with a discussion in person for the more complex 
cases, while recommendations for more evident cases might be given in writing. However, 
this requires the pharmacist to distinguish most complex and important recommendations 
and those that the GP already knows about. Further research is needed to study the 
supplemental effect of such changes in the process of treatment reviews.  
 
Treatment reviews, how to perform them 
If we combine the information from the intervention study and this process evaluation, we 
can identify characteristics that should ideally be present when performing medication 
reviews.  
• It seems logical to start the process of treatment review with a pharmacotherapy audit 
meeting that focuses on polypharmacy and on special considerations for prescribing 
for the elderly.  
• The medication reviews are performed by a pharmacist with supported by a 
computerized screening tool. The results of the treatment reviews are given to the 
GPs in case conferences for the most complex cases, and the more familiar 
recommendations can be given in writing or are talked about briefly.  
• It seems advisable to draw up a pharmaceutical care plan that records the names of 
those responsible for each task. Three months after the meeting, the pharmacist 
checks whether all activities have been carried out.  
• Treatment reviews should be repeated periodically because 
1. The effect of the intervention diminishes in time.  
2. Use of other medicines or disorders can be identified in a reviewed case so that 
evaluation has to be repeated. 
3. Pharmacotherapeutic guidelines are continuously improving, which gives rise to 
new points of attention for a patient with the same medicines. 
4. There will be new cases in the population that must be considered for treatment 
review.    
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In the general discussion of this thesis the main findings from our research project are 
highlighted and the strengths and limitation of the individual studies are discussed. 
Furthermore the implications for our studies for health care professionals, policy makers 
and pharmacy practice researchers are elaborated.  
 
Main findings  
Part I Problems associated with elderly and use of medicines  
In a first study among elderly > 75 years using 4 medicines or more we found that in two 
thirds of the participants user-related pharmaceutical care problems could be observed. 
User related pharmaceutical care problems of potential clinical relevance were identified in 
a quarter of the study objects. High numbers of problems were associated with the use of 
medicines with complex administration forms (e.g. eye drops and inhalation devices). 
Different risk factors could be identified for problems in general and for problems with 
direct or potential clinical relevance. These risk factors can be used in daily practice to 
identify patients at risk of user related pharmaceutical care problems.    
 In the study regarding prescription related problems we observed high numbers of 
problems of potential clinical relevance. For almost all elderly patients recommendations 
could be made concerning prescribed medicines. For one third of the patients at least one 
recommendation with direct clinical relevance could be made; meaning that following the 
recommendation will lead to improvement in general health. For two thirds a medicine 
may need to be added to optimise pharmacotherapy. One quarter of these prescribing 
omissions were of direct clinical relevance. 
In the study regarding our composite screening tool we found a number of existing 
screening tools in the literature as well as many studies concerning geriatric prescribing 
and medication reviews. All existing screening tools proved to have some limitations, 
therefore we developed a composite tool for medication review of patients in primary care. 
A wide range of issues that should be taken into account when reviewing pharmacotherapy 
is included in this new tool. 
In our study in the Rotterdam study database we saw that hypoglycaemia is seen in 1 
out of 12 patients during the study period. The risk was four times higher in insulin users 
with or without oral agents (39.11 and 39.04 per 1000 person years) than in users using 
only oral antidiabetics (9.88 per 1000 person years). In the multivariable analyses use of 
insulin and renal impairment (both associated with an increased risk) remained significant 
for all users of hypoglycaemic agents. Use of tolbutamide (associated with a decreased 
risk) and use of medicines having an influence on CYP2C9 (associated with a increased 
risk) remained significant for users of sulfonylurea derivatives. As the risk for 
hypoglycaemia is greater in insulin users than in users of oral antidiabetic drugs, it seems 
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particularly relevant that elderly insulin users can adequately recognize and rectify 
upcoming hypoglycaemic events. As the risk of hypoglycaemia is also greater in elderly 
users of glibenclamid than in users of tolbutamid, the latter sulphonylurea derivative is the 
drug of choice in this drug class. Finally, more attention should be paid to interactions 
between sulphonylurea derivatives and CYP2C9 modifying drugs (such as co-
trimoxazole). 
  
Part II  Improving medication safety in the elderly 
After identification of problems as seen in elderly using medicines we searched for 
possible solutions. As prescription-related problems were observed most frequently and as 
many are of potential or direct clinical relevance, we were interested in interventions 
specifically aimed at improvement of prescribing for the elderly on polypharmacy. In so 
called “treatment reviews” pharmacotherapy for individual patients is screened and in most 
instances recommendations for improvement of pharmacotherapy can be made.  
 Our intervention study aimed at improving the collaboration between GPs and 
pharmacists. In particular we studied if a more labour intensive intervention leads to better 
results. A cost-evaluation was performed as well. We found that performing treatment 
reviews accompanied by personal communication in case-conferences leads to higher 
numbers of medication changes with direct clinical relevance than treatment reviews with 
written feedback only. Furthermore, supplemental costs as caused by case-conferences 
seem to be covered by higher savings on medication costs.  
 In our process evaluation we found saw that the health care professionals also preferred 
treatment reviews with case conferences, it improves the collaboration between the health 
care professionals, since both health care professionals can show their own expertise. Both 
GPs and pharmacists had recommendations for optimising the use of treatment reviews in 
daily practice. For example, they recommended a combination of case conferences and 
written feedback, case conferences for complex patients while for other patients written 
feedback will be sufficient. 
 
Strengths and limitations 
The studies concerning user related problems and prescription related problems were 
performed in a population of elderly (75 years or over) using 4 or more medicines 
chronically. During these studies we saw that the elderly were having practical problems 
and that prescribing in this population could be improved, nevertheless we saw an increase 
in the number of problems when higher numbers of medicines were taken.      
 Although user related problems were studied before, our study is the first one that 
includes all kinds of user-related problems in one study. Because clinical relevance of the 
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problems was variable we determined the clinical relevance of the indicated problems and 
made separate risk models for all problems and for problems with potential clinical 
relevance. Although we tried to study the user-related problems as reliably as possible, 
there were some limitations to our study. We relied on self-reports of problems, which may 
have led to an underestimation. Furthermore selection bias may have occurred in the 
response of the invited participants. Participants familiar with non-compliance may be less 
inclined to take part in a study concerning drug-taking habits. We concluded that the 
finding of one quarter of elderly patients (using 4 or more medicines) having potential 
clinically relevant user-related problems is rather conservative.   
 The study regarding the prescribing quality of polypharmacy is the first in-depth 
analysis by a large expert panel and focuses on a wide and comprehensive set of 
prescription related points of attention. This analysis was performed by means of a 
consensus approach, which entails the risk that some panel members are more influential 
than others. However we did not notice such influences. Furthermore, although a sample of 
100 patients is rather large for a comprehensive analysis of prescribing, some problems 
that occur rarely may have been underrepresented in this sample. 
 Our new tool for medication review gives an overview of all different types of problems 
that should be taken into account in the implicit reviewing of medication patterns. Articles 
were identified from Medline following a free text search on the term “medication 
review(s)”, supplemented by an incremental search strategy that comprised manual 
searching of previously collected literature, on-line searching for additional papers of the 
research groups prominent in this field and manual searching of the bibliography of useful 
articles. Probably most relevant articles and many examples were included in this tool, 
however, it is not a systematic review. 
 The incidence of hypoglycaemic events as determined in our study in the Rotterdam 
study database is probably an underestimation of the total number of hypoglycaemic events 
in the study population. This is partly caused by GPs who will use portable blood glucose 
measuring equipments in acute situations, these values were not included in our study. 
Furthermore, our study did not take in that more experienced diabetic patients may 
selfadminister a source of glucose to cope with an upcoming hypoglycaemic event. Other 
limitations of this study were the limited number of cases and the low frequency of some 
of the cofactors. To overcome these last limitations this study should be repeated in a 
database containing larger numbers of diabetic patients using all kinds of medicines. 
 We studied the process of medication reviews in a large sample of pharmacists and GPs 
by means of a cluster controlled trial. Furthermore a cost-evaluation was performed. There 
were some limitations to this study. We only took medication changes into account, so a 
considerable number of recommendations with solutions other than medication changes 
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were not taken into account. This loss of data undoubtedly reduced our ability to detect 
differences, and made our analysis conservative.  
 Furthermore we did not measure outcomes at the patient level. In the trials that had been  
published at the time, no statistical differences (nor positive nor negative) in health status 
or patient satisfaction were found 1-4. Because of the information from the literature and 
because our study was indicated at the differences between two procedures for treatment 
reviews (case conferences versus written feedback) we decided not to make our study more 
complicated by measuring health status at patient level. Afterwards, however, positive 
trends in clinical outcomes were found in a study by Sorensen 5. In a systematic review 
some evidence was found that pharmacist-led interventions incorporating a medication 
review are effective in reducing hospital admissions6 and in another study concerning 
elderly living in homes for the elderly a reduction in the number of fall was found when 
performing clinical medication review7. New studies should measure the impact of our 
outpatient approach on patient outcomes.  
 Our process evaluation is based on questionnaires, structured interviews and various 
features of treatment reviews recorded during the intervention study. The combination of 
these data gives more insight in the process of treatment review than the different sources 
individually. There were some limitations to this study, the response rates of general 
practitioners were low for the questionnaires and time logs, in particular in the written 
feedback group. Perhaps the general practitioners in the written feedback group were not as 
motivated as the GPs in the group with case conferences. As it is likely that the non-
responders may have had less positive experiences with the interventions, the actual 
differences between the two groups might even be more pronounced than our findings 
showed.  
 
Implications for improving medication safety 
When performing treatment reviews some problems can be identified retrospectively, but 
as far as this is possible prevention is preferable. In daily practice older age should be 
considered a contra-indication for certain medicines and groups of medicines, whereas for 
other medicines dosages should be adjusted. These types of problems can be tackled easily 
by means of alerts in electronic pharmacy practice systems (and general practice systems). 
Nowadays such alerts are not yet included because no official list containing medicines not 
suitable for use by the elderly or dosage adjustment needed for the elderly is available for 
the Dutch primary care setting. We propose that a group of experts in the field of geriatric 
prescribing and dispensing composes a national list containing medicines not suitable for 
use by the elderly or dosage adjustment needed, specifically aimed at the situation in the 
Netherlands.  
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 In our study considering drug-induced hypoglycaemia we identified risk factors that can 
be used to identify patients at risk of hypoglycaemic events. By using these risk factors in 
daily practice it may be possible to reduce hospitalisation caused by hypoglycaemia. In 
2003 a guideline for prevention of NSAID related gastro-intestinal complaints was 
launched in the Netherlands11, yet NSAIDs still are identified as one of the drug-classes 
causing gastrointestinal bleedings leading to hospital admissions in a study that was 
performed in 2006 12. So just identifying risk factors and take them up in guidelines is not 
enough to prevent hospital admissions. Guidelines should be implemented in daily practice 
by means of well developed and effective implementation programs13. These programs 
should ideally consist of dissemination of the guidelines by means of professional 
publications, supplemented by personal communications (education programs, audit 
meetings or even visits from advisors)13-16. Optimal implementation will be reached when 
risk factors related to drug-induced hypoglycaemia are included in pharmacy and general 
practice systems, and electronic alerts will be given in daily routine.  
 Although we looked at home-dwelling elderly in our studies, other studies have shown 
that  performing treatment reviews will also be useful for patients living in nursing homes 
or homes for the elderly 7,17-19. We excluded persons living in homes for the elderly 
because they get help with managing and administering their medicines. Furthermore, for 
high amounts of elderly living in nursing homes repeat prescriptions are requested by the 
pharmacist by means of a medication overview that can be signed by the GP. At this time 
most pharmacists and GPs do have a regular look at the complete pharmacotherapy for 
these patients. A recent study considering drug-induced hospitalisations in the Netherlands 
indicated patients living in nursing homes or homes for the elderly being at increased risk 
of potentially avoidable drug-induced hospitalisation12. Hence we recommend performing 
treatment reviews for these categories of patients as well.   
 Although we decided to focused our research project on improvement of geriatric 
prescribing, and hence did not study interventions aimed at user-related problems, we think 
that patients can benefit from a medicine consultation with a pharmacist. This has been 
proved in studies performed by others; the numbers of user-related pharmaceutical care 
problems were reduced by performing medicine consultations 3,8,9. Other studies have 
shown improved knowledge and adherence to pharmacotherapy 10.  
 
Implications for daily practice  
A practical problem that frequently was addressed by the elderly in our home based 
interviews was dividing tablets. Because of physiological changes elderly have to use 
lower dosages of some specific medicines, so tablets with dosages suitable for healthy 
adults have to be divided usually by these elderly patients themselves. Many tablets are too 
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hard or too fragile to divide, when they break the parts are unevenly divided or multiple 
parts arise. For as long as lower dosage tablets are not commercially available and elderly 
have to divide their tablets themselves tablet splitting aids are available, but this still is a 
second-best option. Another solution for this problem would be preparing capsules in 
lower dosages, but this is a labour-intensive activity and because of high work-pressure not 
all pharmacies will be very enthusiastic about making them. The ideal solution for this 
problem should be the availability of tablets with lower dosages. When this is 
commercially not very interesting for manufacturers some compensation should be offered 
by the government to make this activity more interesting for companies.  
 A number of problems that were identified in our study could be solved by giving extra 
information and instruction about the use of medicines and their administration devices. A 
number of tools making the administration of medicines more easy exist (eg. eye drop 
tools, aerosol aids), but not all patients seem to be are aware of them. Not all 
administration problems can be solved but probably a number of patients will benefit from 
these tools. In the pharmacy knowledge about these tools should be present and they 
should be offered proactively whenever there is a suspicion of problems. In future more 
emphasis should be given to complex administration forms. The pharmacy assistant can 
realise this in daily practice by asking the patient about practical problems when dispensing 
medicines. Furthermore use of complex administration forms and associated problems 
should be discussed when performing medicine consultations .  
 As we have seen in our study concerning prescription-related problems, improvements 
regarding pharmacotherapy can be recommended for almost all elderly patients on 
polypharmacy. Prescribing for the elderly should be considered more carefully and repeat 
prescriptions should be monitored more systematically, for example, by means of treatment 
reviews. Different types of problems and problem categories that are to be expected in the 
elderly are described in our tool for medication review. When performing medication 
reviews all problem categories described in this tool should be kept in mind. To get used to 
this process a medication profile form can be used in which all medicines (vertical axis) 
and all problems categories (horizontal axis) are shown. For each point of attention a mark 
can be made in the row of the particular medicine in the column of the particular problem 
category. This presentation of medicines and problem categories helps to cover all relevant 
problem categories for each medicine. As copying all medicines on such a form is labour-
intensive this process should be computerised. Forms should be printed with all medicines 
and dosages on it from the pharmacy system.   
 We recommend performing treatment reviews for elderly patients on polypharmacy, but 
not all pharmacists may be willing and capable of performing these reviews. Firstly,  
performing such reviews takes a lot of time, especially in a pharmacy population 
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comprising many elderly patients. However, most participants in our process evaluation 
indicated that it should be possible to perform treatment reviews for the elderly population 
if they were spread over the entire year.   
 Secondly, we offered participating pharmacists a training session about treatment 
reviews. In this training problems related to ageing and medicine use and the categories of 
problems that could be identified were discussed, but there was no time to give an update 
of complete pharmacotherapy. In the interviews on telephone we asked the pharmacists if 
they felt capable of performing these reviews and performing case conferences with the GP 
(defending their own points of attention). All pharmacists indicated that they felt capable,  
although they needed time to prepare the recommendations regarding the pharmacotherapy 
of a particular patient. In our study most participating pharmacists were younger 
pharmacists who had had a good undergraduate education in pharmacotherapy. 
Furthermore these pharmacists were specifically interested in the subject. Because of the 
variability in the knowledge of (and interest in) pharmacotherapy between pharmacists in 
the Netherlands we propose that an adequate training (including pharmacotherapy and 
prescription guidelines for most common diseases) should be offered in the continuing 
education program to train pharmacists to become licensed treatment reviewers. Valuable 
input for these training can be extracted from the composite screening tool that we 
presented in chapter 4.  
 In the past the focus of the pharmacist was aimed at preparing medicines in the 
pharmacy. This focus is nowadays shifted towards pharmacotherapy, while in future the 
pharmacist should become more patient oriented. This is also proposed in a report of the 
Dutch Patients’ and Consumers’ Federation 20. This report made clear that patients would 
like to see a community pharmacist to act as a personal adviser on pharmacotherapy, for 
example, by means of medicine consultations. Although we think that patients can benefit 
from such a consultation they are not yet performed routinely in Dutch pharmacies21. The 
opportunity to talk about pharmacotherapy with a pharmacist should be more emphasized 
in the individual pharmacies. A national campaign by the Royal Dutch Pharmaceutical 
Society (KNMP) may be helpful to communicate this service to a broad public. 
 To deliver this service adequately, pharmacists should have the skills and interests to 
perform patient consultations. Additional training should be offered in the continuing 
education program for pharmacists who need to improve their skills in the area of patient 
communication. Another problem is the large amount of time that medicine consultations 
may take. Not all pharmacies are nowadays organised in a way that allows to spend large 
amounts on these kind of consultations. Probably pharmaceutical consultants (pharmacy 
assistants with higher vocational education aimed at pharmacotherapy) can contribute and 
take their share in performing patient consultations. Recently the first group of 
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pharmaceutical consultants finished their studies, these consultants do have to find their 
way and tasks in daily practice. Pharmaceutical consultants should have enough knowledge 
to perform medicine consultations with patients using plain pharmacotherapy, when 
necessary they can call the pharmacist for help. Medication consultation with patients 
having complicated pharmacotherapy (patients using higher number of medicines 
prescribed by different physicians, suffering from a number of different conditions) should 
be performed by pharmacists.  
 To diminish user- and prescription-related problems clinical medication reviews can be 
performed. This involves a complete treatment review (with the GP) supplemented by a 
patient consultation. Worthwhile patient information concerning actual use and practical 
problems using prescribed medicines and OTC (over the counter)-medicines can be used. 
Although we think it should be preferable to perform these clinical medication reviews, no 
studies considering this subject in the Dutch situation have been published yet. 
Furthermore, we think that high numbers of Dutch pharmacists have not yet started with 
the regular performance of treatment reviews. Because the combined form is even more 
labour-intensive, we think that pharmacists should start performing treatment reviews with 
the GP, when this becomes common practice patient consultations can be supplemented.   
  
Recommendations for treatment reviews 
On the basis of our intervention study, our process evaluation and earlier studies by other 
research groups, we would like to present the following conclusions and recommendations:   
• Performing treatment reviews is effective in reducing the number of prescription 
related problems 1-3,7. 
• It seems recommendable to start the process of treatment review with a 
pharmacotherapy audit meeting with GPs and pharmacists focusing on special 
considerations for prescribing in the elderly, polypharmacy and treatment reviews 
(Chapter 7 Process evaluation).  
• In daily practice it will be recommendable to focus the case-conferences on the most 
complex patients; frequently encountered recommendations can be given in writing or 
can be talked about shortly (Chapter 7 Process evaluation).  
• Treatment reviews should be repeated periodically, firstly, because the effect of the 
intervention declines after a period of time (Chapter 6 Intervention study). Secondly, 
because other medicines may be used or conditions can be identified the evaluation has 
to be repeated periodically. Thirdly, because pharmacotherapeutic guidelines are 
continuously improving, there can be new points of attention for patients with the same 
medicines. And lastly, because there will always be new elderly patients who qualify 
for a treatment review.   
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• Treatment reviews with the GP should ideally be accompanied by consultations with 
the patient (chapter 4). Patients also have worthwhile information about their 
knowledge and actual use of prescribed medicines and OTC (over the counter)-
medicines. By means of patient consultations knowledge and motivation for use of their 
medicines can be optimised 3,8-10.  
 
Responsibilities of health care professionals 
Different health care professionals working with medicines can help to prevent drug-
related problems in the elderly by performing different activities. In textbox 1 some 
examples of such activities are shown.  
 Extra attention should be given to each first prescription of a new medicine, clear 
information should be given by the prescriber (why using this medicine, how to use this 
medicine, is this medicine for incidental or chronic use, are there side effects to be 
expected etc.). In the pharmacy basically the same information should be repeated. When a 
medicine is intended for chronic use attention should be given to the second time a 
medicine is dispensed at the pharmacy. At this time the patient has some experience with 
the use of this particular medicine and will be more interested in extra information and 
probably does have some questions about the medicine.     
 Problems can emerge when repeat prescriptions are continued without proper 
monitoring22. Treatment reviews can help physicians to reassess periodically whether 
repeat prescriptions are still necessary and whether dosages still are suitable for the 
particular patient. Furthermore they can help to ensure that regular checks to monitor the 
effectiveness and safety of repeat prescription are performed (e.g. by measuring blood 
pressure, potassium level etc.).  
 Moments with a high risk of drug-related problems are hospital admission and 
discharge. In most hospitals a pharmaceutical transfer-point is active. Pharmacy assistants 
working at these transfer points are in most instances responsible for identifying current 
medicine use for patients being admitted to the hospital and furthermore they also play a 
key role in the communication about discharge prescriptions.  
 The responsibilities of different health-care professionals concerning medication safety 
should be described in a National Primary care Collaboration Agreement (Landelijke 
Eerstelijns Samenwerkings Afspraak = LESA). In such a document all points of attention 
considering this particular subject are highlighted. In local settings (e.g. pharmacotherapy 
audit meetings) agreement should be reached considering the responsibilities and practical 
performance of the tasks related to this subject.     
 
 General discussion 151 
Textbox 1  Responsibilities of different health care professionals in primary care considering medication 
safety in the elderly 
 
Health care professional Activity Activity aimed at diminishing  
Check for problems associated with 
practical use of medicines  
User related problems 
Synchronise repeat prescriptions User related problems 
Offer administration aids when necessary User related problems 
Provide extra information in case of a 
first or second prescription 
User related problems 
Pharmacy assistant 
Assisting in performing medication 
surveillance 
Prescription related problems 
Pharmacy assistants at 
pharmacy transfer point in 
hospital 
Improving communication between 
community pharmacy and hospital 
pharmacy at hospital admission and  
discharge 
User and prescription related problems 
Pharmaceutical consultant Perform patient consultations (for patients 
on plain pharmacotherapy) 
User and prescription related problems 
Medication surveillance Prescription related problems 
Perform patient consultations User and prescription related problems 
Community pharmacist 
Perform treatment reviews Prescription related problems 
Be alert when elderly indicate having 
problems with practical use of medicines 
User related problems GP assistant  
Assisting monitoring repeat prescriptions 
(perform regular checks when necessary) 
Prescription related problems 
Provide information when prescribing a 
medicine for the first time 
User related problems Practice nurses 
Monitor repeat prescriptions for their 
specific area of treatment  (perform 
regular checks when necessary) 
Prescription related problems 
Provide information when prescribing a 
medicine for the first time 
User related problems 
Perform treatment reviews Prescription related problems 
Monitor repeat prescriptions (perform 
regular checks when necessary) 
Prescription related problems 
General practitioner 
Discussing need for repeat prescription Prescription related problems 
 
Nowadays more and more outpatient pharmacies at hospitals are opening and they 
dispense medicines to patients who are being discharged. Furthermore, special pharmacies 
for night and weekend hours are opening, they provide medicines and pharmacy services to 
the patients after closing hours of their regular community pharmacy. A recent 
development is the dispensing of some specialist medicines by only one pharmacy in the 
Netherlands. It is critical to have good communication between these types of pharmacies 
and the community pharmacy of the particular patient about the medicines being delivered 
and about dosage changes in medicines already used. In most areas communication is 
realised by means of computer networks or computerised messages in a secured system, 
but in other instances, especially when communication is necessary beyond a certain 
region, communication is arranged by means of fax or postal messages. This is a second-
best solution because messages can get lost and hence medication surveillance can become 
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suboptimal. Probably such problems will be solved when the nationwide computerised 
pharmaceutical register is implemented 30, but until then community pharmacists should 
take the responsibility to keep the pharmaceutical register of their patients up to date. 
Medicines not delivered in the own pharmacy should be entered in the pharmaceutical 
register to maintain medication safety. On the other hand, when dispensing medicines to a 
patient not registered in a particular pharmacy this should be communicated to the 
community pharmacy in which the patient is registered (with consent of the patient). The 
patient also has his own responsibility, of course, in this respect. When the patient orders 
medicines on the internet and gives no complete information about his medical and/or 
pharmaceutical record no optimal medication surveillance can be performed. This is also 
the case when patients do not give consent to send a message to their own pharmacy. 
 
Policy implications 
In the Netherlands, as well as in other European countries, the population is ageing. When 
people are getting older they suffer from more diseases for which medicines should be 
used. This high number of medicines used by the elderly is responsible for high expenses. 
Because of deterioration of body functions (e.g. liver and kidney) elderly are more prone to 
drug-related problems. Side effects, drug-disease and drug-drug interactions and 
hospitalisation caused by use (or non-use) of medicines are responsible for healthcare 
problems associated with even higher expenses. Consequently, pharmacotherapy for 
people using high numbers of medicines, especially for the elderly, should be monitored 
extensively. This can be done by means of regular treatment review. A small minority of 5-
15% of the health-care professionals included in our study felt that a financial fee would be 
needed to compensate for the additional time spent on performing treatment reviews. It 
seems that the majority of GPs and pharmacists included in our study found it a self-
evident part of their professional quality standards, but we do not know whether this is a 
proper representation of all GPs and pharmacists in the Netherlands. Treatment reviews are 
still an extra service in The Netherlands that is not yet part of routine practice everywhere. 
Rewarding the performance of treatment reviews within the upcoming new rewarding 
system for pharmacists may encourage health care professionals to take up this activity.   
 In the Netherlands the role of pharmacists has changed from just dispensing medicines 
to guiding pharmacotherapy, and this role will further develop towards a patient-centered 
approach. The community pharmacist has recently been included in the Dutch law on 
Medical Treatment (“Wet Geneeskundige Behandel Overeenkomst”). According to this 
new law good pharmacotherapeutic treatment is a shared responsibility of physicians and 
pharmacists. Performing treatment reviews jointly can be considered as one way to reach 
this goal. When the pharmacist has this shared responsibility for good pharmacotherapeutic 
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treatment, different financial fees should be offered for performing quality improvement 
tasks such as treatment reviews, patient consultations or elaborate information about a 
medicine when dispensed for the first or second time to a particular patient. A rewarding 
system that differentiates according to the efforts made, replaces the current fixed financial 
fee for each prescription that is dispensed independently of the activities related to that 
dispensing. 
 
Recommendations for further research  
Although we decided to focus our research project on the improvement of geriatric 
prescribing, and hence did not study interventions aimed at user-related problems, we think 
that the number of user-related problems should decrease as well. To study how both user- 
and prescription-related problems can be diminished, studies considering clinical 
medication reviews should be performed. A clinical medication review involves a 
complete treatment review (with the GP) supplemented by a patient consultation. In 
clinical medication reviews, medicines are not examined in isolation but considered in 
context of the patient’s condition and the way they live their lives. This means listening to 
the patient’s views and beliefs about their medicines, reaching an honest understanding of 
their medicine taking behaviour and taking full account of their preferences in any 
decisions about treatment. Involving patients as partners in such a review will lead to 
informed agreement about medicine use, leading to better understanding and adherence, 
this principle is also known as “concordance” and is already being used in other areas of 
health-care.   
 When such a study is performed it should include outcome measures at the level of the 
patients themselves, to measure the clinical consequences in terms of health status, health 
related patient satisfaction, numbers of falls, functional status, hospital admissions and 
mortality rates. Such studies should include large populations of the elderly because 
medication is just one of the parameters that influences these clinical outcome measures. 
These kinds of studies have already been carried out for home-based interventions after 
hospital admissions to prevent readmissions 23,24 and variable and unexpected results were 
seen.  
 Drug induced hospital admissions are seen frequently and, as we have seen in our 
introduction, a small number of drug classes is responsible for more than half of these 
admissions12,25,26. A number of researchers have studied risk factors related to these drug-
related hospital admissions27-29. Further research considering risk factors and risk-models 
for all kinds of frequently seen drug-related hospital admissions should be performed. 
When these risk models are known they should be used to identify patients at increased 
risk of hospitalisation. To implement these risk models in daily practice feasible 
154 Chapter 8 
implementation programs should be offered. Uptake of risk factors in pharmacy and 
general practice systems should be preferable (if possible).       
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Summary 
 
This thesis is aimed at improving medication safety for the elderly. In our introduction 
(chapter 1) the rationale of our study is described. We give an impression of the problems 
associated with ageing of the population and the increasing numbers of medicines used by 
these elderly. The elderly using multiple medicines will experience problems by the 
practical use of medicines and probably improvement in pharmacotherapy can be made. 
Furthermore we focussed on medication reviews, in which complete pharmacotherapy is 
being screened and points of attention are highlighted.  
  
Part I  Problems  
In chapter 2 we describe our study in which we wanted to investigate the type, number, and 
clinical relevance of practical problems using medicines self-reported by home dwelling 
elderly on polypharmacy. Furthermore this study was aimed at developing a risk-model to 
identify elderly drug-users at risk of user-related problems.  
 The study was a cross-sectional study conducted among 286 home dwelling elderly on 
polypharmacy (≥ 75 years, ≥ 4 medicines) in the Netherlands. The user-related problems 
found were divided into problem categories and subsequently a pharmacist and a general 
practitioner classified the problems into those with low and those with (potential) clinical 
relevance. Factors possibly associated with problems (both for all and relevant problems) 
were identified, and subsequently tested in multivariate models using logistic regression. 
 In this study 398 user-related problems were observed in 189 patients (66% of all 
participants). After classification of user-related problems only 26 % appeared to be of 
potential clinical relevance (26% of all participants). When including clinical relevance a 
shift in predominantly present problem categories is observed. Furthermore, the risk model 
for problems with potential clinical relevance contains more factors than the model which 
considered all problems. Factors associated with potential clinically relevant problems are 
emotional or physical problems interfering with social life, communication skills (vision 
and hearing), using tablets that have to be divided, using inhaled medicines, and the 
number of medicines used.  
 Out of this study we concluded that although user-related problems are seen in about 
two-thirds of the participants, in only one out of four participants the problems were 
considered to be of potential clinical relevance. With inclusion of clinical relevance, other 
problem categories become more dominant. A more specific risk model is designed to 
select elderly patients that are most likely to have problems in need of more urgent 
intervention. 
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 In chapter 3 we describe our study aimed at determining nature, volume and clinical 
relevance of prescription-related points of attention in the elderly. This was studied by 
means of an in depth analysis of pharmacotherapy by a multidisciplinary expert panel 
consisting of general practitioners, geriatric specialists, clinical pharmacists and 
community pharmacists. Pharmacotherapy of 102 home-dwelling elderly on polypharmacy 
(> 75 years, using ≥ 4 medicines continually) living in the Netherlands was included in this 
in depth analysis and was studied by means of a two-round consensus method. 
 We saw that in pharmacotherapy of almost all elderly (98%) prescription-related points 
of attention could be identified. Points of attention could be identified in prescribed 
medicines concerning 94% of all elderly, thirty percent of these points of attention were 
considered to be of direct clinical relevance. In 61% of all patients a medicine could be 
added to improve pharmacotherapy, 25% of these prescribing omissions were considered 
to be of direct clinical relevance.  
 From these results we concluded that the regular performance of treatment reviews 
should be part of routine in primary care as it yields significant numbers of prescription-
related points of attention. Although not all prescription-related points of attention were 
considered to be of direct clinical relevance, all points of attention do ask for a signal to the 
prescribing physician.  
 In chapter 4 we describe a composite screening tool for medication reviews. The regular 
performance of medication reviews is prominent among the methods that are advocated to 
reduce the extent and seriousness of drug-related problems, such as adverse drug reactions, 
drug-disease interactions, drug-drug interactions, drug ineffectiveness and cost-
ineffectiveness. Several screening tools have been developed to guide practising healthcare 
professionals and researchers in reviewing the medication patterns of elderly patients, but 
each of these tools has its own limitations. In this chapter we describe a wide range of 
prescription-related, treatment-related and patient-related issues that should be taken into 
account in the implicit reviewing of medication patterns. A broad selection of concrete 
examples and references that can be used as basis for the explicit screening of medication 
patterns in outpatients is also offered.  
 In chapter 5 we describe our study in which we studied drug-induced 
hypoglycaemia. In this study we wanted to determine the incidence of drug-induced 
hypoglycaemia caused by different kinds of blood glucose lowering drugs. Furthermore we 
tried to identify a risk-model for the occurrence of these drug-induced hypoglycaemia. 
Hypoglycaemic events were seen in 1 out of 12 patients during the study period. The risk 
was four times higher in insulin users with or without oral agents (39.11 and 39.04 per 
1000 person years respectively) than in users using only oral antidiabetics (9.88 per 1000 
person years).  In the multivariable analyses use of insulin and renal impairment remained 
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significant for all users of hypoglycaemic agents (both associated with an increased risk). 
Use of tolbutamide (associated with a decreased risk) and use of medicines having an 
influence on CYP2C9 (associated with an increased risk) remained significant for users of 
sulfonylurea derivatives. Because insulin users are at higher risk for hypoglycaemia than 
users of oral antidiabetic drugs it seems particularly relevant that elderly insulin users can 
adequately recognize and rectify upcoming hypoglycaemic events. As the risk of 
hypoglycaemia is also greater in elderly users of glibenclamid than in users of tolbutamid, 
the latter sulphonylurea derivative is the drug of choice in this drug class. Finally, more 
attention should be paid to interactions between sulphonylurea derivatives and CYP2C9 
modifying drugs (such as co-trimoxazole). 
 
Part II  Improvement of medication safety 
In chapter 6 we studied the process of treatment review. We determined which procedure 
for treatment reviews (case conferences versus written feedback) results in more 
medication changes, measured at different moments in time. Another goal of this study was 
to determine the costs and savings related to such an intervention. This was done by means 
of a cluster controlled trial in primary care. Treatment reviews were performed by 28 
pharmacists and 77 general practitioners (GPs) concerning 738 elderly people on 
polypharmacy (≥ 75 years, ≥ 5 medicines). In one group pharmacist and the GP performed 
case-conferences on prescription related problems, and in the other group, the pharmacist 
passed the results of a treatment review on to the GP as written feedback. We counted the 
medication changes following clinically relevant recommendations and calculated the costs 
and savings associated with the intervention at various times. 
 In this intervention study we saw that significantly more medication changes were 
initiated  (42 vs 22, p = 0.02) in the case-conference group. This difference is also present 
6 months after the treatment reviews (36 vs 19 p = 0.02). Nine months after the treatment 
reviews, the difference lost significance (33 vs 19 p = 0.07). Additional costs in the group 
with case conferences seem to be covered by the slightly greater savings in this group.  
 Out of this study we concluded that performing treatment reviews with case conferences 
leads to greater uptake of clinically relevant recommendations. Extra costs seem to be 
covered by related savings. The effect of the intervention declines over time, so performing 
treatment reviews for the elderly should be integrated in the routine collaboration between 
GP’s and pharmacists. 
 In chapter 7 we looked further into the process of treatment reviews, we aimed to  
describe the feasibility of two methods for treatment review (results were given to the GP 
either in case-conferences or in written feedback), and to determine if and how the process 
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of treatment review can be improved. This was studied by means of written questionnaires, 
structured telephone interviews, and analysis of various features of the treatment reviews 
that were recorded during the intervention study. 
 In this process evaluation we found some differences between both intervention groups. 
The pharmacists in the case-conference group made more recommendations to the GPs 
(non significant). Significantly more recommendations were identified by the pharmacists 
themselves in the case conferences group. Health-care professionals accepted an 
intervention with personal contact in case conferences better than an intervention with 
feedback in writing. They were more positive about the process of treatment review 
presented personally, although there were not always as many medication changes as they 
had hoped for. They also had concrete suggestions for improving the intervention, such as 
using a combination of written feedback and case conferences, and reserving the case 
conferences for the most complex cases. From this process evaluation we concluded that 
treatment reviews for the elderly in primary care are feasible, although improvements in 
the process for treatment review can be made. 
 Chapter 8 concludes this thesis. In this chapter the findings and considerations regarding 
the studies as performed for this thesis are discussed. From our studies we can conclude 
that the elderly are suffering from user- and prescription-related pharmaceutical care 
problems. Furthermore, we saw that performing treatment review leads to a decrease in the 
number of prescription-related problems. Because of positive findings in our studies we 
recommend performing treatment reviews for the elderly in primary care. For patients with 
complex pharmacotherapy feedback should be given in case-conferences, for less complex 
patients feedback can probably be given in writing.  
 Because user-related problems were also seen frequently we think that treatment 
reviews ideally should be supplemented by a medicine consultation with the patient 
(clinical medication review). Because the combined form is even more labour-intensive, 
we think that pharmacists should start performing treatment reviews with the GP, when 
this becomes common practice patient consultations can be supplemented.  
 Because no studies regarding clinical medication review in the Dutch primary care 
system are performed yet, we recommend to study the effectiveness of these reviews. In 
such a study outcome measures at the level of the patients themselves should be measured.   
